var title_f18_52_19264="Sterile pustules with IFA sting";
var content_f18_52_19264=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F76841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F76841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sterile pustules due to fire ant stings",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 242px; height: 372px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF0APIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDyxJ40sYVX/nmOPwFZ3mOZDjj0qCxnBUJJyBwOauSqBg4wT0xUM6I2SK14Sy8nk1TjYxnqc1edDMOeO2O1UpIihIPPakmXHYlErOhxnJqNkcE5B45zSQyGNskfWtaJoJAMkbjTG3YpwwPJGSQRjnNdt4dFrPZokpRWXg5ArMsLQyDag4PGRVe9s7jTrhWRiqseRWcnd2FF33NLxI8MMSrERu5AHbHrXJ20LyiZsYBGQf1rq20l76AOpLHHPpis2REt7mO3HVvlNKMrI6cLFe0SfU5kA561LCvzD6066hMV1KnYMQPpmi3UlxitW9CJwcZNH1D8IAkHhHToMnc0ZfH1NelxAFVJzxx14rgfh5bCPQrFRwRCg/TNd9bsCvoCe1fJVHzVWzux0UrJEwGKCSFGDyT3oOdtIAcYPpxWvQ8zqRuQADzzmqUrHJ457fT1q+6jA9+tZ9wcA9Sc4z6VjUbXU6aJXZhuI3ZqGViSM9R2p0wC7T3J60nDEnBB6euazjJnoWRCpO7Hao3UqjjJOTkHNW/JGO4xyTUV0FSJsZOB3rWLbBSXMkeR+JL46dqOu3AYrutwM9Dk8V4xc3UrbwzZLdR0Nd98V79hqz2yn5ZAGb3GTgfSuG0ywk1O9WNfudWY8BRmvpMNL92uYHQlPEOnSWrL3hq1KJLeuOCNseeOe5rO1e5MlwcnOOPrXSa3cRWNmLW0w20bQSB+JrlrWI3VykYGdxyfp3NbR1bbPaxqVKnDA0tX19TodCia203zPumQ5OfSqV4xuL2OLOQPmI7da2LthbxBAMKq4A6596xLBjJcyOTuC/KD6VK6s9fEwjTjSwq+ZqqAP5U5ZSpwh68HNRA8ikZvnA7d6zT5j0pWitC6iZRctziihEj2L8r9KK0D3ex58hwM1etbkHCSdR0NUF6D6UvvW1j8gg01ZmvIQOUyQapSs2TkZpIZimA2SKu20InOR071NrMvSO5nCMvyAaaymNhkEGtxIET5V696DppuZOOADzQ5WEnqVbLWLi1A2gMB65qXUtYub6IBkIX6E1cNnaWOGkILD15qlf6ikibIU49fSp0ZStc1NC8RGysWjYFmxgHPNZ8sjzXi3EvyktkD2zVPR7Vrm4yc7VP4U/Uptt2VU8Jx+NDXQqFW015D9ch2Xm4dHG6oLJQZ0X1YD+lXNYy8NrJ94GPrTNCTzdTtU253SqOPqKTdoano4uK+svl2bX4n1h4QjEenW4XA2oBgfQV1duRsx75FcxoJ2wx7TjgfyrpoCMdOfWvkXK1S5eOj7xYHTFLTV4/+vTwK6U0zymtRpGeKrXCbvvdqtkADg/jUTrnk9unOKzqIqEmmZUinJ24OPaiJM5xx61bkiPcHn0pY1ReXOAOpPasEtTsdT3SIRkEZ79TWXrZC2zkk7RnAH9a2ZApTcpyOxFcz4wuhb6ZM3QkE/pXTC3MkVhbyqK588+Lcap4wlRm+QEKSPQcmrV9c2mm24is40RQMAgYLfU1zL32dXnuG53szVUvJ3uCWP3T0Havo4xtFJnuYTH08PTnUirzbfyILuZ7iZnbknp9K1dDsSqm4dSuRhc8cVBpOmPeTAkbY15Y88/SuiupxDGEjwFVcAHtVyldWR3ZTg3OTxdf11/MxdXm8pNjfKx5GOhH1qLSlC224/wARz71nX0zzOdzZycACtq2iHkRjbghRxQ1aNjXC1freMlUWy2JeMZBpYAGly3IFKVCRFvbkGnWeRz3I+tZWsj2nq7G1HtMa8dhRVmKLMaEOgBA7UVZHtV2PIh0p3GKaBxSgEHnpXRufkER454q7a3zQDbjg96oqeafg4oaTOuPvK5v2m2T587u/WpLrUUt48JjceoFc9FPJD9xuDSmbzP8AWDPvUcupm4pu7JXke7cl269B6Ujska7R94VGXGPk4+lT6TaPfahHEo4JBP0zTasDlY6XRrVLTSftEgG5gWJ9K5S4bzJnc92JrsPFh+wWEVuvDsBkD0ri84HNO1mZ01f3maTTCTS4Y+6OT+FaPg9c+I9PHT98v86wo2O3bnpXR+CF3+JtP/66A/oaxraQZ6tKTq1I38kfT+gECMe+e1dJAOF/Wua0M/ux6V0lrnI3HjtXx1TSZ1Y5e8y33p688U0DJJHryKeoropvoePITB6DvTdvGT16U8nnimMe3eiT0CK6kZUbueoqO4jLLhVBzwQelT7R1PWmyZBzmsr6XNU2miqwWKPGBwMYFeZ/FfUTb6JPhsEqQOfwr0m8bCnHOOc14X8ar0+SkCnO58H6df6V0YRc9VHoYVcsJVH2PGXYdT1xVvT7qKOXbcKCn0yBVR1PTGcUtvazTttiQsT6cD86+qsrak4N1FUi6au+x28epWv2ZfIhyuMZ6Vz2q6isrMixqT0JHak8t7CHbM4YkcDuDWRK+SW/iJqYxVz6THZlUjCNJKze6JLRDNdJGvTcCfpXWWyhABKgZD0I6isnwxZmRnnxjHyjNdEW2HZIMMB17fnU1Hd2R35LQ9nQ9pLeRlXoUEiNi6ngH/61TWUR3Dbj0wTiqkzk3IU8gjj8607RVPyE7SOSKhnpKSk5NFgM4A+RvwNFMU/KPmPT1op2ZOh5mtOpq5AzjIp36V03Px+OwL1qU9Kip8fPXmmdVJ20A4xTTUpxUft6UDqQVtBBnNdr8P7MZlu5BjHAz6Vxkal3VF6scCvRbdf7I8N5Iw5Uc9O1Gl9Tlqt8tu5y3i6++16s4B+VDtGOlYhp0rF5WdvvM2TQi7iBUtmsVZJDlwMGup8Bc+JbMjsSR+RrmpEKL26V1Xw+t3bXbWXZlFYgn8Kwr/w2ejgoynVgoo+j9EkPlKSfX+ddJbzZT5ug9OK5PR22qoPPf+dbYfdCyqcZGK+Qqp8x6mMp802b0UyOMqwI9qtZHGK5bRYpYHcM+YyeB6V0UTHABwccZHpVxnyux5GIoKErJk+M1Hs+brUgHze3akK85oldnLcbgZyQc0yUjHHBNTEGo3BHJNQ09ilLUxtSYxoSBzjr6185fFW4NzrUUAOSMnHvnFfRWuMFt5COwPNfLvji63eKZ3b5hGwUY/WvRytc0m0exS5VQ97q0aOleFrZYN2oN5juAQFJGOKbdRQaWjRwYRe3Q5+tYr6+5JKggDpk89Ky77UJbpssTjHTNe6k29T6JY/B4SF6CuyPUbkzzszc46d6pIpkcKBkk4FDnPXp3rb8Nab9quTKw/dxjIPPJrZ2irnh0YTxuIs93ub+jw/ZrRIhgEDJPfPpmjUGGz5jwOnrVsKu0qMDHOe9Y2ok7yMknoKwWrufdpKlC0dkU7MGW8YuMgfKK02+RiqnI7Dv+BqOxgQfKRy3JI9fWppUBbY4AOcgj+L/AAptmVGDpwtLdipjYuQc49aKsxwx+WuVfOB3oq+YrlOU07Trd7eNpMbmQHH4Vj6jb/Z7llUgr2INNju5lRArbdq4zULszEsx3E96tJp3Z+QU1bcbT09qZjNSxLk1dzakveQu04prDgcdetXI4C465/CmXMBQZ7DtRzLY6ZrQteGrU3WqR8ZRCCa6HxxehIorZD15IHpTPA9r5UUt04wSDjPpXPeILw3mpSvn5QcAUrHnbzt0KBbPOKFY5pmaM07I3LJcOvHb1rtvhexfX0gZwqgFjk4ycdq4RCM57HtXVeA4TJ4jtVHbLEj0rnxCtTZ6GXzcKsbH0Tph3gMjY9vat22U9OvesPRVBjGemK6OFVCqRnPoK+QrS1sj2MXK0mieOEbDg4B4PrV+xjEaqOWUcDJzWNJqsEEpiuBgjHIySK1rGZJYQyMSpPB6EisXCV02eVXjNK7RpcYoA5qNJFkJwDx609iFGT0FdKmrXPOcXewpFQOQDk9KI50lB2daZMRsz+YNY1aia0LjBp2ZznieQC0lwcCvlTXWa41a7cfMWlOO+e1fTPjK4EdjM3baT+lfPfhuOOXVJJ5uQmSPckmvZyhWg5Hv0MK8RGnRXU5NwyseOfTnOfem5PpXpGq+HbW/BkiJglbqUGQT7isZfBt1uGJ7cDpk5zXtqquptVyWvCT5NUcvaWr3M6xIMsTivRNMtFsLdYEQcgA4PU+tQaf4cSxDu0nmTMOoAwv0omtTAD+9dyRzn1rOc+bY+hyrL1hoNy+JjtUh8nOCQD6HvWBJmSUEnpxVy7lyuCxBHFVbaImTLSZB9s0krHpy6RLcQKBXweO/rTpEMjeg61NInlxIvmOAOegOfwqMpJnhsHt2OOxoQ5jljXaP3zdPSipEguAi5kGcetFVcxueXqflB70uTTRnbxSjJ4rqR+QJ6WHDrWjp9qZBnFSaRpoutzucAdPet6CxNuvtXPVrKOiOijKKepQEJiXkVXkBmlCKv3jityQxNHjqfyplhaxLdh3YYXnBrOMr7m1SVo3Rb1CVdL0PYmFYgKB0zXn5JJy3U8mui8X3onuVhQ5Rea52uqOxxQWl2FKOtIKctUaLcemBj0zXc/DKFz4jjfBwI2Nchp1v58u0nAWvSvhbav8AaLi4ZMpEfJD985zXHiprkl6Hq5ZFSrpfM9o0iILECR1NbaJL8rRkcdQeRWXpYPlgHkGuhgAKgcD68V8XWk1OyOzFz95kRtIpTudAzdzgVb8qIQlHUFO4wKesZKjOFYdStTCIMu0nPrnrS5ZPQ8yVTmWrIrS5jkQ+UHRRwAwqSGSSaFvMXaxJH4etCRJApIABPbHU1IpJQFlx6ilNtGcrXuiCGMW6AdWJ60ly3y59Knbkjv7VVuyNp7c1nsi4+9K7POPiZdeTpF2wOMRHH1/ya+erG9e2nyjcMeR2r234uzj+xblM8khcfjXiS2Mz27ToMoDgfpX1mWR5aR7TVaM6bo7pXO00/VTKoDEc4zk1ri4DjCngd88GvO7KZouHJDY4FbVlfhW2yl9vt2+ld/IfXYPFwxUFfSR0+5ScHgj3rL1GYrz1YVWe+AAKnn3POKz7u73HA5/lmpSR3O1PVkNxMJMr1yc59Kkt2EZ459zziq8KmR8kZHYCtGG3dmG0EDucYwauRnB3uyaGEseGLgjvT0hwWBGCOhzVuCEKhDde+KZcIV5A69M1nfUJMVIn2LwOlFSK7hRz2orQy5TyyG0LwK/qKltbB5nAYYAPar2nsn2WFT/dGc1ftZYYpDkjn1pynJXPx5TaVi1pdiUIROMdc10MumiS1wD06HPNZEd9EpDqQfWntr4jYqmCDzXG1KWpCuzLvbWeKRsA8dBnFY1zeSxuVDHcOuTk11NzqKPCXfAYjjPNcpdypJKWI5NdNJvqbwnLqZ8jO7lpMlj60ytL7Msq7lIAFILHByMHvXQpJbl3M/FWLeEyDPQVe+yxqoLDrwfappFihhG0AH88ilKolqhKVtCG1R4csn516F8LJpftd9GzHaQrkds8jP1rA0hbT7GHdhuxnnFdL8O41bUNRkj+78q/pXBiJ3g0ellE3LFJHsmh3Ili2jrnBro/s/nxBVcqRzmuX0SIKoK8H2rfS6FsyCbgE4yee1fLV1+9909HGR998hrxR+VEqs+eOpzTbmeeIosabgeCR0xT4WBRcMSD0Dc1OMDk8n1qVe/MtzyL63kgVQdu/wDh55ppmRnZB1HJzTbhmRSY8H1B5qKHZIhlGNx4zjqKVS6WnUSjpdkzMMZU/Q9qzb6dNrA8n2p+6VYJg3JOQp7VhTTNFAfOOZADk1lCPtHY68PQvI8u+LMwksQoPzPMBj1GKxoNOiOmRwqPuqCTjvjmrnjdDd6pYKAShlOfTIFTpGQM8ivrsLHlppH2mApKDlL0RwepaS8UhfO7HbHIqrGjr1GPbHau6v7UyoxBO4dq5u9hMZbeH9AccV2KVtDsjgqUZe0hozOmlAXlsGqoMsjBVAz1IPpVtLR5znaMdRkVoW+nFfmdRn15ptoTo1K8/e0iiG1tj8u4kA9Mdc1r20ZUEZ3fXrmnxwBNpKnI7gcfjU4aJgAIyrZyWzwRUt3O1tR0Q9BjHy/hUd+AsO7vjkE5xUzZjQfMSD6dfyqhekGJgSQ3bd6VCVyGrlUXPHB4oqmrEKOnSitrC5Tgop5AigNwB60rTOwwT+NRpC5RWCkrjg1e0+xFyrBuo/CtpOK1Px1NJFRJpFGA5APvU8E7K3zHNFxYTwvgrlexphhKqHNK8ZbGisyeW6kcbQPl9KrzN0PQ+1O4xk1E3J9aSikUkkOinkQnBwvpUjXTnoearcA89KdjBH6YqmkxWSLC3Lkbc9OtMEhyc85qPbkY9e9PaJlAYjiiyGrFu3lcLjcQB2r1b4UzWKabfC4Ev26SQGMjldoGOffmvIou/wDKvX/hoLYaA+LOb7T5p3XG7KEcYFcWMSVNnqZXDmxCPVNNlCIhDAH2710FttnPzruAx1AP5VxullnAEUWcA/LuwR7+9dXpr7FjMjgE8EnjJ+lfLYilb3lueljYcrdtzooowAADgY71IAADkgjsMUkRG3rxjrnFSMowD+IpQiuU+elJ3KV/aNdQCNZTCx6MpxUSQrFbeTuJ42knrn1q5dQfaIWQnBPQ88HORWWtpcSKyzuUIzgpkD61hWV0rnRSlzRs3oQXdwIYYo0bJzj3/Gud1qQxxOScmtOC0l82dpiWCjAZq5rxLdCOMoT83StsLTSmknc9rBU1zpLU47V3Q24mILNHLuH5YqK2nSZRhjke/FaT6Y1xol4XB3CMuoHr1rh7K7EbjD8A96+ppq0bH0GW14VeeDetzqyqsTkA+1QTWkb/AHgDnsRmm2txE4Vt+SQeKuh1JGOa09T0neLM9dPVOQvB6AcU8Q7eoH5VoDnpwPSmMv0oYKq3uUJPKTqu0duM1WmICjywMHtwKvvGCTgZ9c1n3SKoxuQMOnPNTctO5DKx3DnJ7g1m6uypB98Enp6067vQX45cd+tRS2ovIPMQjzF6jruFaWtqU00Zasdo57UVbS3cIuUGcelFXdGN2crp/wA0EUbD5SOT+NdBZaacBo+vp04pdH06JrS2ZsDMYPrk11MmlrFbpNEcDaAeDXPVnq0fjbk3scVqEc/mmHbn0rKvYJVATb8o5z716FNBAyiQgFwO1cxqxD7ti4PeilVs0hxm72ORkBzgGo+QcVMQfNfPY1Gw3McA13pnUNpwNBRu4xShT06e9PRoFqOQ+tWfODpg9qqhT25pVUk8cUmVFItQgcnp6V7R4MTU9N0W2sZ4Eht5oxcc4LMSeCcdOK8Xh+U89hXsXgOK4j0mI3PmGVgMK+cgY4A9sV5+Mb5T3MlipVndbI7aG2HyOQQw4+XjP/1q6TSJYJoTFJyynoR0/GuftJJCAJAQR2I4FdHpCxSSlWxlhkjvXzmJ0Wp6ONu4+8dZDGjQheGBA78YqdVCjbnAqnaKkMe0HIUcVZjmilTKOGHQgHoazoNTj7p8tNO7tsS7cD29qrybVYL3PSp9rYwuCKilwq7jgsOgJANOrBvRCg9TD1VHjyYFwzY3N26+leeeLAWnVVUAluQO/vXpMjF1bzOGIzjrjrXH3Omm9u5SDjb0PvV5RB1a3Ij2aGIWHpym+iM3Qg8geOZCwZdpxzxjBzXj2q6fNY6rdRbSFjkKj16//Xr6V8N6EY7aaRhiRcBfevHPi1p89l4qvJPKPkyEOCvuOp/Gvra1L2VmYZRi/bVpLsrnGRXssDAEvt7Yrasdbif5XyG6A4rmJmXqOMdah88Y3KeOxFZxV0fYUcyVkqjuj0mCYSoGXDA9881Iy5zyfcV5za6pLD0ldR1zk9a1bXX7jOGk3A9cihw0O2nWpVX7kjr9p2kjn3qje2QuEI37W7cmo7PV0lBEvXrkVejmRxlWAz+dRaxvyyicbe2b2zMrndjqRRpN2sMwEgyG45rsLi2iuY9rqGz3rJfR7aMtuUAjkHmnzX0Y3O+5IIFIyAMGinoMIuM4x6mirsiLHE6XeFdOtfmyAgrYbXJPJWLf8vcVyOnTFrWNGyFUDFXFUykrngVjUinJn44oHQQ3fBJOSfWqylJ3dSo5rNMc+0bCStDtLAVUDJPtUKCWxXKkQXmmIjs6YGaqLbRKQOpzzV7UxOsIY9TxisoRzkFhlwOoPFbwbtqy1drcu3tvGIwyDnrjNZcsZGGC49akR5nYqQTjj6VZhgMjYYceta/Buyl7u7I7K18xju4HarE9gEI2d6nKiEgZ59B2q9GgkCrn/GsXUle4uZmQbdkI3KcGvWPB95c3emRPeSMzqNqt3wOmTXEGAOyp24rs/DAKWIVEYKCQcjAPuD6Vy16nPGx7/D83LEOPkdlFOyBSxLYGMnkmtO1u2MkM1jIBKvBLDIx3rnIEuPsrTqCYQ205IIBq5aXcVxJELGOUE4GxsZ3Z54rzZ029T6OvSi9P6+Z6XZ3DSBQ7DcR345xT4LdjI0rBolU5IUjDH1Nc/pepqtzHb3DCGQE5ZzgdK6uC6jki3KQy+pHFeVKlKk7ny2JpyovRDo5ZpZQFCGDs4yCfwqvdi3mci+TeY/mwAcAdqmlu5QoW2gyx6FuAKS3WaS3Y3Cgsx5A7e1aTqK107s5UuX3np+ZmB4fLuJYHLxg8eq8dKg0iIM8uRliev/1quXMKxoI0jwpJJx0NYs18+n3kLJwhzuXseRzXTlNdU8QqiOmpT9vRlTj1O7tYhFAqe2TXmXxisEkubS5ZdySRmJh9D/8AXr0iwvYry3VoWzkcjuDVLxJosGu6ebeY7XU7o5P7px3HpxX2dZe3p3jqeXlWKWBxkalTZaP0Pk/VdJkglIjG+MksAByBXPzRvCxUrtU9ARjH4V6/4g0WWwvpbW5XbPH36AjPUVzF7p6zoUmj3Y5DHg1wRk46H6G8up4he0w8tzz51YjI/wAaUSyRt1PpyK6v+x0iIZOg5OeabNYoUyuGI5IPetVNMVPJalubmszEtNQeNsuHIHcV0FhrCFflbIHcisx7YqS4XCjtUW5lONvFDsz08NCrRXLUldHRLrLrxuOO2BViPVvPAVo93qcdK5qO5dDhWIPpUq3TxuGViTn5h2xUuKN24yVzoxcoR0NFUo7y3ManDcgUU7E6dzNstDgbQ7KYcyPGCcVCdOeKFmRPmB69609JvYU0WwUnIWIZ+vNUNT1gKHWIDHOK43zObPx0owXYjYoT8w7GpROk8qg8Ec59657z98jPn5iatwSFQDnHf8a29noDgzfvFR4183BXtVWYxJDhME470GQSwgA5OKpmxnZ9xb5MdM1kkm9WSlYqgrvyRhgaR7lUBEf3s1LLbhFbuexrIJO84BIB610U0p7msdS+jMTuY5Y9KspcEEY4xVO0OFy5ps0pzxx7VUo3Lsa4vtg67j15rv8Awdq11PaC1urdZbcnbC+QCh6kEdx7mvKd2MMeg6n2r1b4W3NrJos1sTG0/m72DoCyjHGG649q5MTBQhc9bKFbEJo66LSi0fmwT8kgFN2QD64rUkTS1v7R4JZiMhZjCMEPjgj0Ga1oZLJIYEtysu9SJSgyQenWqupWjxwuYYo5tyjdvBJyDxz+FeR7bW0j3Z4iVWVndb+RTjs21e5mjjiKHJYqxGRg9fet2zvL6yjVVAuAoC4xjA/xrIhWa71C1mtIDZ3BYDarYGcc8+lbu1yCk53SA4Zl7nB5rLET5bPdGGJkpWjK1u3VHTWMjSwBpVKuQCVbGQKe91brIImcGY/wHg/WuYV3VNiSLuBB8wsdw9vcdq09PeS5ZpZgJk6D5MH6VguVR82eLUw3K3JvQ1J4lKABgPXHpXJ+J7MLFHKi8LIcn2IroEv4pU2ojIwYr5b8MvvjNRXirdpJashVyPlB6H0INTQXsq6FRlKm9TM0WWSOIYcDHQjIrprS/V8LIQrngE9DWdaadLFDskXDKB9KSSFl+VxxX2NGnUormieXiKtOrN3Mj4m6Sk9jHqSDDwfu5COpUkYNeQ30IK7uuOmOc17lNKk9nPZX4L20ilSw5K+h9+ea8Z13T7nQdSmtZQZIMlkcDh17Ef4UqrvLmj1PtOF8ben9Xk9Y7eaOVurrapTbjJwapCUL87MDkcCti7tBcqZbUhm/ung1zV2XilKshUr2IxUxPs/aLqWri4Ric/eOOB0/KqM5H4/QVAzFyc8E85FRMG5K8n3q3G5y1MTyq6WgSMFO70oEy4xux2x71Vm80gheD6k1mTPKrHc35VooX0PHq5i4S91G8L5VGM9OKK50vk8sc/Wiq5Dk/taXYv6fqBW0hiJxhcfzqxNGkkW7dkntWCjgQoQpOB1H1qSKZyMEnHYdaydNXbPhlDQkkh8tvlb/AAqxbSBiFb/JqW3tJbiP5OnoRnNTxaY3Rsg59KmUopWuXfuWYUAHyN9cVozSpHbqA25iMVWt9LuM4Q/KfY5q6ujy/aV83JGMjPSuNpXuZSiUCoMfzKeaz3tGXlVO013S6fCwCmP5Vxg4/nUdzYxNkLGdvXPalGq46CSaOI8gLHnGT3pPsvmfNjBrorm0jUfLwe4qvHaZOF5zWirMak0YptiinqT1AFej/B+7tob+TTrpI4lvMf6W2cpjoPxJArm10huGb5s10Ok6fp0as99PJACrIrxjneegI9OKirPnjZndgqjVaPQ9fguNPSaWCymdRGdpjZQd5yfmB9K1hCTZefIm1HxjkYriNFvILJUieFnmKbUYDgfU1qW5nCO09xJJGMlEJ4XivFr0VfmPpa2ElF7/AH9TYv8AT4bqz27iApH3cAj3zU1lCI41VckgYyecisrTijszJdvMpXJLk/KfSrsl1c288a2sSyFhtCsOD+Ncsqbb5LnPKMl7l/0J3tY1uFuHBaReijvV+S+X7N5eZbdnwqMB0P1rIkupIQHKCVk+Zo9wGQD0qVdaF15VxBbNFa9Widctu9evSrhRdueRhUpTna6uaLST2cSRuC5fG6XqSfcVPG11JKZT5RiQZUgEE/WqtjLf3SmSWQLEclQEwR/9b2qe4ljhiWQBZJkOQpOM1g5XnynPKNny2VzpYHE0SOOjAE/XpRNCkoKsv0PeqOg3RntSGQRuDu2Bs4HetKvvsFW9tRjPyPm8RT9lUcTHurEorFfmUdx2rk/FemRX2kXEMyZkjQvC6nlDjkfQ16IeRiqV3p0F2rB1KlgVJHHHvWs6EZXNMJip4eopxex8oPqQjlwfldTglfWnvqNpfkxX0fzdPNUYI/xrf8S+E7VdUuYopDDJFIykgZB5PbtXOXHha5RgYrmJs9cgg15cdD9Qo18Q0m1zJ9StqWnNbxiS2AuLc/xp1H1FYM07DKjk9ziutsLW806Q7xvhbggdPxp2o6NbOplihDK3JVeo+grTnsdeIoVK0bRlY4KaVyec59+lUHbc3I/OututJSNd+zfEe/Qj61mTWEDElQQT0welbxmmeNWyustb3MEE460VuDS4sdaK0ucf9mV+5d0bSYJtLidkG5lPP4mtbTtBi8srImGPQ1W8PMG0yEjkqpyPfJrVtdTdbpPMXCCvJqVJ8z1PkVG1rm3pXhyC2gO77zcgVbXRYInVtmVJz61BLrCKAyKfT1zVzTtQeedEYYXAwa5ZOfU09mrlyS0s0VAq4ye45z6GpodPgu54ogOehHer09pCwXPzE85zzmqv2aeyuluI8lQQSPSuf2rasnqKVNJmlceHYrWEkLk45P41lvooa2dljyO9dDaa0bq+iSUALnt9MVf1JTYyLIW3wMACCB+dYOdWD1ZmknKzPIrnQWNwd2QD0+lWE8PCK38xOW7iu7S1gvbx3LhIwMYxg+1WINNhCSxE784wemDXR9aaRoo076nG6dok9xaFokJ/pWRrel3a6ZczDnycOQODgEV6fbA6dCYkbc8hOQO3tWXqOmO2nXhfB86F1KA9sGlDEtt32LXKmmilpaSNY20rRsQ6jacdeBW7CSYsDB9RXA+H9ZuoYoRJdwGOKJSoiyQgHUFf71dZZ3i3UheA7kPIJBBI9aqrTdz7SMnWpqRu2E9tBuWRhCAMgHqTV6eOSeJXikKvkEFTyK51gVuVnWJGaPBw/Q1rWOoTzHdJAELN1XG0ewrkq09qi3OWtSa9+JI2nCTBmyWB5JPX61KiyWBVoIfPyCMMeEFXyuVV8nng+lLC1pG2IiTOeGGOF+prnVWVnc5JVm1Z6odZ3s8pjgnhjjjAz5wOMn0xVmWCEsGaNCRkg4GKS4EMsWdyNgEkZGcA1Tt72OSCSVmVdpASPoWH0rCVOc/fSsctr+9FWNLQ5JI75ULDyCuAMcg59a6XGOPTNclbSrEVlLBFyCWPQV1iMHUMCCGAII5yMda+qyGq5UpU30PHzWFpqfcWmn7p+lOFIetfQnlLY8f+IFukHia529HxIB9QD/WuTuCqn5hkV13xOYL4lcg9Ik/lXD3M5I2qNzYzXjVFab9T9byhOeEpSf8AKvyILi9RAQBiqcd+pkKnrnqBx0qKc7mJYbfUHvTEa2Tl1kI6/Lg80Kx7PKkiS4hS4cvbuEmPVW6OKw7y0BZhsMU3dD0P0NbgurIAhmcbuuQQaldbS4hEZmDr23HBX6VUdDN9jkhaT4+5+tFdOunKFGJWxj+9RWvMZeziYHh8RW+lW7Zyzqcj8TV02z3nMGBis3Q1jl0i3G75gh/ma3tHeOKNhu2sfWuCorSZ+Tc6aRZs4Sumus2N69DUNteuij5Thecj1zVS41DFw8GQxPpU6XKpaMrKDkccVHK+pPNrdHZaXqUktqsiZyDjHTtWh9qnu4WTb8wH04964Pw1fSedsVcoT0rrjdPDGXPyjjINc86SbvYnV6laKWWG4Il4xwCOlaEHiAlTbzkuSuFGc45rMvL9HsJHUAuck561zmlzS3F2ZMfdIyKbpqatJBezPVdF003cZllbYo+YDuaqaprMVm0kcDBto6985rPi1xpLBYIZApA5wfesK8kgZtpfc3QntWEMNJy98bszX07WUlkka4bPJIUmlGvjeU8wlD8oA4AHpXKXyK7Bbcdhkj61F9mkhhDHJYHk1s6EW7tDjJ38g8LaPcT3WqSooWKCXaxLAcnJAxXaWF1c6aALeBWLjYwYcKMdfrXmxup7HxKk9urzCUozxAcMenP+Jr0yzvLq/iuLy5RIniYB7YYBA55/+vWlVPfofY5XWjPDqDV/60JJriS9Eb7FieNdpKZ+cZ6kVqaCjXE4zMFAzkythQcHtVSGaJQSuACMqGI/KlFkJ5RJc4VD8xSM5FcrataR3VEuRwWh0Nmskvmo1zC0IDFR5hz1pthI8rEW87Og5feuSaZ/Y8AMZmj8oNgKxOAasTrDasq2km+4Q/NCMgEem6uWSVrWPLlKLuou9/Ic9layHzCnzHknp+lQ3UUUckEn2fdI5wjg8D8O1S752jaRYBGSeI1Odh9M1DbyPLdGe6gWElduAxwff2rKK3bYoqW4t5qJjAtxCSuN0oADZHbHoa6bTNchisrVLtiGKkAkY4BOAa5UvDazSPHGNgIJUHO4e1LfatZmyhuRGEikYqFf7yn0I/CvSy+pOnUSgcmNw8KlOzi+9z0aGeOVA0boVPcGpDjrXmEOrJnfDPsx0xT5fGV/ZKABFcL6OcHH1r6WOIa+NHz08J/KzF+KxC+KJBnGYozj8K4CYBTvUvk8cZ6U7xv4g1jWNelvWs1VCoCxoScAAVzLa+YWKTqY5BwQ2eK4prmk2j9GyjMMPDDU6UpWaSRuTXBAAYZPqQf51VldGGN+M9s1Si8R2ZGHcFvXFSHWdOdcytEw+vOaEmuh7X1ui9poZLaup3wlH+pqhMXL5ZQp9AKnl1jTEJaNgo9j/SqcuuacxwWLY56VVn2Ini8Ot5ospJLsX536eporL/tyzHQPiir5Wcn9pYf+Ym8OKZLOFYzjgg/ma19TmhtocqQJF4zXF6bqclnDEI+oBBx9a15yby28yRssRnGa5qlL3ry2Py1LQg0u9M95I8jck8V0Hnqtswdh3wK5K3/cE5XB9a0VuY5EwWGadSN3psNo6bw7dpFJuX73vXRXGqi5hKFQAOnPBrz/AE+58otjketasV0EhVw3ynqK55K2hOpqxrLscvJsQ5wPaqsF0bNnCng9azrzVvMljCE7B97Aq5d2wmt0ntgSuMkVLWgLYu6beEW8rFsE5/xqv9sC2xct8xJzWcsrRxMBxmqQnVlZSfnHQCnFXBJs3rLVXjAZhnPet+xuVn+adcoeoHWuDhmMkgQ8Y6Vv6beMrKrEFQCf6UmrblLQseNJDZok1g+xJ8wyrwQRkEfjkVs+DYZ5YIXF3JCBGQ24Fg5J4B9a5XxG73dtK3VEG7Fba6hdabYadb6e6K8cQmFxE25Jj1AIxwR0okrqyPdyira9+h388Agdo8xT28WCZU5Ck9jxx6Vet3+xwtA2n+YjkN5g5O0/yrlrHUriQLcan5p+0KWlWLgOe2R+tdDZ6lqFjamJY4pYZxw8gLOoxxiuSUNT6GpTqSgr6v7idRDqEkcC3908IGMT/KIzzxWvbjS4FSO2ujM44YZOc+/rWbbW0d4y2+A0zjhV68Cr8FjDpqhr1fJBBKsRyx71zVPeTOKs4r3eZ+nckudVhtF+WMODkBV6g46ioVJu7TcV25B4bgj2p0z21yYhHEEIBHnFgcjI59qmunitLiC1jY+aU3NhshvcelY8iUdFqjKPLGyS1f6GVDaPFhS+5APlTjC1z3xEUW/he5njdWnRkJTPJGeoH4117mSVizRhADjjnIrkfiDCsvh++XYD+6Lbuc9RxWuHlepG5tK9SDXkeKN4h1NJCUupY+fuqeKcfFmrj/l9f2BArGkA3dQPT8qicEcnBUelfUqKPmmjTu/EWq3A2vdyY7gYFY000srl5HLsepYkmpHUjrnDDINNIPoatJIpOxEcgelNAzxUzqcnioyvsQaehfO+g0gDqM+9IcYpzZHODzTSeOlVuZym2GaKUdBRTt5mftBsXAGKvRzyxcq2UPbrWenv0qRHKnjp79Kzkr7nPHYtzytIu7G3saSEhVDFue9V5ZXkjA6UxScYzS5bopWNOC6YsUB2g8VsKQY0jV+DjNcxEpkYFeCO9XA09tMruSU9ecVjVpLZPUmSOit2ihcRgZY5yatw6jLZbolTMTcisBLkNdLJklRVm5vjK2VGRjFcrpu5LRbllMm7LYySQBWQrGK5LYzipmuGEROMY71nxXMjXCjqm7k461rTjZNhEtJNM93uCEA+lbVi8ik7uOOnSqMcj/akWNcgjmr97FKGjEanJ+99KyqtSCTK+s6i8UXljguQSPYH/wCtWv4HZ3kuLxZbXdZx+d9nlOBIM8qq/T0rkddukuL393gqqhQMcZ71Jpk1utpIskZNxvBjYHAUdwRWvsv3ex6GDl7OSZ7jpkyahpRupZIYpmI/0X+IKehFWrSOVMnzmbByofkL7D2rjvC+vfaLq2091hYuoiWeQbfLGTjDd+uOa766tVtYoW+0QSlgSfKfIUjqK8yrFrQ+vo4mNSKTerJDA7otylx5U5J2tG20j2q9apI9skt3ftMgYhVkbJU/lmobMeH/ALJ5j3jrqGCxgK8sfakgt4Jj50Q5PPzcc1zzTSszCUlO62t5fkW0MMDt9tljS3YHLqgBPH60mni0hVxDHNO7HcrdRj3NRR28krYuGG0dEHIFWM30cbvpyxFU+WRX6EVkld2MppWsn+OhIt8kjn90yg8KCO/rWT4igS70+5hZioeJh+ODWnbqRGvmgBznNVrwKcg+n5VELRkhwir2R8xT2uJDntwagkgwODj3zWprcEseo3UeNoErY4PTP0rLaOQHcc4r6qEtD5qfuycWdFqfhTUNP0HSdVuFD2d9GWjaM5xjs3p0rD8vBJwdv8q+hPgrdxax4CfTru2ivEtLgK0UgBGxuc4rK8b/AAkSSSS78LAsCSzWUhIcDrlG7j2PNK7uZSaTszw4hSfrTGVevetTUNLntLhoLiGWGZMhkkUgg+4xWc0DdcEEVUZC5itIoJ4PTtSCIH5WPJ5GP5U6WBhg4OajCspBxyOa06DumW10q4ZQRDIQRnoaK1IvFOqRxognGFAAoqLszMWwsDcQq2SCc4x9atXWntHGuxQR3NLpkoW2hXncQSD+JraaXbCExuJrGdSUZM5Yto5KZQDjaBjtSxW0ko3IhAFdNFpgu2BMeDnqRW5ZaC2UWFC2epxmiWLUVtqac5xNjaSg7iuAexFbETlj5cseVHH1rd1OxME4jC7T34NV5ItpwseWxxx+tc8q3PqKUrmJqluj4NouwryR6020g/0bMjbXHWtbUdOlSNLgcBsAjt0qteWrfZg8ZHPWn7R8qiLmK8aK8JQjnsaIreJVI25I/nUtuRDsV1JLDk1etrcPK4zlOtTzWYXaGaIiNdZkAABwM1v65cwaNZSXLokjuNsYPTOO9YWkQxzan5RBVS2Ae2ad4+t5bWGKKRyUL5XPcYoglKaRUVfU4h2LsSQBkkkDkZqa2lCTDcMjIyD3qvjGTRuxz3Fepa6sdKnY7bSrb7ZG72youcgRDkp2zmvRfCkd15EmnzTBpICTFBtwdpAJPvzXk/hrXLnSJHntPLJkQowcZGD3Hoa7HSdVu2ZLyGYreRjhw5BYZ5GffpXl4imz6DBVoRScdzuILN4b0XUbtHcrkByckD0Ardtp0+VHLM7HBIHBNY8euWWr7J9OgkhG0CSNuQH7kHvV+C62gMVbP+z1B9q8yonezPZk3Wgp2sbYjEfHPHGDVW5LQTpcxHDjnoSD7Ed6jS8ZAHuGkfvzjP41bguoLsHyQQB1yOaw96LujkcGviV0QQXFzcl5rgKrPkgKCMVE0ThCrZbHOSc1oOhC7umOlQTIScs3ynrUqSbuOEknoUtQ8SeEoI4LPXLC2mvY0AZntwTjsc9643Xz4Aviy2lsYZ2OQ8LHaO/TNQfEDwlqWrajbXOl20s7GMrJtGSDk4rEsfhL4tvMhNO8rPGZZFX9M171CaqQWp85ioKlWkjc+BN0LXxLrGnCX5JYi0YPcqePxxXsl27kxuw2Sqm78favCvhdpt5onxJktL6Ipc20Uqygc4O3rn0r2yymLWsZaZJ1ZyC/oM5xWltbHLNXSkWLi303xBCItXs7e5dejSKCRx69f1rmdS+FHhq6YtCl1aN28twQfwI/rWvqsMkANxanJB5A9KjtfEqSQlZQUdAQd3GKIz6SM3TlvBnIXfwd0nYdmpXSN2LRqRXP3/wbky32bVIX64BQg+2ea9TPiO2YANKnUYAIP5Cqd1rkUcj+Q+Sep45rWLitiXGoePf8Kc1w9HsSPXceaK9aXxtbqoUxpkDHWir0J988AsdFT/hG4Lrd+9IOB3HNa8ulRWOn2zytmSQgYPpWl4e01rjw5asR8ioeT0zuNP1hI2ubJWcMIzyB0xXBObk2c6CeFLaOJo4xgjGB396s6VeTRsyxKA3vnii41e0+0CGBN2xdvtn1qtLfBIjIvys+ayfYFpqZ2oNc755pwPmYgH2q7HCsdlHctg5xkYPSktYpNUsnWQgfNjIqb7CYB5bsZIwvGOf0oQ1fUyNXM9wBHB88Q64qqluZbZcfw8EVv2MaW0cisM7s9euOtV4LGWViYRtV24C8455p7iSdtSrHpsbwqZG2huh9qqSqLMtHEd7HgEeldreeHltbONr2cKhG4AmubzYRyllG/bkdzUqXMik7lLTVETCVhiUHIFL8UboXFvpDFdrGJmI79cf0qaK6t5psohVgeBzWL8RLkzXdmjdY4QOO2STXRQV6iNqRx5GR+FMBw3NPpCRmvUvoWWLOTDBQcAkAiuu0OVYrjY7Dj8gPrXFKwByBW7ot1HHcxNMCYgRuC9cVz14cy0O7DTtJNHrWgxpFbr5IAU5Y4+tdLbOpYEkDHTNcPpOpI8irYT7rccFWBzj611tuUkwGIPf2rxa0Lan2NJxqU1Y3o40dM5B9B3qxbrGj4QYJ61mWot4i2ZNsh+6D3rSi2nAJ+Y9CK4prQ46l1dItblzh3A9z0qoD5kzMr5UcY7fWpHgE3yTqqRE4DN0zUEUsSTPFbLlU4LAcE1CjZGUUtbGpol+lncyNLwjJgE9mzT9d8UPAmbaMup5LDpjFYepbpLC5CZV2jOMHBzjjBryfQviBqOmakn2s/aIUyhic456V6uCqScHGPQ8rHUIKaqNbnaw6lZ6j4l17W7dZYUFnHbymUbWMnRj+Q61d0DV4zaoLSIx24YkhzwR61g+LtfhudLjuriFIk1Ng4txjJCjClh+NYp8ViBra2jQLDEgUr0ANdau9TjbivdZ69b3rXUYZcqpGCOo69qxNZ0aUymS2O1yDkf3hVDw/4lglhjCEBeT15zXSTarbC385mHTOQeKLPcj4XdbHn2tWl3bq0kYKLEOepP51zjaqZWEZdy2c5H06V3OpeJLJ5GUgLyQ2eAw96878VJDzdWGAhOWCjAFaQ0RM5dUXVWUqMSrj3AorlE1QhFyTnHrRWl2c1zt9LvnufBmmWdnGwkjRhI4/3jVC832jABHdwRliM81J4cup7DwxbyQhGd1YgAc9TUs8N5cRxvgK7kEgjtivPslJpHG2WdBsoDPuuxlpASc8iq2vWQtNSKr80JXgH866zw7a2VppNy2prunX7h6444/Ws7ampxMZItqqDg981nze8COd0mV0tJUAwrNwe+PrW/o3+if69hJGRyTWFDCzzvb+bsj3Zz0/Kt424js2j3hyF4Ydat7lp2KUd1Bd6yQq/uF/zzV28n+yylrNQ4B4wKxbbTXtN1wzEqzcgdQKvTX0UNmGtRvycNnn3pWtsPmclYqay13dwh53JXoQc4Fa2h6HA9mCzDcy5BOKhk1GK8tBBBHvbALVJ4YsbjUdS8hpHgSNc8n34FD0Q+VdDObS5G1OKGNApEm0kdK4r4l25tPFN1Af+WYUe3QV6kk8VjrKCZ9wil5Pqc15p8WZEm8Z3ssbbkkCMD/wHpW2EbdX5G0FY4zIpp5NKetJXrFDqs2jgDB59qqVJG5Qgipa0LpyszrtAuzHIvOBXpelXO6NXQCQDGRnmvHbGbawOePUda9E8OLJKoe3lRJwP48YI+leZiIa6n0eVYhqThuj0Rlljw01tJbowBAfnIx1HNaJuLWzeJw4uUKhsxZIB9K5XTYbiIYubyWcg/KGYkL7AZ4roNPhY/IZAIskqmAAprzpqKeh6VWm7JzZbG7UizSIYIzz5O7IB9asJbJFHtQAY6YAFEYEb7cZI7jHWre0cZ7/AIVyTkzklK2i2KghyjZ5Pb61yDfCI32oSanb6hH9nLmWWORSvlDqee5613m0KRn7p7g1h+OvEdzongbUILJTvncIJR/yzVvvHH04/GunLqijVcZbM4Mc5zheC1TPD/Hmqpe65mIlorUCGIfw7VPBA/WqWn6Vf6rA8ixPtzkNyAf8an8GaL/bviBI5sm3jy8p5HH1r2GVLaBVgt40WJAQqr6djivafurlR5ih7T3pHl2mWN3ZOFkLorDA9a6M3kphSJT8meR1JH0rR8QrFFFvkALHptHSuGvb6RJ9tsSd/O309aLdyZNQ0NnU1gK71JJBJ6c575rm5BNcSeRGu9CDkKTx+Nb1hbTzwpvO9W4Knr1rsNH0SK3tSzqA556Y49K0tYz5eZnl3/COznoSB2or2FLGAovGOKKu6J9kjzfwes09paIG+SInI9sniuj1zUFS8jVPlRVwAPWsP4fqkdg800gVMEjP1NR6tOJbxpU+cZI4rzp/E0ebc2xdtcr5ZkG8jGOhqnZapcWV29vIN6AgcfWse2kkN6zluRnA61vaRClwd8h/e9SWx61FtNSkZ2vXG6XES7QQTxwQfan6PdTwybd28OCOT0HSuml0GyntJLieTaTkAZ71yN2q2jMyuWRRgHr3qYyUti5RsdLJbQra77m6ARjjb/Sp7ixsILNYLVHZpsEk9q5HQblJ9Rglucvbqd2Ce/uK7u51GG4uXuBGEgiACk8c+tEovmSKi0otnPWELaVqUiCMlcZBPSoLfU7u91qaGAiIg4JHBNa2ralEIROHD5BJK9RXFTXuNQEsB2lySapIJ2Wxrar5tliaZ95LEH/GuF8XzCbWpGGT8ig5+groZbmW9d45DlFPHNchrrbtUm56YH6CunC6TCnN3sUDSUGkr0jZsWlBNNpaA5mW7SUg4JrqNEvpY5ovKIJBGd3Ix7VxqnacjtWxp8xQowPfIArmr0+ZHbhqzTTT2Pa9KuDPErE7SRmt61aF2WOZyFOclQSQcda4LwxrAuUETRYKjAIBFdeib4wUd4z/AHl4Irx6sEnqfaQkq1JSTN6OIQxYR2LdMsTn8akiv44Q39qSsW24TYpIz6Vm2ZFup8yQt35JJNW/tlncNCIZBIxUlgRyp9DXK42bOSpS1s9fM0YfmUsuQpwcE9PwrK8V6eNQ0i6tX5WSI4GeM4yD+YrUhlJ+XaoU9SOtSTrvhPHOOKwjJxkmczWtmeaeAbWPRfDbzz4FxdSHPHO0HAGPTiqmteIBbs6xnn1HXH0qx8QtSXTLhIQuxmTcgAwMe3415Rf30txLvkbJJzg19FR/eRUjxa16bcF0Ni+8QXM8jEuWVuAP7v1FJphluMvNKBk5U8CuckkJJbPJ70ov3RgUOFHynHWt/ZtrQ5HE9BtLoQSqruGC8khh+lbE3iqBERGk3EdRnvXk02pTONiO5Geajtmnu7pUClznBAz09arkaV2SpSWiPZU8VLsXC8YoriorOQRpkkHAopE8zKGk3hTQI1zgDP48mtfS3M9mCi5JP41yujTW50wpPJtdQcAn3zUeiazLZ6iNrboS3HbFc8qLlKTscPKdBqbSWN55hOEA6HrmrmlXsl1do0PyoBhs965fxDqwvNS3E7owedpxV7S74fZpWt22svHNTKlJQTaDlZ19xrggWWC4bMeBjnqa5qbU9zSRjlcZFc7d6k1wyb85DcnPanyzGS5MiHC7eD+FNYbltdamlm9zb8OXyRKXnIwGIx+NdFqGqB7Ty42+SQcjivMhM2/AYhSecVPdXkqSIqyHavStJYdt6CcTsYbhzbyW6fOAO9Q6dbMyO7fK4zjJ7VR8P6in2eVZF3TtkA4/kaJNQ8kMrttbHasJQd7JEWfUvxobW2a5n+6Wxx+Vcx4iKnVJGThWAIH4VduNaMlglrjcN+ST9aztZYPco/ZoxiujDwcZe8ty4qzuUKKKU12Gl7CUUClNAXAVYtJArAHpmq2TSqxU5HWla5pTnys7vwvqBilQKcEnBHYjNen6fdblUbuvQ14ZpdyUkRt2GB4NepeHLwSQIQwGOOeSTXl4mnZn1mU4hO9N7HdQvkDgEVNawRo7OqBSeTjHJrPtZABhuP1rRhOBlTx6V5c1qz06itsaULZAA6irInVUIbHsaoREHpwalbBIyM1zNLY4JQTZxvxX0U6hoIuoATPaHdgd07ivCZeTg+9fU9w0ckDxSKro4KsGGQR3FfOfjKwg07xDe29ojpbrJ8gfkgEDIz6Zr18sq3Tps8vH0uW1Q5pu47VEetWXhPUfjT7TTp7qdY4EeR26KgyT+leypI82+hBbW0l3cJDAheRyAAPXpXq1hoNr4Z0UyXPlvdsuXJI+X2rR8E+DBoNkNS1OOM3hQlUbGIx/jXBePdbF1dyQxvk5O4Dp1z+NZSlzOyIbsrkMviX96+0Lt3HHAorkufSitORGHMRU4sML6jvTaK1aONNj2ORmrNldG3Vl52t1qrg4ozjr09KhpNWZqpF26jRolkjHXr7VGLr/AEbygOSc5quspVSin5T1FMyc0lG2jG5DuhHfNKGG8bhx3poBzTtpxnNV0uQmzTtZQ1wPIO1QOc8c1ZmxIZC3LAdayUPkplgQ56VdsppLiQxsBtYYJ9KwnHXmRT7lBFeWQKil3z/CPep77eDGrg5VcZNdDo95Z2cEsUcO+4z944rD1WUuw3YLbiTjgAVUZ3nYd7meVOaUCmknGc0c4zmtSeo88DNIGycUzJoHBoHckpBSbqdwRQNaEls2xx+hrvPBt8QwQ4JA7158DXQeF7greIobqOgHeufERThc9TLqzjNHtti5IBTBz1JrXgc9CeK5nS5WaFWXIyBwex71sWAkDHzCT3GTXh1Ip3Z9tJc0bs3bflumRVsqMZXpVGDAG1uRV1MADA/CuOW559TcjZDgjgZ9emK8q+I3h25vdatpdPgkledNjBeQCOhNeuOAF3YPI9eKo+YkV4p6AjaTj8q2wlX2dVXOavD21KUbHm2jfC12ZX1S6CIc5jiHP4ntXoGl6TpOgWn+h20USqvMr8sT7ntT9S1a3tgxZ84AyWAArzDxl4xE6GO2kITkEHgmveu3oj51ppE3xJ8ahVNpp7hiT8xPI968fkcySMzHczHJNT3s7XEzOxzniq3eumnHlV2YTbGknPWinUU7sw5iKlHWkFB6gg1oc6FY4+lA6ZpDRSsDDAp7KBGrfxGmUOxOBngd6GUh6AEjmr+nqIZ1ecZVSDg9CKowqjOA52j1rQmibcqxyb17elRLsWm7Gh4itkkKXVug8oABgPStXSdMgn0tJoE2SN8prm7jUn+xNasvzeoPGPSuz8MSiWxhONiIuTn1rkqqUYInmsrGBFpMlvduud7tngfWszXoRDKinh+cj0rtrKaGG8numYbVBAJ6ZrhdeuBc6jI4bdk9R0xRQcpTuNO5QopppK7SRaDSUUALkYxTg2BTKM54oLUiTqK2fCsoTVYlY4zwD071ig4FS28xglSROGU5BFTOPNFo6MNV9nUTPoXTl/crtHbPFXo5grhmI44ya800PxSbmFEZyki94zgn611FpqTzjcQN3Uhs5x9a8OpQd9T76jiqdZKx3C3EcMayScrjJA5JHtU0GpW925e2DeUOBuGCeOa5u3uDIqhsECr0EyRjgdOgrldJJWe4pYdPU23ukClR37YrLmYyEc8A8nvUb3xIwDjPUf8A1qrrKZH2g8Z5zURp8uoQo8urPLvGGtTreXEEzljG5UDnGOxrhLmYyfNk5zyTXoHxS0eSHU1uYRvWUbWKkEZHSvOpAQxUjBHUGvocM4uKkfKYqnyVJRZGemaaKewOKYK6TgqDh0ooHSiixyFXcaTefaiirMkLuPrSbzRRQDAOT1xRuPTiiihghd5B7VNHcSJnaRxRRU9SiMyt5hY4JBrqbHV7hLFYkWMKVPODn+dFFZ1UmtSWZYvpmSSJiNjZyOaymJDYHaiirpJIIbCbz7UFzjtRRVDG7zRvNFFAC7jQHOe1FFAuovmH2pVkbI6UUUFR3Re0+6e3uRIgXdnvmu4i8U3cUKbbe0OVHJVv/iqKK5a0U3se9g6klsyzF421BVwtvZY/3G/+KpbjxzqSxEi3s8jH8L+v+9RRXPyRvsekq1S3xP7yg3j/AFZZyBDZf9+2/wDiqkX4kawto4W208N/e8psj/x6iiiUI9jGVerp7z+8yB461R7R4nis2RmLHMZ6+vWsG41R5gzvbW25ickKf8aKK6aaS0R5OMnJ1LtlSS9aTanlRKAOqg5/nUQlbd2oordHDJsaZGz1ooopkn//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Individuals stung by fire ants typically experience more than one sting because the ants can sting repeatedly. Most sting sites demonstrate sterile pustules (as shown in this picture) by 24 hours.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Vinson SB, Sorensen AA. Imported fire ants: Life history and impact. Texas Department of Agriculture 1986. Copyright &copy; 1986 Texas Department of Agriculture.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_52_19264=[""].join("\n");
var outline_f18_52_19264=null;
var title_f18_52_19265="Colonoscopy versus sigmoidoscopy PI";
var content_f18_52_19265=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F58734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F58734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Colonoscopy versus sigmoidoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 386px; height: 568px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAI4AYIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKCcUUyVtqZ9KGA7NG6qT3ajvURvF9azdRI0VNmjuFG8Vm/ax60fa6n2yH7JmnuFG4VnLdcUv2r3o9sg9kzQ3CjcKzvtVIbr3o9sg9kzR3CjcKzvtNIbo0vbIPZM0twpdwrM+00C5o9ug9kzT3CjcKzftNH2mn7ZB7JmluFG4Vm/aaDc+9L2yD2TNLcKTcKzTde9N+1Ue3Q/ZM1N4o3isl7vHeomvSD1pfWENUWbe8Uu4Vkx3e4dakNwfWn7ZE+yZpbhRms0XJ9acLn3p+2QezZoZo3Cs/7VSG6o9tEXs2aO4Um4Vmm6pPtVL26H7JmnuFLuFZX2r3pRdUe3Q/ZM1Nwo3Csz7V70favej26F7JmnuFJuFZv2r3o+1e9Ht0P2TNLeKNwrM+1UfajR7dB7Jmpuo3VmC6pftVHt4i9kzS3CjIrLN570jXwHen7eIeyZq7hRuFZJ1BQOTU1rdrLIqg8k01VTB0mtTRooorUyCiiigAooooAKiukL28ir94qcVLRQ1cE7Hn76g4kKsSCOCKliumPeo/FNobPVWcD93N84+vf/PvVSB+BXizcoycWe3GMZQUl1NhJie9TJL71nxPmrCNQpMylFF4PnvS7j61XRqlBqrkNWH7j60bjTaM07iHbjS7vemUtK4DsmjJpBRigB240bjTaKLgLuNGTSUUXACTSbqQ03NAxJGNVZXINTuaqTHmpbKii9aMWA5q72rPsOlaNbQ2Mp7kTUwk+tSMOaYRSYITJoyaTFFQULk0maKKACiiigApc0lFAC5NISaKQ0AGaXNMNJmi47EhamM9NLVGzd6VwsK8hA61UmnI706aTArOnl5PNRKRrCIs12wPBrb8J77i5aQ52oP1NcpIdzV33ha1+zaUjMMPKd5+natcKnOp6CxTUKfqbFFFFeueQFFFFABRRRQAUUUUAYHjK1M+liVR80Lbvw71xUEnavULiMTQvGwyGGK8oulNteTQnjY5X9a8zGwtJT7nqYGfNBw7GpFJV2N8isSCbpWhDJmuVM6JRNJWqaN81RR6mR6tMxaLoNIzqOpxUDSbVzVN3LNnNDkJQuaPnJnrUgIPQ1kS5jXc3SpracgjByppc3cpw0ujTFFIrAilzVmQUUmaM0ALRmm5ozQAGmGlJpDSGMfpVSYZNWpDVZzk0mXEtWQwBWgOlULY4Aq6pytaQZlPcUimMKeaQ9KtkohNNzTnqMmsmWh+aM0zNGaBkmaXNR5pwNFxWFpCwHU0E4FZt3IzE4NJuxUY8zLzTxr1YUqzI3QisVU8xiAee+aQM0M+wnqMgio5zT2aNs+1RMcUy1lLJg06QiquRazsN3UySTApjPVWaT3qWy1G4y4lwDWfJJmpLiTOapu1ZtnRGJc0yA3d9DCP42wfpXp0aCONUUYVRgCuC8Fx+ZrAJ/gQt/L/Gu/r0sDG0HLuebj5Xmo9goooruOEKKKKACiiigAooooAK818ZW/la5OQMCQBx+VelVxvj22/fW1wP4lKH8Of61yY2N6d+x2YGXLVt3ONikINaFvN71mSKQadDKRXkpnsyjc6CKQEdanV6x4Z6tpN71SkYSgaTsWj4qmxI4P50qTds1LuVxyBVbkJcpWfzXG0txVm1jbIA6U9AtTI4XpQkDkXIzhRTt1VhJQZKu5jylgtSbveqxk96UPRcOUnLUm6od1LnFO4WJs01nqMvUTPSuCQ92qHq1BOadEmTSL2LUQwBVpG4quOBT1OKtOxk9SxnmgtUWaUniruRYa5qImnOaiLVm2aJC5o3UwtTS1K47E28Uu8VX3Um+lcfKWd4IqjcockipQ9LvB60PUa0Mt0bdlSVPqKdDCd+4ks3rV9gh7Ugwo4AFRymnOPt18tOeppsslRPL71WklptkqN3cfJJVSV+tJJLVWWTNQ2bRiR3EnNV1bJofLNTkXFZs1Ssdd4CTNxdSeiKv5n/AOtXZ1zPgSILYXEndpMfkP8A69dNXt4SNqSPExcr1mFFFFdJzBRRRQAUUUUAFFFFABWD4yh8zSg4H+rcH8Dx/hW9VPWIvO0u5TGcxkj8OazrR5oNGlGXLUTPLZE5qu6EHIrRmSoQmRivAsfQplRXKnmp0nPrTZYT2quVYUXHZM0UuOasRz1jKzA1MkhFUmQ4m2k/vUom461ipMRUy3BqkzNwNcS+9OEvvWUs9SrLTuTymh5nvR5vvVISUu6i4uUvpMKeZRWeGNJvNO4uQuNL703zMmqw3Gp4ombrRe4rJE6HNWIzioo4sdalAqkQ9SUHNPFMQYqVRVEMM4pC9OxTWTNMRE7e9RMalkjOOKqyBlqGWhS3vTC9RsSajLGpbLsT76QyVDuOKaz0rjUSx5lN833qsX96YWPY0rlcpbM3pUUkx9ag+Y00oTRcaihXmqJnJp/l+tLsxU6lKyKrkmmFfWrZUCq8rAUrFJ9iPaBSAfNUZclqkSkWkeh+EYvL0SInq7M36/8A1q2ar6fD9nsbeHGNiKp+uKsV9BTjywUT56rLmm5BRRRVkBRRRQAUUUUAFFFFABSMoZSp6EYpaKAPMrmPZK6HqrFagVOa09ei8nVrpexfd+fP9azwea+fkuWTiz6CLvFNCNHmm/Zg3arirkU5Rg0uUHIomyHpTTZn0rWQCn7AavlJ9ozENoR2py2jVteWPSnLEPSjlF7Qx0tWFTpbmtQRj0pfLHpVKJDqMzxBT1t6vBBUip7U+UlzZSW2qVLQVcVKkC01ElzZWS1UdqmWIKOBUwWlK8VViOYrsuKYanccVXbrUspCq3NWV6VUT71W06URCQ6iiiqIGkZqJ4wanppFAyk8NRmCrpFMK1Nik2UzBTGtqvYpMUrIrmaM82ppPs9aBWkK+1LlQ+dlEQU4Q+1WTx2phfFFh8zZWkjx0qvIMCrM0lVJCWBqWXEqTTY4FV8M5yauC3yckUpQKDWbNk0iiEwavaXD59/bxf35FB+maqt14rc8IQ+ZrMTEcRqz/wBP61VOPNNRFUlywcjv6KKK+gPngooooAKKKKACiiigAooooAKKKKAON8YRbNSRx0kjH5jj/CsEjmus8ZxZhtpf7rFfz/8A1VzKqGFeJio2qs9vCzvSRJb8rVjy+KhiTaauoMiskXIriM1Kqmpwo71IsYrVamLkQqhNSLHU6pinhcVViHIgEdL5dWNtGKdieYgWOpVSngU8CmkJyGBKeEpwp4HFWkQ2MC0FafihhxVWFcqyCqzCrjiq7ispI1gyBfv1bTpVUH56tJ0qIlSHUUUoqiBKQ06koAaRTSKfiigCLbRsFSYoxSsO5EVphFTkU0qKLDuVyM0xo81aIxUb0rDuUniFRMgFWZSBVSR+uKiRrG7GNgCqUzEnFWXYkcVEEyeayN1oQCMnrXUeCIv391L2VQv5nP8ASuebArsvB0OzS2kxzLIT+A4rpwkb1V5HPi5WpPzN2iiivZPGCiiigAooooAKKKKACiiigAooooAyvE8XmaPKe6EN+tcRG2DXomoRedYXEY6tGQPyrzjHNeVj1aaZ6mBd4OJo2/zVbjXFZ1qxDYrTiORXLHU6JqxIFpwGDSrTyK1SMGwBp2ajxSimSSClFIOlKKpEscBTgKQU8VaRLEAqQUwU8VaJYYoPSlobpTEQOKrSCrUlVpKxmawKefnq7H92qTffq9F9wVnE0nsOpcUoFOArSxmNxTSKkxSEUNCuR0UppKkoMUmKWigBMUhpSaYaBiMwqrK5qwVqvItSy42KkhJNQMvc1acYqJqzaNU+xWcYqNjippOhqueazbNUNOTXouixeRpNqmMHywT9TzXA28XmzRxjq7BfzNelKoVQo6AYFd+Ajq5HDj5aRiLRRRXpnmhRRRQAUUUUAFFFFABRRRQAUUUUAFec3sXk308X91yP1r0auE8SR+VrU+OjYb9BXDj4+6md2Bl7zRXhHNXYjiqEDcitCMV5yO+RaU1IDUSjil5Fao5miWgCmhqcDVEi04U2nCmhMkWnimLUgrREMKUUUmcVWwhc0N0ppNBPFFwGPVaSrDVBJWUjSJTb79XIvuiqZ+/VyLpWcdzSWxMKcK89u/Fmsap8Rrzwn4aGn239m2yXF9e30Lz4LgFI0jV0zwQSxb149beqePI9CvLfSNQsbjU/EAsnvrm20hVZY4UJBkzKyYBxwuS2eOeCd1FmDkjuKaa8nm+JCXfjzwtNpuqBfCV9pN1f3G6JR/qg2SxI3KV2nIB7d62NM+Kui301kkllqllHqFvNdafLcxRhbxIgS2za5IOBkBwuRj1puDEpI7002vPfD3xa0TXLnw9HHYataxa95y2M9xFHsd4mKsh2uxByB2xyOeuPQqzlFx3NItPYKKKKkYmKQ06koAYwqvLxU7tjNU5260mUiCVhUBbmklJJpig5rKTN4oSQ8VFUrioTxWbNUX9DTzNXtFH9/d+XP9K9Ari/CEXmaoZMcRxk59zx/jXaV6uBjanfueZjneol2QUUUV2nEFFFFABRRRQAUUUUAFFFFABRRRQAVyHjOLbeQyD+NMfkf/r119c740jzZwSd1cj8x/8AWrmxcb0mdOElaqjmbc5rUhHArItzg1rW5yBXlRPTqFpKfjIpi1IK1RzsbtpRxT8UmKYhaUUlKKBEi1KtRLUq1rEzY6mNT6jaqYkNJpM8UtJUFCNVeU1O3Sq0p61Ei4lf+OrkXQVTH36txfdFREuZyWpeC7lfGsninw5qsWnajc24tryK5tTcwXKr91iodGDDAGQ3QYx1zQ1T4eX9zrsevWXiFYdck019MvJ5rESRzRsd25Y1dNjKcY5PAGc8k+hLT63U2YOKPLLT4NaZavokMd/KdN0/S7rTJIGj+ecXG7e+/PynLscbTTdO+EzxNoq6prgvbfQ7S4tNMRLPymQSqV3SnefMIXAGAg4zXXah/wAlM0H/ALBGo/8Ao6yrpWqnOVtxKKPJ9D+Ef9lW3gWL+2/N/wCEYnuZs/ZNv2nzn3Y++dmOn8WfavVKU0lZSk5bmkYpbBRRQSACScAdakYhqN2A6nFZs15LdSGO2OyMdX7mqV1bKMl3Zm9Sc1ag2rnTDDt/E7G0xz3qvIM1kRSvbNlCQO4J61abVYlTMkb/APAeahxZToSXw6kjJyaiPBpItRtrg7UYq3owxTm61lIXLKLtJETdahkNTP0qs/WspGsTqPBCfNdv7KP511Vc74KXFjO3rJj8gK6KvawitSieNi3erIKKKK6DnCiiigAooooAKKKKACiiigAooooAKyfFMe/RpT3Qhh+f/wBetaqOuJv0i7H/AEzJ/Lms6qvCS8jSk7Ti/M8/h61p2zcCsyH71aVsK8OJ7VQ0IzUq1DHUy1tE5pDqKjlnii/1kiJ9WxWRqOrMf3diRnu/+FUOFKU3ZG2TjrQpB6EGuRyzHdMWdu5JzV1LdSgeJijeoOKtQbN3hUt2dIpqRTXP2eqGKXyrtgV7Sen1rbVwQCCCD0NCdjmqUpQdmT7qaTTN1JmnzGVh1GabmkzSuMGPFVpOtTsagYVEmXEiVfmq2nSolFSikkOTHg08GoxTgatEHN6h/wAlL0H/ALBGo/8Ao6yrpGrmtQ/5KXoP/YI1H/0dZV0rVUtkShppKrXd7DbHa5LP/dUZNUZNZMa7jbNt/wB7/wCtUWN40pyV0i/d3cVsPnJLHoo6msPVdRuni+SIJEfvAckinWt0k7Pcy8lug9PanSo87ksdq+g61ahdXOunSjTfvLUoWF+G4iOW9B1q5I+E3yNz/L2FM22trkyMkQPX1P171mTX8d1O/ktmKM7R/jTvyrU3tzvRGnBF5x+bgZ6VYubaJYj0rJS+CdD0pLjUtyEdKanGw/Zyb0M+8GyUleD7VsabcGeEbjllrnJpzI571q6NlJMHqw6VzPW5tXheGprOeKrt96p5Pu1XPWsJHDA7fwcuNJJ/vSE/yrcrH8J8aLH7s3862K9zD/wo+h4mId6svUKKKK2MQooooAKKKKACiiigAooooAKKKKACq+ojdYXI9Y2H6VYqO6XfbSr6oR+lKWqY4uzR5pCfmrVteayITzWvZ9BXgRPdqFxpEijZ5GCooySe1YNxqs16xW2ZoYOmRwzf4VJ4imBEVvnhvmYe3aspJkiwOAK2iu5tQoq3O1qa1nZKeSSSepNWbiwjCZ4rPh1JUHBqjqmu+XGTn9a6OeEUX7OpKWhZMv2aYLIcpnr3FW57dzGxhkKEjIHUGvK7zxJPqBlmhvIbLTYzta9m5DHuI1/i+p49u9Z48b2Ukf7vX/EMiLwZ0iHlj/x3FaU6MpK70OWvjKdOVo6vr2PT7Wy81ibqRmb0PAH4VqG1mjgAt7qVFXoFcgCvLdN8ZXpYHT9YsdYi7w3aCCX8GUY/MV0EPjWzdPLvGk0m5PHl3fEbf7sn3T+JBpOi4LVXLhjIVna9vU62x8QPbXK29+4dCceZ3X6+tb51KzBwbmL/AL6rh9LgjmUXDnzd/O9fmB+hFbyJZPFtKLmsIxbNa1Cm3dfgdHHIkiho3V19VORS5rhWvpNOvcWW45PKdiPetk6nqFwuYIkjH0yaWr0OeeDlHVPQ6A0wiudbW7yy5vokdPVeDViXVJbzaunDapGS7Dn8qVm3Yn6tNenc2wKeK5ub+0LdN5u2JHOODUFrrV1fR+W22PaxDOvBb/CnytOzH9Vk9U9DqWkRPvuq/U4pJLiKOMyPIoQd81z0scCplm3N3JNYSHN/JjJUYwKclylwwal1Lmoak0nxG0NrePONK1AAv3zNZ/4VqahrF7axlvLhP4H/ABqvEuZUmECeailFkYAFVOCQD1wdq/kPSkuoXuAVkkGPRRmrautC4UYRlqtB9jKGDTSnc5OST3qSd2mQghVU+vX8qxNS1jSPDdtu1XUYISo4jZt0jf7qDk/gK4jWPiXe3CkeHdMEMX/P3qHyjHqEB/mR9K0hCTVrCq16dN3bPTbC0EIZi/7tctluAorl9c+ImjWUjwWs0l7MDjyLIeYxP+033R+deTX2r3/iCYw3N3qXiCbOTbWwIgU+6rx+JrZ0PwrrN0im6nttGtf+eNqgeXHoW6A/nWjpwpr3mcyxFWu37KN/M073xzrNypK2unaJan/lrcv50n4DgD8jXOP4jhluWf8A4SPWLuY8N9htFVR+Qr0Gw8J+GrJVeWwF9OOTLesZiT9D8v5Cr806AeXbxJFEOAqKFA/AVEq9OPwxubU8Fiaj9+dvQ85t/ETLIEtvEl3FOekGq2gCt/wIAEV02g6+17ctY6qsVnequ9SHzFMvqjf0q9r9vaTaDdJqEMcySLtRHGcuemPcdcivL7zS7vRbuLSNRdzDcJ52n3LdUcfw59vT0I9aUeSurWswn7fAtT5uaJ6vJf28bFLEC8uP9n7i/U1Y0aSa1uvNu3Jd2yw7Cn/D+9s9U8ORXP2eOC5QmGeMD7si9fwPBHsaNQbM52+tcs4OG56lOpGstNmdVJ0quetFm5ksYWbrt5pSOa5pHnpWbR3fhT/kCQ/7zfzNa9Y/hP8A5Asf+83862K92h/Dj6I8Kv8AxJeoUUUVqZBRRRQAUUUUAFFFFABRRRQAUUUUAFMmOIZD/sn+VPqK8OLSc/7DfypPYa3PMoeta9p90VlQjmta1+7XgRPdqGL4j+XVLdj91o8fqawtXmWCVC/ywsMb+wPvWt4xn3ywRQYM0WSfx7Vz0klxLCY54GZT1GM1pfSx6eGi+SLY4zvGcA5B6GuN8a37XN5a6THIVEw865IONsI6j8Tx+ddfFot5BZCSzcPnJEEvOPYHtXkuvzzXEWuant2TzzCwhQHOApwQD7kE/jW+Gpc07y2RzZjiFTouMHq9DoPCum2/jTXP7S1KJf7BsD5NpZn7sjDqWHcD9T+OfbYL+GK3WGJUSNRtVVGAB6AV5voNl/Y2k2ljFjbDGFyO57n8Tk1rR3T0p4pyk+xVHARp00uvUTxfoGg6ujm606ETt/y3hXy5c+u4cn8c1xp8E+JLGIpo13FqVk3W0vj8wHscYP6V2iSM8uX5C811OjsoVSaqlWnfcnE4Ok46rXueCO0nhm7LTwat4WvWb76AtbSt+qsPzrrdE8day0WbqCy1q3A/11lJ5Uw9yp4J/KvYr+eGa2aGaNJI2GGVxkEe4ryjX/BGg3OoBtOgk024Jy0llIY//Hfu/pXTOrD7aPPp4SvH+FL7yzpvjvw698yXl1NYTt/DeQMmPqwyv613OmaxZ36Z0zUrO6X/AKYSK/8AI150fh5rrQZ0/WLa8GMbNQtsn/vtef0rldV8Fa5ZlmvvCVhdqOstlchT9QDg/pRGnTteLsOWIxCdpwv6HteqQTXkibiu1Tk9angRolAD4/3Vr56ge/syFis/GNggOCLaaRlH5cVafXruHH/E/wDGMA9JEc/zpKgm7pjePaXLKDR9ASpJKpBlfn/ZqtbacYARuOCSfSvBj4qlXIbxD4rkGOgTafzqqdQu9UkIEfjXUkPRDJIR+Qp+w7sX9oaWjFn0RN9jtoi9zcW0SDq0j/1Nc9f+PPCOlbt+s2s0o/gtAZmPt8gI/M15HbeENWvH8yDwReOT/HqFyE/PcQa1LHwdrjXPlSx6LpYI58uMzMv8h+tDhCHxMSr16ulOB1N/8UWlVj4f0K6nAH+uu2WJfr3P8q4LXPG+vX7eXf6+tmHOPsulqd59t3LZ+hrvtM+F2nXLCTW9V1DUAP8AlkHEMf5Lz+tdrpuhaHoMPl6PplraccuifOfqx5P4mnzU0rrUn2OIqO03Y8O0fw/q15kaVogtHflrzVGw5z/Fjlv0ru/Dvwv093W48UX02qyjnyFJihB+gOT+YHtXS3cmL0MOjcVNDdmPIrF4mTZ2Ry2nFX3ZrRW1jptmLbT7aC1tlHEUKBFH4CufuEVrgmH+I8j1qS7vXfhc1b0LT5Lq5VnBCDlj6VhOXOzshFUI8zM+SxuRwyMM9Misu7vrOwfbNL50/aKL5jn39K9cXAAA6V5zdWNhea/dyQ26oDIQdvG49z+NRy32POr53Rwsb19L7W1uc/DHPqd7HPe4VQf3UCnO3/69SfFnR3vvB880Kn7Vpu27jI7bPvf+O7vyFd1Do8FrEskUaq/UNjmpJ4UuonhmUNHMhR19QRgit6cXB3PDxfEyqrkhT083/X5njPgTUymsNHFuMOp263CAf89F4b8wR/3zXbYd51VlZSTjkV5L4akbSdT0gO37zT9VNk5/2Wby2/QmvZ9ci8tSw6rzV4mneXN3FUz+tl6jCMFKPzudEsYihSMdFAFQt96m6ZcG702GVvvEYP1FPfrXnTVme7h6qrQVWO0lf7zuPCRzoyD0dh+tbNYng850j/to1bde3h/4UfQ8jEfxZeoUUUVsYhRRRQAUUUUAFFFFABRRRQAUUUUAFQX5xYXJ9I2P6VPVPWG2aVdn/pkw/Spm7RbKgrySPO4vvVrWv3RWTH96ta26CvAie7UOLvZd+tXDMc5kI+nNa0aJ5e4Y5FY3iGJrPW5sj5HPmKfr/wDXzSR6lhMZrWE0tz1OTnhFx7GhNeizsr6c8rbxNNj/AHRk14noentqDeELG6JIurh7qTP8WAWyfyr0fxNdH/hF9cK87rCdSPqhFchoTqniTQItuGtNOdx7Zwv9a7aMv3UpHlYyDeJpwOm1bTb7RW3WUxlt/wC4/OK2PB9pN4is5pgqQtC4RgSeeM8VDd3jTjax4xiu88HaYNM0ZF2gSTN5z49wMfoBXCrN6HpYqrKjTvfU5zVtBuLCITcMhODt5x9aq2V8YvlY4NekOqyIVcBlPBB71zuo+GIpWLWrhM/wt0/Or5bao5qONjJctUwpdQLKcNmsqOTN3uJ5JroR4Wugf+WeP96srW9FudMCTPtaNjj5TnH1qXzbs7KVSi3yxe5v2WoiGIAYqnqt55iNisOG7+TrSSzl+PWrdVtWEsOlK5Y0mXa45966ePUCqAZrjI/Miw+DjpnHWrYv/lwQc0Qqco6tHndzS1i8LRsAetQ6POIkQf7IrNZ3nOACc8Voy6TfWlskjxMBjqOcfX0pczbuDjGMVBvc2pb0eV15rmL2Q/a/M96eZJz8uDVvTdFu7+YMUKx93boP8aJScxRjCim5MiiupIR3wehFEl9I/Cgk12cehWKQLGYt2OrZOTT4tHsYzlYAT7kmnqcn12lvY42wsJ76YDYTnv6V0Z8NxFVzO27HJ21uxxpGoWNVVR2AxSmhKxzVcbOb93RGLB4etYjl2ZyPwrUiijhQJEoVR2FSmmMaDCVSc/iY9a87lB07W7mGTj94WUnuCcg16ChrkfGwtrq4igjUi8QAmQdlPY/zqos8HPaKnQU72cX9/kWzqSyQKuRxUlm4d4znjcRXMwaTNtBNxIOK6G1ASKJVGCnyn/Gtbs+WjKTd5Hzv40jax1vxUkfDQXqXAx2JCtn9a9fvb1biNjvBDDI5rzT4sREeM/FCquBLbQyHA6kIBn9K77TLIN4f06cov7y1jc8eqA1tX+GLPQzNN0aTXb/I63QU26TF75IqaXrWd4a1AzRNZSDDwrlSO61oz9a8yotT7HKakJ4Wn7N3SVvuOy8FnOlOPSU/yFb9c14GfNlcp6SA/mP/AK1dLXsYZ3pROXEq1WQUUUVuYBRRRQAUUUUAFFFFABRRRQAUUUUAFZniV9mi3PuAPzIrTrC8ZSbNKVf78gH6E1lXdqcn5GtBXqRXmcdCPmFatuOBWXb8uK1oOgrxInszON8RzpqOpmIjiL5VIqsmi7hkSPUYYx6rPvGMOQc/WuksrmIRkHGa1pxjLc9RydKKUDjfGFp/Z/gzWyDvaS1ZOewNYnhGGM+NXDhXA0NVIPvJH/hXQ/FCcHwXq+3k+T/UVz3g0g+L7oqORoiMT/20Su6kkqUkjycS28VTbO7OmQLEXjQDFbnhC+ae3ltpDl4DwT/dNZX2lfs+M9qPBzN/bc+PutGc/mK45WVrHfWi50pc3Q7cUtIKWmeMFMngjuImimQPG3BUipBT1FNIL21Ry9x4OtZJC0MzxA9iN2KltfCVpE4aaWSUD+HG0GumAp4FUqaNnja1rcxnXOmWtxbLA8KiNfuhRjb9KyD4TtS2RLIB9BXUFaTbTcEZwxNSGkWY9jolhp7CQKXkHRn7fStFZoGOAwz9az9WtpZ5QNzeUoyQD1rPMFuF/dIwf2zmobt0Kd6nvSd2b5t4CdwijJ9doqTbVbTI5kgUTkk9s9RV3FWlcxk7O1yIrTCKnIqNhSaBMjpDTiKaahlIaTULtUjcVXkPNS2WkSxnmuF1FiPFN4JTzuHX0wMfpXbxHmuU8bafLHcJqdsuVChZQO2Oh/pVQep4+e0ZVMPzR+y7mh5kYtwOM0yMjLfgf8/nXL215d3AHlQk+7HArc0rzi7i5AVtvygc555/pW17nyXtedrQ8j+LSFPH94vAW50tH+uC4/pXb+GLxZ/A+iEn5hZRKfqEA/pXKfGiIDxdpEneWxlj/Js/+zVf8BrPN4H0tkI2iNlA+jEf0rep/DR6WNb+qQaOk8O5OvLt6bG3fTH+OK6i4HNY3g6OMPcl/wDj5GB/wH/9dbtwK82rqz6Lh2HJhE77tv8AT9Dd8CyYlu4/UK38/wDGuurifBb7dVkX+9Ef0Irtq9LBO9JG+NVqrCiiius5AooooAKKKKACiiigAooooAKKKKACuZ8byAQWsfcsW/If/Xrpq4vxlKH1OOMf8s4xn6k//qrlxkrUn5nVg43qryMi1GWrVh7VnWo5rRh6ivJienM4/wAY2xt9SSWABjMNxUHofX8f8azYk1AgFYuPrWnfsbrXp2kOQr7B7AcV0VrFCIR0raFPnZ6SqulTinqzzLx7Fet4M1cyxbVEDEnNZPw3Yf8ACeATMNs2hFT+Dx13XxMKjwRrm3oLST/0GvMfA1xjxzpXPEumPHn8VP8ASu2lHlpyR5eKnz4im9j0WSz1BmIiUGMHg56it3wY8NtNLFcnbeSHAz0IHYe9a9p5YtscVzGufubtJ4TtZGDAiuSVPlXNc9JzddOm9D0IUtQ2U32i0hmH/LRA35ipqDxWrOw5alUVGtSrVxIY4U6milrREC0EUZopiExTRGgOQoz9KfmlpWC4mKMUtBp2C401GwqQ0w1LKREwqNqlao2rJloieqspqy9VJTzWbNojojWZ4vuXg0UqnWZxGT7cn+laMZqn4ktjdaNMF+/HiQfh1/TNEXqcuYRlLDzUN7MxtGtPMjXBwMZrR2BZE55Bx+dY2mXwEQCNzirqTksg6sXA/Wuq6sfBxnHlS6nnHxqhY654YkYfIyXMf4/JWj8LUU/DqyB+9HJOn/kV/wDGmfHJAp8MyDqt5In5p/8AWrO+G1+IvC0kJOPLu5hj/gWf61tL+Ej1KzSwUb9/8zrdJkMOvQYPEmUI9c11lwK5Lw1Gb3W1kH3IVLk/yrsZxxXn1T2OG1JYdt7N6E/hVtmuRD+8GH6Z/pXeV53oreXrVoc4/eAfnxXolduAf7trzPRx699PyCiiiu44QooooAKKKKACiiigAooooAKKKKACvP8AXnMus3THs+38hivQCcAk15tM/m3Usn99y35muDHv3UjvwC95smtxgVfg7VSh4FXYK8+O52TOL15TY6xMx+UO29T6g802LWtqgcn6VoarKurXwXCmOM4TI/WrX9jrEgJAraMJPWJ6cZxUIqotTk/E9y+p+HdWtYo2ZpLOZcY/2DXlngKQyeKfCrKfmkimh/Hymx+oFe6Twxp8mMBhtOPSvnXw5M9je+HN7bXttSFuxHbLbT/M12UF7kkzzMe0qtOUdP8Ahz3Ua28IMciMrDjkVRmvnvbhIl5LsFA9Sa6q3sI5ofnUGqN9psMILKoB7VxyhO2568KtNPRanbWEH2ayghzkxoFJ+gqeud8Iag9xFLazMWeLlSf7vp+FdFQjxK0HCbjLcetSrUS1KtaxOdjhSikFOFWSFFFFMQUooFKKACilxSGmIY1MNSGmMKhlIiNRNUzVC9ZSNEQvVSWrUhqrJ3rJm8RsZ5qLW5/s+i3kncRED8eP60+PrTNWtmvNJuoEGXdDtHqRyP5Uo7meKUnSlyb2dvuOE0vT2l2skjKT6GtyKxltpUm8xmaM7gD0NUfD9ysezd1HBBrpJrhJMFRXUkj85pwjy36nnPxw+az8OuvK/wBoAA/WNsfyqh8LrCOfRNRZ1BKahKv6Kf61rfGPb/YOgMRwNVh/9FyiqXwsnWLSNcT01SXH/fEddD1pHrySlglfubVpctpWqROhxEW2uPVTXbzHivO9TbzZ1VOWZuAK9AcEIAeoGK8+qejwzUk41KfRWt87/wCRWjl8q5jkH8DhvyOa9PHIrymc4zXp2nSebYW0n9+JW/MV05e9ZI9zHrSLLFFFFekeaFFFFABRRRQAUUUUAFFFFABRRRQBBfSeVZTyf3Y2P6V5zCOa73X32aPdH1Xb+dcLAK8vHv30j08CvcbLUdWHz9nk2/e2HH5VAnarUdckTok7HE6fceXKT3zXQPqQaIAkVz/iCyls9UZbVC0b/OMfw57VXjhv2/5Z4+prWFSUdD1nCFVKdzQu7jdMoXua8B8ZxnStY8QwRqN1tqf2lB6BjvH8xXvWlWU73oNyuxE+Y5Oc47V5D8W7Iw+NNTVl4v7CO4Huy5T/ANlFdeFbu79TzM0iuRW6HtNnqYNpG6HhlBqtfX3mocGud8F2s+reFNJvI5z+8tUDY/vAbW/UGrd3p9xAxDStiuWbmtLHp0Y05pST3Ok8Eqx1CdwflEeD+JH+FdnWD4NW2Gkg24PmZxKT1Lf4VvUR2PJxcuaqxy9alWoRUqGtInIyUUtIKWtCBaTFFKKYgpc0U2mA/NIabmjNK4WENMNPNRtUsaGtUD1KxqCQ1lJmsUQSGq7mppDVdjzWLN4iL1qzHVZetWY6S3HLY4HWYFh125+xHcpfLLnox64/GnwTXYO0QOfqRUNr8+oTtNw5kbOfXNdAUiUKVYE11RWh+bVI+1qTmtNWcV8ZAP8AhEtAKHOdUhJP/AJM1j/DaKVrDXBGBt/tOTqe+xK2Pi/geF9GXOAdUix/3zKab8JYVk0TV5Sfv6lKf/HUH9K6d6R6co82Bsu5raLBFFrUT33b7mOgbsTXaTLXE6vhJQVOCDXX2cpm0+3kblmQZPvXn1l1PQ4ar/HQttqUrxeDXoPhmTzdBsm9I9v5cf0rgrrBrs/BTZ0GNf7rsv65/rWmAf7xryPoscv3SfmbtFFFeueSFFFFABRRRQAUUUUAFFFFABRRRQBj+K226O4z95lH61x8IrpvGcmLS3j/ALzk/kP/AK9c3F0rx8a71bHrYNWpFhKsKQoyegGTVdKlcFoXUdSpA/KsImsjmrOU3l3JJJzubP0roPsqLECBXMaa4ikP1rf+2ApgniuqnJJandWTTSjsRFAt0hHc4ry/44WIGr+Hb/gI5ls5D9QGX+TV6Ysvm3cYTkA5rjvjjZef4Ga7XPmafcxXIx6Z2H9Hz+Fa0Ze8ceLjem0R/Aa6UeDZLWZv+PO8mgA9BkP/AOzmun1+eNmISvJ/hPfyQ6vrllGGYSiO6QD3BDf+y13dy07y4kVlHuKjET5ZOJ05fDmpxnc6PwEzCe7T+AgN+IP/ANeusmuYITiWVEPoTzXnfh28k+1zxQylI8AHbwT+NdRDDbKuX5Y9c1nTjdCxVFSquTNZdTtCcCdfyNXYpFdQyMGU9wc1glbYjhaLdGhcvbMV9R2NW4WOaVCNtGdKrU4GqNpcecnIww6iranimmcUouLsyUUopgNOBqkyRxppoJpM02xCmm5pSaYTSbGhWNRMaGNMJrNstIRjUMhqUmoJDWcjSKIJDUDdaleoz1rM2Qi9asx1AKr61cvaaPczRHEirhT6EkDP60LcitUVKDnLZK/3HJeJY44Nak+yOJN/zOq/wN3FFrM6lRIsmTwBjqal0e2jdQ0hySckmtC6iVXCxc/MMfnXSlofnNZ+1nKrFWTexwXxmkMb+FdPc/O9xJO2DwNigf8As9TfDGQweEFcdZ7meX/yIR/7LXLfGDVPtHjWdlcGPSrMR8dpXyx/QrXcaBo/9n+F9NhG5Jlt0L/75GW4+pNdE/dppHo4u9PBwjHrqF67XE6qoyc13ltD9nsYIj1VAD9a53wtBFcXshmx5kIDKPX3rqJzxXn1XfQ9ThvCuMZYiX2tF+pm3R6113gVs6TMv92dv5CuQue9dV4C/wCPK7H/AE1H/oIqsE/3p9HjNaLOoooor2jxgooooAKKKKACiiigAooooAKKKKAOS8aPm7tY/wC6hb8z/wDWrHi6Vf8AFr7taA/uxqP5n+tUY+leFiHerI9ugrUokqVZjqqp5qxGamLHJHK+I7SSwvBcQA+VMeg7N3FMsree4ALuQD2FX/Ft0FNtb+uXP8h/Wm6LMoHJrSEU2d8JSdFSa1LtrCLLDEZ7EmofFenjV/DGrWHBNxbSRr7MV+U/niptRuFaMhaS2m8yIrn78eB9a6F7rsjCUHNXZ5h8N/BE2jX2kau+tRXd5c2pjurGKE/6PGV3De+eGDBVwQDycdDXdawmM4HIrVtLpfI69OKy9SkD7jU1Pe1bHhKLo+6c7FMY7nzIlxKvJA/iFdTaWmpX0SyRqUQjgtxXJSHbeoy+tesWEvnWNvITyyAn64rGDOjG1HSScVuc6dF1KMhhKjY7A1oacJBlJlIcdQRW1mk2qTkgZ9a0TPNliZSVpIZDEF5xzVhTSClHFM5W77klKDjvUTuFGTXM6h4oiikaOzQ3DjgsDhfz71Zy4jE08Or1HY6vcKAa4B/EOqyNlViQegXP86fD4n1KF/3sMUq98AqaLnnrOcPe2v3HeGmk1gWHimyuCqXG62kPHz/d/P8AxxW7uDKCpBBGQRSZ6VCvTrq9N3GMaQ0Gmk1mzpQjHioJDUjmoW5NRJmkURtUZqVhUTVBohRWL4ovEexlsYQXnkxnHRcEHn8qt6lqEdrZyukiGUDCgEE5+lZeixRhPMY7mY5JPOa0pxvqeDnOYezj9Xp7yWvktjFtTeWi/PHlB1xV+fUoLPT59SuDi1tY2mkPsozj6noBW5OqMwEYyTxivIvi54ktryZdAtJB9hsH87UHU/K8g+7F74PJ9wO4rqhBylY+aw2EdWooX0OT8OWs/ifxRaxXg3veTnUL49ggOdv0PC/jXuuoyr5Rx1rzj4fW0ml2Umq30DRz6iA6gjlIh9we2eT+IrqLu9DrlTxinWnd2XQrMcUp1HCOy0LfhlyNeXaTgqwP0xXZTHiua8H2T5e9kXAIKpnv6mujlNcNR6n0/DtKdPCXl9p3XpoZ9zXU+Av+Pa7/AN8fyrk7lua6vwF/x7XZ/wBsD9KrB/xkezi/4LOqooor2zxgooooAKKKKACiiigAooooAKKKKAOC8StnXrj22j/x0VXQ5FWfF0LRa0z/AMMihgf0/pWdFJXgV9Ksr9z3aWtKNuxbBqZGqqGqRHqEymjnfGUbC7gmH3fL2/kT/jWdp9ztxzXV6vafbrMqP9YvK+/tXCTpJazFWBABrVO2p6OGkp0+XqjflvAy4JqKyvzGGQnkHI+lYpu+OtRyT7sFTgiq9p1NvYq1jblvPKmO3hX5/GqN5eE55qsLpZY9snBqrIrvwmWFTKV9io00txYGM16g969bsVMNlBGeqoAfyrh/B2hvLcfarlCIk6ZHU+ld2TzRHRHm5hUUpKC6EoalDVCDS5q7nnWLAanbuKrA1W1W9+xabcXAI3Ih25/vdB+uKpMzqNQi5PZGJ4m1J7mZ9Pt2IRf9cwPU/wB3/GqlhpwCDIxVXSo948xySzcknqTWzFJtOK2ij4atXeKqupMkXTkxUM1gqnkVeWcBetAlWRsH9at2Bxg1oYVzpyv0qTS7zUdNVkjCyQ9o3J4+npV++uLKzb/Srq3hzziWRUP6ms+PWtKeUeXqNlJ7LOp/rU8oU1OlLnptpmhH4lmSTF3Z7U/vRtkj8DW5b3kFzD5sMilO/bH1rnbt4plBjUEYzkVm2NirTSSuuSzYA9qiUOx6FHN69GVp++vuO1WRJM+W6tj+6c02RkjQvIyoo6ljgCufnsREokiJjkHIZTg1RDz6hIBeSGQRnCjoPr9azdN3O7+3lGLUoe9010OljvLadtsE8UjeisCaw9Vunu52toWKxKcMQfvH/Co7uwiRNwUBuxHUVQ0n93LJG5OVOefSmqaT1OHF5xVr0/ZNct97duxbfSFWAPmoNOiniuvJhRnVsnA7e9axLPGSzhIVGWdjgAetebeLviFtM9h4Slj+X5bjVXwUT1WPsx9+n16jeNPneh59LCuvJKCNb4g+MF0Qf2Rpbq+tzofMkBBWzQj77f7XoPxPbPn3w+8Lx+JdQ8yRHOgWMm53fk3k2c4J7jufy71T8O6HJ4lv1c+dFpDSE3N45PmXbZyQD15PU/1r2iA22m2MVpZRJBbRLtSNBgKK1lJUlyx3O2tXp4OHsab97qyDWnjbOQMdMU/wzoltfWv2mZ2KrIR5Y4HHv+NYmqXO9iFNdr4UtmtdFiD8NITJg+/SuOcrIwybDxxWKtUjeKVzT2rGgSNQqKMADoKgmPy1O/Sqk57CuWTPv4JLRFGbkmuy8CJjTJ2/vS/0FcbIK7zwcmzREP8Aedj+tdGBV6tzLHO1Kxt0UUV7J44UUUUAFFFFABRRRQAUUUUAFFFBoA4fx3cA6hBCvVI8n8T/APWrm1kYGr2qzfbdVuZjyC5A+g4FQCKvnq8ueo5I+gox5KaiOin7GrUbg96qiHmnKjL0rNXKdjQRqqanpkN+hJ+WXH3vX60qSFetWY5AauMiU3B80Tir3w9dQ5KozD1XkVnjSr1jhYXJ9lNelg1IrVejOlY6aWqPP7TwvqM/LR+WP9s4roIPDX2G08zzPNmX5mXHGPQe9dIGpwarSSMJ42rJmHolw0F6bVj+6mXzI/YjqPy/lW61c4w8u60xl6iZk/DmuhJpy0ZOIS5k11FBpwqPNPU0kznaFrl/HNzths7QHmaQsfov/wBcj8q6muC8cSf8VLYxnosG782P+FXDc8rOKjhhJ266fiW9O+WMA1bLYPNQWOGhGKmki3A5rU+IV0iN7pVB3sFVeSScACvN/E3jg3Vs8ttdyWGjAlRcR8TXRH9zP3F9+p9q0viHcS2umLp/P/EwkFuH9EPL/wDjoI/GuP8AB2n23iTxHPc3sYfStKAjghP3Hk7ZHcADOPUiuikko88j1cFCEKUsRVWi2GaTpWtazCbzSPDtqkEh4udSYNJL75bJP1xVi48J+LNh36Fo90B/AjRgn6ZxXqlrfFlTpgitmJ4JIcscNVKtJmkcyqS1SVj50nvL3w3N/pNhq/h+TOA0e5Ym/DlW/Wun0P4m6hDtSU2mrQ/3gfImH/sp/IV6/I37tkPzI3BU8gj6VymsfD7w7rTmR9PW3nPPm2n7pvxxwfxBo9pGXxIr63SraVYfNDLT4j6Jc4W9mn09jx/pMLYH/AlBX9a39M1PQblA+n65ZTluW2zoefpnIrzi++Ft9Zqx0fXWYDpDexZB+rL/APE1y83hHxEJJEfQNPvXXqYpEX8fmxS5Kb6k/V8JN6Tt6/0j3m91PSbeIPeaxZwx/wB6SdFH6muU1D4ieFbKWT+zRNq14BwLdCVJ93OFx7jNea2fgPxLIv7vw1YwE/xSzxnH5E1sR/DfVDATrGrxQIBzBYp19txx/Kjkpx1bKeHwtL3pzuYfizxdq/iu6WzvHYW7t+70qwy24/7ZHLfy9hXS+Ffhnd6iIpvEp+z2UZzHpsTDLf8AXRh/IfmK7Hwfo+j6Hp4/sy0SKRxiSU/NI592PP4dK2X1DYrBTik6ytaOiM55jHl5aS5V+JT1CKGC2SGBFjjjUKqKMBQOgArEM7t8u4nHFTanfF8ovJNdb4V0dLTT0mvIVNzIdw3DJQdvxrllJLU4sHgp4+q4Q0XVmP4f8PvcyJdXqlYAchW6v/8AWrsi2BgdBSySVUlmxnmuac7n3OX5fTwVPkhu933JJH4NVJHGaY0rOcCm+Wx5NZN3PTUbDJORkV3nhBg2iRAdVZgfzrhHGK6rwNcfLcWx7YkH8j/SurAy5atn1ObGx5qXodXRRRXtHjBRRRQAUUUUAFFFFABRRRQAVn69dfZNKuJAcPt2r9TxWhXK+OZsJbQA/eJciscRPkpuRtQhz1FE5OBe9WAKbEMLUqjJrwUe42OQVKEBoRKlVa0SMmyu8VNClTxV0LSFBScAUiushHWp0cGmvGCKj2lTS1Q9GW1NPBqtG/rUwNaJmbRlgK91pwA4WWTd9QDWu1ZDQSpqMWxCY/NMm/sAQcj9a1xVydzSq9rDCSKer0pUGmFCKixne5OrV534/wAjxTZnsbZR/wCPtXeg1xfxFhIudNuR/tRk/kR/WrpvU8jO4c2Dk10t+ZZ0lsxLzWs0Z2ZFc/o037sA10MUwZME10LU+MpWaszyj4rXP/E8soc8WtlNcY92IUH/AMdNU/hnFc2fgy3uhCssV1JJKwHDD5iuc/RRVX4oTb/FGtnP+psIoh+O5v8A2au28AW4h8DaJEw4Nqj/APfQ3f1reppSSPTxi5MHCK6/8Ebp10ssREZIeM4KtwQPpV9Lxl/i/CqWs6cu/wA63cxTDoy0zw3FdatqJspVQOqGQyg4BAIHT8a5rnj0VOpJU4LVmxaXxlJyeAcVq218EU7a5/UtPudDmAuAGgkJ2yL0z6H3qNLwKOGGKalY1k6mHm4VFZo27i7LkkVlRzMt+7A9V/rVWXUFweRSQR3cg+0rDJ5JGA+04P40N3M5SlPVI6K2v9iYJrJ1e9DhsHiqjNN0CtWhpPhy81OVHuFMNtn5mPBI9qTkVTjVxElTpq7MvTob9rfzIbad4SThlQkH8asxaVqt22I7WVQT1cbR+temQxR21vHDCoWNFCqo7CmSSKByazc7H0tPhym7c838jmtE8Mw2DrcXhE9yOQP4U+nqa2pZMd6SSUscKKI7ZnOWrGUnJn0OGwtLCw5KasiuzM54pPsxblq0lgCDpSMuOKPZ9zo9p2KKwBe1JInFW2FQyCk1YalcoOtaHhmb7PrEPOFk+Q/j/wDXxVSUVHA5jlR14ZSCKmEuSal2LmueDj3PT6KZDIJYUkXo6hh+NPr6Lc+fCiiigAooooAKKKKACiiigArg/Fsvm60y9o1Vf6/1rvK80vpftGoXEuc7nJH0zxXBj5Wgo9zuwEbzcuw1RgVNGOaiFTRCvLielIsxrUoSmxCrKLW6RztkYSkKVaCcVna/qtjoGkXOqatP9nsbZQ0suxn2jIHRQSeSOgp8tyeYlK0xkrG0TxnoOt6mun2F3ML14Bcxw3NpNbtJEejoJEXcPcZroSlKUGtylNPYptH6UKxXg03V7610nTLrUNQl8mztY2mlk2ltqqMk4AJP4CotPvLbVNNtdQsJPNtLqJZoZNpXcjAEHBwRwe9RytalKSehbVs08Gq4BU1Kpppg0TA1IKhU1BqWp2OlWjXWp3lvZ2y9ZZ5Aij8TVrUhl7aK53x9aGbw7JKgy1u6yjHp0P6H9Krr4qutS+Xwxot3fKel3d5tLb6hnG9h7qhB9ac/hvVNZjZfE2tytbuMNY6YDaxEejSZMrfgyg+lWo2d2c2Igq9KVPujjtI1m0+1R2ZuYRdspYQ7xvKjqcdcV08dwMDBri5NBg8KalcafaW8cERO9HRcGRT0JPc+ue9a9pNIcDBNaeh+fTi6M3Te6PMfiHKX8R+KTnpFCP8AyEtep+HiIfC2kp2WzhH/AI4K8l8dgjXvFYcfMY4T/wCQlr2fw1CJ/DekueQ9pE35oK6KyvCJ6uOTeGpW7fojJvppZQVjUkV03w70oRR3OoSSK00n7oIOqKDk59zx+VSG0ijU/KKpaXenTNehCHEE7COQdueh/A1zNHJltSOHxUZ1F5el+p3E1vHNGyTIsiHgqwyDWJceEdKmcsIXiJ7RuQPyrpMUYqNj7arQpVv4kU/VHO2nhDSbeUSGBpSOQJWyPy6GugVVRQqgBQMAAcUpprGgKVCnRVqcUvQYY4w2RGmfXaKHcCo5Hx0qBmLGocjeMEtgll9Kr7HkbnOKsxxZ61YSP2qeW+5rzJbFeG3C4q0EwOlPVQKDVpWMnK5E9QPUz1C9DKRE1QyVM1QvUM0iVJBVc8NViXrVaQ1gzeJ6F4em87SLc91Gw/hWjXPeCpt+nSxnqkmfzH/1q6Gvew8uanFnh148tSSCiiitjIKKKKACiiigAooooAralL5Gn3MmcFY2I+uK82irvPFMnl6JcY6thfzIrhI+leVmEvfSPUwC9xslFTxVXWrMVcUTrmXIRV2McVThq7H0roic0iQCuI+Ndjdaj8LfEFrp9tPdXUsKiOGCMu7nepwFHJruFp2K0i7NMyeqsfPmi6D4l0fxjaS3tvqOoy3nhxbXStRa3IGlzCP/AFMoRQq/N/Ewz0BP3jWV4J8Ka9BJpM8bajpniWG3uoLhF0SZBO7o+17i7aQxyYbaVYAnkDHHH0uRUbVbqvsQqaPnTw54Xs7j4Q3Okp4R1CHxQ2nXCzvcae8O+X5mTdI4CyEkKVwW2nH3ahh0aW3svhVfWHh/ULaLSpiuqpHpkscqzGKENIyBNzg7DlwCDjrmvop6gcVLrM0VJHzFpPhrWJINDS50PUhGPGklzKklo42wERfvGGOE4PzdODTpvC2r2um6l9g0TUYprTxeHsPKtZA0NrljuiwOI+nK8dK+lGpuaX1h9h+wXcydWs9bvbwR2eqxadp+0bmhtxJcse+GfKKP+AsfpRpfhXSLC7S8aB73UV6Xl7IbiYdPus+dvQcLge1bG6lVqx5nsbcq3ZZRqnQ1UU1PG1NMho4vx+6PrNhCwGViLk/Vsf8AstO063iCjaBVX4hIy69ZzfwvBsB9wxJ/9CFP0iXIFbx2Pg8yf+2T5u/6Hj/xVh8vxV4iC8b7WF//ABzH9K9i8CP5vgrQJCME2MH/AKAK8q+LiA+K9QB6yaZGw/BnH9K9B8A3X/FCaEVOQtpGufoMV1zfuI78RJfVqbOqu3AQ5rkNVmzMgT724Y+ua0bzUAcgmqGjQNqniK1iUZRHEsnsqnP/ANb8a5ZM8V3rVYwhu2es0U0NTXesbn6JYGYVBIxPApHemBsmpbLUR4XPWgR80qmng0WC45FwKkAxTFNSCqRDFprU6mmmIgfrULVPIKheoZoiFulQv0qdqhepZaKkveqstWpaqyDrWMjoidD4Flxd3MWfvIG/I/8A167KuA8HybNcjXP30Zf0z/Su/r18DK9K3Y8nGxtV9QoorF8WeKdF8JaW2oeIdQhsrccLvOWkP91FHLH2ANdhyG1RWL4P8Tad4t0KHVtIeRraQlSsq7XRh1Vl7Hp+YraoAKKKKACiiigDA8aPt0lF/vSgfoa46PpXWeOD/oVsuesmf0NcpH0rxsa/3p7GCX7oetWI6hQVPHXPE2mXIaux9Kow1ej6Ct4nPImUU/FIgqTFapGLZGRUTirBFRutJoaZVYVE4qyy1E61DRomVHWoSKtutQOKzaNEyI0mcGnGmNUlk0b1YQ+lUAakWXbTTJcSr4q0o6rpmIv+PmE+ZF7nuv4/4VymiTgjaQQwOCD1B9K7tJc1yfiWz+xarHfwgCG4O2QDs/r+I/lW0JHzGfYC8frMN1v6d/keX/FpM+KkbjEml7fyd/8AGuv+F8IuPhxox3f8s3H5SMK5b4tL/wATjSJMcTWlxH+RU/1rofg3OD8O7CMdYpJkP/fxj/Wu2X8JHBWd8DB/11NXUrJYs/Ma6nwVZ29tpCXMKfvp8l3brwSMfTiuZ1EyXt7HZ2w3TSHA9vc+1d3ZwLZ2UNuh+WJAufXHeuObNeH8O51pVmtFp8/+G/MtGSmNJULNTN1Y3PsOUlJpVqNTUq0IGSLT6YtSKM1aIY9KmUU2NasKvFXFXM5Mj201hU5Wo2FNxJTKzioHq04qvIKzZqiBqgkqZ6hepZoitLVWQVakqs/SsZG8SfQH8vW7Q5/5aAfnx/WvRp5o4IXlnkSOJAWZ3YBVHqSeleJax4otdA8y5C/abi2UzCBGxuK84J7dP/rV4R40+IuseNrpR4iv5Z4ZmH2bQdNDCInPyhgOZGzjrnnpjpXp5ffkZ52PtzJnvXj345WsMk+meA44dUvkysmoynFlb+p3f8tCPQce56V8+Xt7rHjHxQkOlfbPFniiXCNeOv7qAZPCD7saDnngV33gn4FeI/FbRS+MWfw/oKgOlhAR9ok9iOQnHrk+3p9L+EPCui+ENHj0zw7YRWVovJCDLO395mPLH3Nd5wHIfAz4eX3gDQbxNX1V7/UdQkWedF/1MLAYwmeSfVuM4HAxz6VRRQAUUUUAFFFFAHMeOP8AU2v+8a5iMcV1Xjcf6JbH/bI/SuWj+7Xi43+Mz2cH/CRKtTJUS1Mg5rGJpIsw9qvQ9BVOEVdiHStonPIsoKkApiVIK3RgxCKYRUhpDTaAgZahdassKiccVm0WmU5BVdqsy1WasmbRImqJqlao2qGaojoJ4oPFNb7tSUKku09ap+Jf32hXXqiiQe205/pSuSDUV0xktJ4zzvRlx9RThKzMcTR9rSlDumjy34qfNp/h+8xkLO0J/wCBp/8AY1N8Gbgf8InewZ+aC9kXHoCFP9TUPjy6s9Q8DXEdrcRS3lhJFK8SOC8ZDY5HUcbqyvhJfJa6xq1lMSI7pEuIz2yMhv5j8q9Na0vQ+Gi3PL3HrF/1+Z634NjD32oXTjLLtiQ+g6n+ldO8lc14OYG2vnXobggH1wordJrzpvU+pyWmoYKn56/iPLZoWmDrT1FSeqSpUy1GgqZRVozY9amQc1GgqdBVozbJoxU6jiokFSitomMgNRuKlqNqbEivJVWSrcgqpMQqlmICjqTWMjWJA9QvWXqniXT7MEJL9okH8MXP69K5DVfE99eErCfs0R42p1P4/wCFSoNl86R1Or6zZacCJpQ0n/PNOW/+t+NcVrHiW6vFaOAfZ4j12n5iPrS2Hh6+vyHdTDEeS8g5P0HU10thoNlYAME82Yfxyc/kO1TLlj5mkeaXkcTY+GrjVlaO4LW9tMpQuR8xB44H417B8N/hV4W8AwK2j2Im1EjEl/c4knb1weij2UD3zWAv/Hwn+8K9bHSuzAzcua/kcmOio8tgooor0DgCiiigAooooAKKKKAMDxmu7TI2/uyD+RrkYuldp4tXdo0h/usp/WuKh6V4+OVqvyPWwTvS+ZYWpUqFamjrnibSLkNXYqow1eiraJzyLK1IKjWpBW6MWLTSKdig1QiI1G/epWqJ6hlI5X4g+JIPCHhPUdcuY/OW1QFYt+zzHJCqucHGSRzg1y/h74maVqHgOTxPrKNpEFvO1tdxNumMEgYKFO1cnO5T90Yz+NXviv4P1Hxp/YVhb3cNrpMF4Lq+O796wUfIEBRlPVvvcdODXB+I/hN4gntPGWnadqlpcWOuSwXccl8+yVZ1cNIXEcQQBvm5Udl46mhRg17z1K5pp6I74ePPDbRapIdRKDTIlmulkt5UeONgCrhSoZlII5UEcj1pV8beHXubWD+0kWS6sP7Ui3xuqm2wT5hYgBRgHgkH2rkdU+Guo3+seJ7h7uzjt9V0aLT4ipYusqKvLDbjblexzjtVHTvh1riappN1qkOi3VvY+H/7FktRdSgTkbgCW8r5QQeeCR2z1qOSnbc0U6nY9D0LxHpuvrv0truWEp5izSWU0UTr6q7oFb8Cam1jWdO0aAS6pewWqNwvmOAXPoo6sfYZNcb8O/BOp+GdYv5pbr7No0sIig0qK/lukjfIy4d0QrwMAAdO/FdTpPhvStJma4tLRTeOMPdTM007/WRyWP0zWU1BPTY1g5NamW+uapqYI0HRpViPS71PNtH9RHgyN+KqOetQSeGp787vEOq3N8D1trfNtb/98qdzD2ZmHtXXPVeQVnzW2NVG++pjxaDpMdn9ki0+2gtwu0JCgQAfhiuHOmRaLqyl4A7RnI3EkOtekv0P0qhqelJqtkoyEmTJR/6H2qoVGtGY1cHSn73Ir+iNfR7m1ubBJLFVSHpsUY2n0xV2vMra4vtBvWXlHH3kblXH+e9dXpviqzuAFugbeT35U/jTlB7oqMklbY6VamQVUtLmC5G63mjkH+wwNXEqUNslQVMoqNamWtEZMkQVMgqB5Y4V3SyIi+rNgVTn8Q6XbKS95G5HaM7yfyrSKuZSZtLUgrjbjxvbICLW1lkPq5Cj+tZN54y1KYEQCK3X1Vcn8zWyizJyR6QzKilnYKo5JJwBWPfeI9Ltch7tJG/uxfP/AC4rzz/iaau4z9qujnHdgP6CtWz8F38wzcyRW6+hO5v04/WqcUtyU30LGqeNSSV063wP783+A/xrl7ifU9bnIJnuW67FHyr+A4Fd1ZeDtPt2DXDSXLDs3yr+Q/xraWGOCMJDGkaDoqjArKUktjSKb3PO7HwddykNeyJAn91fmb/AV0dhodjp/wA0MO6Qf8tJPmb/AOt+FbbioWrGUmzeMUipMOKpyCrsoqpKKwkdEGVoRm6iHq4/nXq9eU24zfQD1kX+derV6GX7SOLMN4hRRRXonnBRRRQAUUUUAFFFFAGb4jXdotz7Ln9a8+NxFBjzZFXPQE8mvR9YTfpV2vrG38q8umE8V9HLaxo+5Nsgd9owOmODzya8rHr30/I9TAv3GvM07eWOYZikVx32nOKtIOayoxNJewSm1aIjKyNuUgrjjvk8gdq1krlidEy3D2q5HVKI9KtxmtUYSLS1ItQp0qZa2iYsfSGlpDVkkbVE9TGonqGUitJVZ+tWZKqv1rKRtEhYVE1TNUTCs2aoiNRmpWFRNUM0RE9QPzU7VA/FSWiGQfKfpS2X+qFNkb5T9KdZf6r8aCnsSXVjbX0YS6hWQDoT1H0Nc9feDwSWsbjHoko/qP8ACuqSpKqMmtjKUU9zzubw/qls2fs7Pj+KI7v5c0Ry6vbNgNfRkdvmH6V6QlWErZVO5jKn2PN/t+suMefen6Fh/Kn7NbnADLqMg7ZDmvTEqUVan5Gbh5nmsHh3V7gg/ZXGe8jAfzNa9r4JvXKme4gjB67csR/L+ddxHVhKtTZm4I5q08E2KYNxPPKfQYUf5/Gtm18P6XbYMdlESO7/AD/zrRFPFXdkWFVQqgKAAOgAprU7NMakwRG9V5KsNVeSspGsSs9QPU71A9ZM1iVpe9VZO9WpO9VXrKRvEj09d2q2i+syD/x4V6hXmujrnW7PP/PVT+telV6OXr3WcGP+JBRRRXoHAFFFFABRRRQAUUUUAMuE8yCRP7ykfpXkWrxNPDFCpAEkm1snGRtJxntnGK9gPINeXahbl2liXGVfoTgHB6Z7fXtXm5gvhZ6OAfxIZHqI+1R24t7gSN975OEHuemPpWqlYFoBdXAMd1cpLD1+4wwe2QOenrmt+OuGB1zLMdWozVSOrMZrZGMi3GamWq8Z5qwlaxMZD6Q0tNNaEDTTHp5pjVLKRVlFVnHNW5aqyVlI2iQGo2qRqiY1kzVEbGoXNSOagkNQzRDSahlp5NRtUloqyHrU1h/qj9aikHWn2B/dke9Bb2LyVKKijqUU0ZskTrVhKrrU6VSM5FhKlUVElTpWiMWSJU6VEtSr0rRGbJBTqaKdWiM2LmmmlpDQwI2qB6neoXFZyNIlZ+9QPVmQVXesmaxKkneoH6VYkqvJ0NZSN4kuhru1y0H+3mvRK8+8ODdr9qPQsf8Ax016DXp5ev3b9Tz8e/fXoFFFFdxwhRRRQAUUUUAFFFFABXnesJt1O7THV2/WvRK4PxKnl61Mf72G/SuHHr3E/M7sC/fa8jnNClkYqkggLLEFcpjKkcAHnPc9QMGt6PpWDY/Z4NTEA5lwwTkggdTlenb7w69+eu8lebA75lhDVmM1VSrUVaowkWo6sJVeOrKVtExkPpDS0hrQgYaY1PNRtUMpEElVZOtWpKqyVnI1iQNUD1M9QvWLN0QtUUnSpnqJ+lSaIgPWmtzTmpppFEEg4NNsj8p+tPk+6ais+CaRfQ0o6lFRR9KkWmZslWp0qutTIapGci0lTpVeOrCVojGROtSLUa1KtaIzY8UopBS1oQxaQ0tIaBEbVC1StUTVmzREL9arSVYkqvJWbNYlWTrUEg4NTvUEvQ1jI3iWvCo3a/F7Kx/Su+rhvB67tbY/3YmP6gf1rua9XAr918zzca/3nyCiiiuw4wooooAKKKKACiiigArjPGCY1RG/vRj+Zrs65fxpH89rIB1DKf0rlxqvSZ1YN2qo4e1mWXUAs/2gssr7DgbMjIGO/Tj610CVUt0WPIQAbiWOPU1djryIHpzJUFWY6gQVYjHStkYMsx1YWq6VMprWJjIlFBpBQa0JGmo2p7GomNSxoieq0lWWqvLWUjWJWeoXqd6has2bIheoX6VM9QyVDNUQNTGp7VG1Isik6GorXqalfpTLXq31pFdDRj+7Ui1ChqdaZmxy1MhqEVKlNEMtRmrEdVYzVmOtUYyLCVMtQpU61rExY4UoooFWSOFMandqYxoYkMao2p5pjdKyZoivJVaSrMtVZOlQzWJXeoJBxVhhUUo4rGRvE1PBY/4mNwf+mWP1FdjXJ+ClzcXbeiqP1P8AhXWV6+DX7pHlYt/vWFFFFdRzBRRRQAUUUUAFFFFABWZr9p9rtUUdVbP6Vp0jruGKmcVOLiyoScZKSOJOmSIehp62jr2rrzboetMa1Q9K4vqSWx1/W29zl1gcdqnSFh2rf+yr6ClFsvpT+qieIMVYyO1PVTWubZfSkNqvpR9XaJ9sjMANBBrS+zD0pDbD0p+xYe0Rltmo2rVa1HpUZs6h0ZFKqjJYVBLWy1kTUEmnMah0ZGkasTEeonrbOmN6VE2lv6Vk6M+xqq0e5htUMgrebSn7CoZNJl/u1Doz7GirQ7mCRUTCt06RL/dNNbR5v7hqfYz7FqtDuc844NMtRy1bzaNNz8hqO10edd26M9aTpS7F+2hbcqIKnQVfXTJcfcNTppsn9w01Sl2M3Vj3MwCpFFai6Y/92pF0xv7tWqM+xDrR7mfGKsxirqacw7VZSxx2rSNGRjKtEpIKmUHFXVtMdqf9m9q1VGRk6qKVFXhbe1L9mqvZSJ9oihzTGzWn9mz2pPsg9KHRkCqoyiKYynFbH2QelIbRT2pfV5Fe2RgyKarNGxPArpTZL6Ugskz0qfq0mUsQkcz5DntQbKRx0NdUtog7CpBar/dprB33D61bYzvDFp9mScnqxH6Z/wAa3KjgjEakAYzUld1OHJFRRx1J88nJhRRRVkBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFGKKKADFGB6UUUAGB6Um0elLRQAm0elG0elLRQAm0ego2j0FLRQAm0ego2L6ClooATYv90UbF9BS0UWC4m0elG0elLRQAm0elLgelFFABgelGB6UUUAGBRgUUUAGKMUUUAGKMUUUAGBRgelFFABiiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During a colonoscopy or a sigmoidoscopy, you lie on your side, and the doctor or nurse puts a thin tube with a camera into your anus (from behind). Then the doctor or nurse advances the tube into the rectum and colon. The camera sends video pictures from inside your colon to a television screen.",
"    <br>",
"     A colonoscopy allows the doctor to see the whole colon (shown in pink and green). A sigmoidoscopy allows the doctor to see only the last part of the colon (shown in green).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_52_19265=[""].join("\n");
var outline_f18_52_19265=null;
var title_f18_52_19266="Clitoromegaly1";
var content_f18_52_19266=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Clitoromegaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 264px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Clitoromegaly in a 46,XX infant with 21-hydroxylase deficiency.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher P Houk, MD and Lynne L Levitsky, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_52_19266=[""].join("\n");
var outline_f18_52_19266=null;
var title_f18_52_19267="Antibiotic-associated diarrhea caused by Clostridium difficile";
var content_f18_52_19267=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/52/19267/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/52/19267/contributors\" id=\"au6610\">",
"       Ciar&aacute;n P Kelly, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/52/19267/contributors\" id=\"au6453\">",
"       J Thomas LaMont, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/52/19267/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/52/19267/contributors\" id=\"se1937\">",
"       Stephen B Calderwood, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?18/52/19267/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/52/19267/contributors\" id=\"de1811\">",
"       Elinor L Baron, MD, DTMH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?18/52/19267?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Antibiotic-associated diarrhea refers to diarrhea that develops in a person who is taking or recently took antibiotics. One of the most serious causes of antibiotic-associated diarrhea is infection with a bacterium, Clostridium difficile. C. difficile infections are most common in people who are hospitalized, producing disease in more than 8 hospitalized patients per 1000 (0.9 percent) in 2008 in the United States [",
"     <a class=\"abstract\" href=\"UTD.htm?18/52/19267/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     This topic review discusses the causes, symptoms, diagnosis, and treatment of C. difficile-associated diarrhea (CDAD). Other types of diarrhea are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/29/36308?source=see_link\">",
"      \"Patient information: Acute diarrhea in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/14/7395?source=see_link\">",
"      \"Patient information: Chronic diarrhea in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS C. DIFFICILE?",
"     </span>",
"    </p>",
"    <p>",
"     C. difficile is a disease-causing bacterium that can infect the large bowel and cause colitis. The intestinal tract of normal people contains millions of bacteria, referred to as the &ldquo;normal flora,&rdquo; that have a role in protecting the body from infection. Taking antibiotics can kill these \"good\" bacteria, allowing C. difficile to multiply and release toxins that damage the cells lining the intestinal wall, causing diarrhea, abdominal pain, and fever, as well as other symptoms (see",
"     <a class=\"local\" href=\"#H4\">",
"      'C. Difficile symptoms'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     C. difficile can be found on the surface of bedside tables, door knobs, counters, lavatories, and sinks in the hospital. The organism can be spread between patients via contact with contaminated objects",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     the hands of healthcare workers. Handwashing is important for preventing the spread of C. difficile infection (see",
"     <a class=\"local\" href=\"#H15\">",
"      'Hand washing'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     C. difficile infections have become more frequent, more severe, more difficult to treat, and more likely to recur after initial treatment. Although most people become infected with C. difficile in the hospital, the infection has also become more common in the community.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      C. DIFFICILE RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     A number of factors can increase a person's risk of becoming infected with C. difficile.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Current or recent hospitalization &mdash; Up to 20 percent of people who are hospitalized and up to 50 percent of people in long-term care facilities (eg, nursing homes) carry C. difficile in their feces but many do not have diarrhea or other symptoms. Exposure to these carriers significantly increases a person's risk of becoming infected.",
"      </li>",
"      <li>",
"       Current or recent use of antibiotics &mdash; Certain antibiotics increase the risk of becoming infected with C. difficile more than others (",
"       <a class=\"graphic graphic_table graphicRef79514 \" href=\"UTD.htm?24/0/24587\">",
"        table 1",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Older age &mdash;The risk of becoming infected with C. difficile is 10 times greater in people who are 65 years or older.",
"      </li>",
"      <li>",
"       Severe illness &mdash; People who have a weakened immune system as a result of an underlying medical condition or a treatment (eg, chemotherapy) are at increased risk of becoming infected with C. difficile, especially during a hospital stay.",
"      </li>",
"      <li>",
"       Recent infection with C. difficile &mdash; People who have been recently infected with C. difficile and treated have an increased risk of becoming infected again soon after stopping the treatment.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      C. DIFFICILE SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Symptoms of C. difficile may begin during antibiotic therapy or five to 10 days after the antibiotic is stopped; less commonly, symptoms do not develop until as late as 10 weeks later.",
"    </p>",
"    <p>",
"     The symptoms of C. difficile can vary in severity:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Some people (called carriers) carry the bacteria in their feces but have no signs or symptoms of the infection. Carriers can spread the infection to others.",
"      </li>",
"      <li>",
"       The most common symptoms include watery diarrhea (three or more times per day, or diarrhea associated with abdominal cramping).",
"      </li>",
"      <li>",
"       In more severe cases, the colon can become inflamed (colitis) or develop patches of raw tissue that produce pus (pseudomembranous colitis). Symptoms of these complications can include profuse watery diarrhea (up to 10 to 15 times per day), blood or pus in the stool, dehydration, abdominal tenderness and cramping, fever, nausea, loss of appetite, and weight loss. Anyone who develops one or more of these symptoms should seek medical care as soon as possible.",
"      </li>",
"      <li>",
"       Life-threatening complications of C. difficile infection develop in a small number of people. Signs and symptoms of severe infection may include abdominal distension, severe lower abdominal pain, fever (often greater than 101&ordm;F or 38.3&ordm;C), and profuse diarrhea. In rare cases, the bowels can rupture, potentially leading to a body wide infection (sepsis), organ failure, or even death.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      C. DIFFICILE DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The diagnosis of C. difficile is based upon laboratory analysis of a stool sample. However, the results of laboratory testing are not usually available for several hours. If there is a high suspicion that C. difficile is the cause of a person's symptoms, treatment may be started before the results of the tests are available. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"      \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      C. DIFFICILE TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The most important step in treatment of C. difficile is to stop the antibiotic that allowed the infection to develop. If an antibiotic is necessary to treat an ongoing infection, the healthcare provider may choose an antibiotic that is less likely to allow further growth of C. difficile, when possible.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Antibiotic treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;An oral antibiotic is usually recommended to treat people who are infected with C. difficile. It is important to take each dose of the antibiotic on time and to finish the entire course of treatment (usually 10 to 14 days).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Probiotics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Probiotics are \"healthy\" microorganisms (bacteria, yeast) that can be taken by mouth. Benefits of probiotics have been suggested for several digestive diseases. However, these benefits have been proven only for some types of probiotics in selected situations. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21015?source=see_link\">",
"      \"Clostridium difficile and probiotics\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Several studies have found that probiotics reduce the risk for antibiotic-associated diarrhea in general, but their ability to prevent C. difficile infection is unclear. As a result, probiotics are not recommended routinely for diarrhea related to C. difficile, except in selected situations.",
"    </p>",
"    <p>",
"     While probiotics are generally safe, case reports have described serious illness and deaths related to their use in people who were critically ill or who had a weakened immune system.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Treatment of severe disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who become severely ill as a result of C. difficile are treated in the hospital with both oral and intravenous antibiotic and intravenous fluids. The person is monitored closely for signs of worsening disease. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=see_link\">",
"      \"Clostridium difficile in adults: Treatment\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;If a person fails to improve with antibiotics and supportive care and the infection worsens, surgery may be necessary to remove the infected colon. This procedure is generally limited to people with life-threatening illness.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Supportive treatments for diarrhea",
"     </span>",
"     &nbsp;&mdash;&nbsp;Diarrhea can cause a person to become dehydrated quickly, especially if it is severe. To avoid becoming dehydrated, several strategies are recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Drink adequate fluids",
"     </span>",
"     &nbsp;&mdash;&nbsp;It is important to drink an adequate amount of fluids to counteract the loss of fluids from diarrhea. The fluids should contain water, salt, and sugar. The fluids used for sweat replacement (eg, Gatorade) are not optimal, although they may be sufficient for an adult with diarrhea who is not dehydrated and is otherwise healthy. Diluted fruit juices and flavored soft drinks along with saltine crackers and broths or soups may also be acceptable. Fluid replacement in children should be handled differently. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=see_link\">",
"      \"Patient information: Acute diarrhea in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     One way to judge hydration is by observing the color of the urine and how frequently the person urinates. Normally, urine should be light yellow to nearly colorless. A person who is well hydrated normally passes urine every three to five hours. A person who urinates infrequently or has urine that is dark yellow should drink more fluids.",
"    </p>",
"    <p>",
"     If a person becomes dehydrated and is unable to take fluids by mouth, a rehydration solution can be given into a vein (intravenous fluids) in a healthcare provider's office or in the emergency department.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Diet",
"     </span>",
"     &nbsp;&mdash;&nbsp;There is no particular food or group of foods that is best for a person with diarrhea. However, adequate nutrition is important during an episode of acute diarrhea. For patients without an appetite, it is acceptable to consume only liquids for a short period of time. Boiled starches and cereals (eg, potatoes, noodles, rice, wheat, and oats) with salt are recommended for people with watery diarrhea; crackers, bananas, soup, and boiled vegetables may also be eaten.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      C. DIFFICILE PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     It is uncommon for people who are not taking antibiotics to become infected with C. difficile. However, it is still important to avoid spreading the bacteria. A person can spread the bacteria for as long as the diarrhea continues.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Hand washing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hand washing is an effective way to prevent the spread of C. difficile. Hands should be washed after using the bathroom and before eating. Hands should ideally be wet with water and plain or antibacterial soap and rubbed together for 15 to 30 seconds. Special attention should be paid to the fingernails, between the fingers, and the wrists. Hands should be rinsed thoroughly and dried with a single use towel. Patients and family members are encouraged to remind healthcare providers to wash their hands, as well.",
"    </p>",
"    <p>",
"     Alcohol-based hand rubs are less effective against C. difficile and are not recommended alone to prevent the spread of this infection.",
"    </p>",
"    <p>",
"     Fingernails that are artificial (eg, acrylic) are impossible to clean adequately, even after vigorous scrubbing or use of an antimicrobial soap. For this reason, healthcare workers are not allowed to wear artificial nails.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Contact precautions",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who are hospitalized with C. difficile are placed on contact precautions, which means that anyone who enters the patient's room must wash their hands before entering and after leaving. The person must also wear a clean gown (over their clothes) and clean gloves. These measures can help to prevent the spread of infection to other people in the hospital.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      C. DIFFICILE RECURRENCE",
"     </span>",
"    </p>",
"    <p>",
"     Recurrence is defined as resolution of symptoms during treatment followed by a reappearance of diarrhea and other symptoms after treatment is completed. If symptoms return, it is important for a healthcare provider to confirm that C. difficile is the cause of the symptoms (rather than another condition).",
"    </p>",
"    <p>",
"     Recurrence occurs in 25 percent of people who are treated with metronidazole or vancomycin: in some patients, the recurrence is caused by the original infecting strain, and in others by new infection with a different strain of C. difficile. About one-half of people who develop recurrent symptoms probably have reinfection rather than recurrence. It is not always possible to determine if a person has a recurrence or reinfection.",
"    </p>",
"    <p>",
"     Most recurrences occur within one to two weeks after discontinuing antibiotic therapy, although rarely recurrence can occur up to two to three months later. People who have at least one episode of recurrent C. difficile have a 50 to 65 percent chance of additional episodes.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Treatment of relapse",
"     </span>",
"     &nbsp;&mdash;&nbsp;A first episode of relapse is treated in the same manner as initial infection (see",
"     <a class=\"local\" href=\"#H6\">",
"      'C. Difficile treatment'",
"     </a>",
"     above). People who develop subsequent relapses of C. difficile (eg, a third or fourth episode) may be treated with one or more of the following strategies:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Longer treatment with vancomycin that is slowly tapered over a 6 to 12 week period.",
"      </li>",
"      <li>",
"       Other antibiotics, such as fidaxomicin or rifaximin, may be used. &nbsp;",
"      </li>",
"      <li>",
"       A treatment known as fecal bacteriotherapy may be considered in certain situations. Fecal bacteriotherapy involves giving feces from a healthy person (by enema) to a person who is infected with recurrent C. difficile. This treatment is discussed in detail in a separate article. (See",
"       <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23960?source=see_link\">",
"        \"Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H19\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784827624\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21383470\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/47/28402?source=see_link\">",
"      Patient information: Antibiotic-associated diarrhea (C. difficile infection) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/62/27618?source=see_link\">",
"      Patient information: Probiotics (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21383479\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/29/36308?source=see_link\">",
"      Patient information: Acute diarrhea in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/14/7395?source=see_link\">",
"      Patient information: Chronic diarrhea in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=see_link\">",
"      Patient information: Acute diarrhea in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/25/23960?source=see_link\">",
"      Fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12184?source=see_link\">",
"      Prevention and control of Clostridium difficile in hospital and institutional settings",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=see_link\">",
"      Clostridium difficile in adults: Treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21015?source=see_link\">",
"      Clostridium difficile and probiotics",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/\">",
"      www.nlm.nih.gov/medlineplus/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Centers for Disease Control and Prevention (CDC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/ncidod/dhqp/id_Cdiff.html\">",
"      www.cdc.gov/ncidod/dhqp/id_Cdiff.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?18/52/19267/abstract/2-7\">",
"      2-7",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?18/52/19267?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Agency for Healthcare Research and Quality file://hcupnet.ahrq.gov/HCUPnet.jsp?Id=42781ECF48D93FDD&amp;Form=SelDXPR&amp;JS=Y&amp;Action=%3E%3ENext%3E%3E&amp;_DXPR=DX1 (Accessed on February 10, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19267/abstract/2\">",
"      Sazawal S, Hiremath G, Dhingra U, et al. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis 2006; 6:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19267/abstract/3\">",
"      Dendukuri N, Costa V, McGregor M, Brophy JM. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review. CMAJ 2005; 173:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19267/abstract/4\">",
"      Riggs MM, Sethi AK, Zabarsky TF, et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 2007; 45:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19267/abstract/5\">",
"      Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006; 145:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19267/abstract/6\">",
"      Miller MA. Clinical management of Clostridium difficile-associated disease. Clin Infect Dis 2007; 45 Suppl 2:S122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19267/abstract/7\">",
"      McFarland LV. Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol 2005; 54:101.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f18_52_19267=[""].join("\n");
var outline_f18_52_19267=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS C. DIFFICILE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           C. DIFFICILE RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           C. DIFFICILE SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           C. DIFFICILE DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           C. DIFFICILE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           C. DIFFICILE PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           C. DIFFICILE RECURRENCE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H19\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?24/0/24587\" title=\"table 1\">",
"           Antibiotics C diff PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f18_52_19268="Stromelysin in synovium of RA";
var content_f18_52_19268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51875&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stromelysin in rheumatoid synovium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Darkfield photomicrograph of rheumatoid synovial tissue probed for expression of the gene encoding stromelysin (MMP-3). Bright white dots are localized to the synovial lining layer and represent areas of stromelysin expression.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ellen M Gravallese, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_52_19268=[""].join("\n");
var outline_f18_52_19268=null;
var title_f18_52_19269="DCRV";
var content_f18_52_19269=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Double chambered right ventricle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transesophageal echocardiographic views of double chambered right ventricle (DCRV) without (A) and with color (B) at the base of the heart showing an obstructive muscle bundle separating&nbsp;the proximal high pressure (PC) and distal low pressure (DP) chambers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission: Ammash N. Ventricular Septal Defects. In: Adult Congenital Heart Disease, Warnes, CA (Ed). &copy; 2009 American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_52_19269=[""].join("\n");
var outline_f18_52_19269=null;
var title_f18_52_19270="Ipilimumab: Drug information";
var content_f18_52_19270=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ipilimumab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/33/40468?source=see_link\">",
"    see \"Ipilimumab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F12706580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12743392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Yervoy&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14225438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Yervoy&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10940809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Monoclonal Antibody;",
"     </li>",
"     <li>",
"      Monoclonal Antibody",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10940812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Melanoma, unresectable or metastatic:",
"     </b>",
"     I.V.: 3 mg/kg every 3 weeks for 4 doses",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15670372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15670373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Impairment at baseline:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Mild impairment (total bilirubin &gt;1 to 1.5 x ULN",
"     <b>",
"      or",
"     </b>",
"     AST &gt;ULN): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Moderate or severe impairment (total bilirubin &gt;1.5 x ULN and any AST): No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Impairment during treatment:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     AST or ALT &gt;2.5 to &le;5 x ULN or bilirubin &gt;1.5 to &le;3 x ULN: Temporarily withhold treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     ALT or AST &gt;5 times ULN, or total bilirubin &gt;3 times ULN: Permanently discontinue.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F12706630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Temporarily withhold scheduled dose for the following:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Moderate immune-mediated reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Symptomatic endocrine disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Grade 2 hepatotoxicity (AST or ALT &gt;2.5 to &le;5 x ULN or bilirubin &gt;1.5 to &le;3 x ULN)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     If receiving prednisone &lt;7.5 mg daily (or equivalent), may resume with complete or partial resolution (to &le;grade 1) of symptoms. Resume ipilimumab treatment at 3 mg/kg every 3 weeks until all 4 planned doses have been administered or until 16 weeks from initial dose, whichever occurs first.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Permanently discontinue for the following:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Failure to complete treatment course within 16 weeks of initial dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Persistent moderate adverse reactions or unable to reduce corticosteroid dose to prednisone 7.5 mg daily (or equivalent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe or life-threatening adverse reactions including:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Central nervous system or neuromuscular toxicity: Severe motor or sensory neuropathy, Guillain-Barr&eacute; syndrome, or myasthenia gravis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Dermatologic toxicities: Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated by full thickness dermal ulceration, or necrotic, bullous, or hemorrhagic manifestations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Gastrointestinal toxicities: Colitis with abdominal pain, fever, ileus, or peritoneal symptoms, increase in stool frequency (&ge;7 over baseline), stool incontinence, require I.V. hydration for &gt;24 hours, or GI hemorrhage or perforation; grades 3/4 amylase or lipase increases (Weber, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Hepatotoxicities: ALT or AST &gt;5 times ULN, or total bilirubin &gt;3 times ULN",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Ophthalmic toxicities: Immune-mediated ocular disease unresponsive to topical immunosuppressive treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Severe immune-mediated reactions involving any organ system (eg, myocarditis [noninfectious], nephritis, pancreatitis, pneumonitis)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F12706635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Yervoy&reg;: 5 mg/mL (10 mL, 40 mL) [contains polysorbate 80; derived from or manufactured using Chinese hamster ovary cells]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F12706584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F12707872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM249168.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM249168.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10940813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Infuse over 90 minutes through a low protein-binding in-line filter. Flush with NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W at the end of infusion",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F12706609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F12706585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of unresectable or metastatic melanoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F10940805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F12706601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (41% to 42%; grades 3-5: 7%), headache (15%), fever (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (24% to 31%), rash (19% to 29%; grades 3-5: 2%), dermatitis (grade 2: 12%; grades 3-5: 2% to 3% [includes Stevens-Johnson syndrome, toxic epidermal necrolysis, dermal ulceration, necrotic, bullous or hemorrhagic dermatitis])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (35%), diarrhea (32% to 33%; grades 3-5: 5%), appetite decreased (27%), vomiting (24%), constipation (21%), abdominal pain (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (16%), dyspnea (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Urticaria (2%), vitiligo (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypopituitarism (grade 2: 2%; grades 3-5: 4%), hypophysitis (2%), adrenal insufficiency (&le;2%), hypothyroidism (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Colitis (8%; grades 3-5: 5%), enterocolitis (grade 2: 5%; grades 3-5: 7%), intestinal perforation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Eosinophilia (grades 3-5: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Hepatotoxicity (grade 2: 3%; grades 3-5: 1% to 2%), ALT increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Nephritis (grades 3-5: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Antibody formation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Acute respiratory distress syndrome, angiopathy, arthritis, AST increased, bilirubin increased, blepharitis, conjunctivitis, corticotrophin decreased, Cushing&rsquo;s syndrome, encephalitis, episcleritis, erythema multiforme, esophagitis, gastrointestinal ulcer, Guillain-Barr&eacute; syndrome, hemolytic anemia, hepatic failure, hepatitis (immune-mediated), hyperthyroidism, hypogonadism, infusion reaction, iritis, leukocytoclastic vasculitis, meningitis, myasthenia gravis, myelofibrosis, myocarditis, myositis, neuropathy (sensory and motor), neurosensory hypoacusis, ocular myositis, pancreatitis, pericarditis, peritonitis, pneumonitis, polymyalgia rheumatica, polymyositis, psoriasis, renal failure, sarcoidosis, scleritis, sepsis, temporal arteritis, thyroiditis (autoimmune), thyrotropin increased, uveitis, vascular leak syndrome, vasculitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F12706590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to ipilimumab or any component of the formulation; active life-threatening autoimmune disease, or with organ transplantation graft where further immune activation is potentially imminently life-threatening",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F12706591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immune-mediated adverse effects:",
"     <b>",
"      [U.S. Boxed Warning]: Severe and fatal immune-mediated adverse effects due to T-cell activation and proliferation may occur. While any organ system may be involved, common severe effects include dermatitis (including toxic epidermal necrolysis), endocrine disorder, enterocolitis, hepatitis, and neuropathy. Reactions generally occur during treatment, although some reactions have occurred weeks to months after treatment discontinuation. Discontinue treatment (permanently) and initiate high-dose corticosteroid treatment for severe immune mediated reactions. Evaluate liver function and thyroid function tests at baseline and prior to each dose. Assess for signs and symptoms of enterocolitis, dermatitis, neuropathy, and endocrine disorder at baseline and prior to each dose.",
"     </b>",
"     Uncommon immune-mediated adverse effects reported include hemolytic anemia, iritis, meningitis, nephritis, pericarditis, pneumonitis, and uveitis. Initiate prednisone 1-2 mg/kg/day (or equivalent) for severe reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Central nervous system or neuromuscular toxicity: Severe peripheral motor neuropathy and fatal Guillain-Barr&eacute; syndrome have been reported (rare). Monitor for signs of motor or sensory neuropathy (unilateral or bilateral weakness, sensory changes or paresthesia). Withhold treatment in patients with neuropathy that does not interfere with daily activities (moderate neuropathy). Permanently discontinue for severe neuropathy (interferes with daily activities, including symptoms similar to Guillain-Barr&eacute; syndrome). Consider initiating prednisone 1-2 mg/kg/day (or equivalent) for severe neuropathies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dermatologic toxicity: Severe, life-threatening, or fatal dermatitis has been reported. The median time to onset for dermatologic toxicity is 3 weeks (range: &le;17 weeks). Monitor for rash and pruritus; dermatitis should be considered immune-mediated unless identified otherwise. Mild-to-moderate dermatitis (localized rash and pruritus) should be treated symptomatically; topical or systemic corticosteroids should be administered if not resolved within 1 week. Withhold treatment for moderate to severe dermatologic symptoms. Permanently discontinue and initiate prednisone 1-2 mg/kg/day (or equivalent) for Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated by dermal ulceration (full thickness) or necrotic, bullous, or hemorrhagic manifestations; when dermatitis is controlled, taper corticosteroid over at least 1 month.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Endocrine disorders: Severe or life-threatening endocrine disorders (hypopituitarism, adrenal insufficiency, hypogonadism and hypothyroidism) have been reported; may require hospitalization. Endocrine disorders of moderate severity (including hypothyroidism, adrenal insufficiency, hypopituitarism, and less commonly hyperthyroidism and Cushing&rsquo;s syndrome) which have required hormone replacement therapy or medical intervention have also been reported. The median onset for moderate-to-severe endocrine disorders was 11 weeks (range: &le;19 weeks); long-term hormone replacement therapy has been required in many cases. Monitor thyroid function tests and serum chemistries prior to each dose; also monitor for signs of hypophysitis, adrenal insufficiency and thyroid disorders (eg, abdominal pain, fatigue, headache, hypotension, mental status changes, unusual bowel habits); rule out other potential causes such as brain metastases. Endocrine disorders should be considered immune-mediated unless identified otherwise; consider endocrinology referral for further evaluation. If symptomatic, withhold ipilimumab treatment and initiate prednisone 1-2 mg/kg/day (or equivalent) and appropriate hormone replacement therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gastrointestinal adverse effects: Immune-mediated enterocolitis was reported to occur at a median onset of 6-7 weeks. Monitor for signs and symptoms of enterocolitis (abdominal pain, blood in stool, diarrhea, or mucous in stool; with or without fever) and intestinal perforation (peritoneal signs, ileus). If enterocolitis develops, infectious causes should be ruled out; consider endoscopy for persistent or severe symptoms. Withhold ipilimumab treatment and administer antidiarrheals for moderate enterocolitis (diarrhea with &le;6 stools over baseline abdominal pain, mucous or blood in stool); if persists for &gt;1 week, initiate prednisone at 0.5 mg/kg/day (or equivalent). If severe enterocolitis (diarrhea &ge;7 stools above baseline, fever, ileus, peritoneal signs) develops, permanently discontinue ipilimumab and initiate prednisone 1-2 mg/kg/day (or equivalent); when resolved to &le;grade 1, taper corticosteroids slowly over &ge;1 month (rapid tapering may worsen symptoms).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatotoxicity: Severe, life-threatening or fatal hepatotoxicity and immune-mediated hepatitis have been observed. Monitor liver function tests (LFTs) and evaluate for signs of hepatotoxicity prior to each dose; if hepatotoxicity develops, infectious or malignant causes should be ruled out and liver function should be monitored more frequently until resolves. Withhold treatment for grade 2 hepatotoxicity (ALT or AST 2.5-5 times ULN or total bilirubin 1.5-3 times ULN). If severe hepatotoxicity develops (ALT or AST &gt;5 times ULN or total bilirubin &gt;3 times ULN), permanently discontinue ipilimumab and initiate prednisone 1-2 mg/kg/day (or equivalent). If transaminases do not decrease within 48 hours of steroid initiation, consider adding mycophenolate mofetil (Weber, 2012). May begin tapering corticosteroid (over 1 month) when LFTs show sustained improvement or return to baseline.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ophthalmic toxicity: Administer corticosteroid ophthalmic drops in patients who develop episcleritis, iritis, or uveitis; permanently discontinue ipilimumab if unresponsive to topical ophthalmic immunosuppressive treatments. For severe immune-mediated episcleritis or uveitis, initiate prednisone 1-2 mg/kg/day (or equivalent); taper over at least 1 month (Weber, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F12757387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F12706586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12706587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects were observed in animal reproduction studies. Ipilimumab is an IgG1 immunoglobulin and human IgG1 is known to cross the placenta, therefore, ipilimumab may be expected to reach the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F12706588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12706589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue ipilimumab or to discontinue breast-feeding should take into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Yervoy Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/10 mL (10 mL): $7308.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/40 mL (40 mL): $29232.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F12706632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor liver function and evaluate for signs of hepatotoxicity prior to each dose; if hepatotoxicity develops, liver function should be monitored more frequently until resolves. If liver functions tests are &gt;8 times ULN, monitor every other day until begin to fall, then weekly until normal (Weber, 2012). Monitor serum chemistries prior to each dose. Monitor for signs of hypophysitis, adrenal insufficiency and thyroid disorders (eg, abdominal pain, fatigue, headache, hypotension, mental status changes, unusual bowel habits). Monitor TSH, free T",
"     <sub>",
"      4",
"     </sub>",
"     and cortisol levels (morning) at baseline, prior to dose, and as clinically indicated. Monitor for signs and symptoms of enterocolitis (abdominal pain, blood or mucus in stool or diarrhea, and intestinal perforation (peritoneal signs, ileus). Monitor for rash and pruritus. Monitor for signs of motor or sensory neuropathy (unilateral or bilateral weakness, sensory changes or paresthesia). Monitor for ocular toxicity at baseline, then at 4-8 weeks with further evaluations as clinically indicated (Renouf, 2012).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13276709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Winglore (AU);",
"     </li>",
"     <li>",
"      Yervoy (AU, CH, CZ, DE, DK, EE, FR, GB, IE, NO, NZ, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F12706610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ipilimumab is a recombinant human IgG1 immunoglobulin monoclonal antibody which binds to the cytotoxic T-lymphocyte associated antigen 4 (CTLA-4). CTLA-4 is a down-regulator of T-cell activation pathways. Blocking CTLA-4 allows for enhanced T-cell activation and proliferation. In melanoma, ipilimumab may indirectly mediate T-cell immune responses against tumors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F12706620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      ss",
"     </sub>",
"     : 7.21 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Terminal: 15.4 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2011, 103(21):1572-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/52/19270/abstract-text/22010182/pubmed\" id=\"22010182\" target=\"_blank\">",
"        22010182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hodi FS, O&rsquo;Day SJ, McDermott DF, et al, &ldquo;Improved Survival with Ipilimumab in Patients with Metastatic Melanoma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 363(8):711-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/52/19270/abstract-text/20525992/pubmed\" id=\"20525992\" target=\"_blank\">",
"        20525992",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lynch TJ, Bondarenko IN, Luft A, et al, &ldquo;Phase II Trial of Ipilimumab (IPI) and Paclitaxel/Carboplatin (P/C) in First-Line Stage IIIb/IV Non-Small Cell Lung Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(15s):7531 [abstract 7531 from 2010 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Margolin K, Ernstoff MS, Hamid O, et al, \"Ipilimumab in Patients With Melanoma and Brain Metastases: An Open-Label, Phase 2 Trial,\"",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2012, 13(5):459-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/52/19270/abstract-text/22456429/pubmed\" id=\"22456429\" target=\"_blank\">",
"        22456429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O&rsquo;Day S, Hodi FS, McDermott DF, et al, &ldquo;A Phase III, Randomized, Double-Blind, Multicenter Study Comparing Monotherapy With Ipilimumab or GP100 Peptide Vaccine and the Combination in Patients With Previously Treated, Unresectable Stage III or IV Melanoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(15s):4 [abstract 4 from 2010 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prieto PA, Yang JC, Sherry RM, et al, \"CTLA-4 Blockade With Ipilimumab: Long-Term Follow-Up of 177 Patients With Metastatic Melanoma,\"",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2012, 18(7):2039-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/52/19270/abstract-text/22271879/pubmed\" id=\"22271879\" target=\"_blank\">",
"        22271879",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Renouf D, Velazquez-Martin JP, Simpson R, et al, &ldquo;Ocular Toxicity of Targeted Therapies,&rdquo;",
"      <i>",
"       J Clinl Oncol",
"      </i>",
"      , 2012, 30(26):3277-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/52/19270/abstract-text/22649132/pubmed\" id=\"22649132\" target=\"_blank\">",
"        22649132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vogel WV, Guislain A, Kvistborg P, et al, \"Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(2):e7-e10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/52/19270/abstract-text/22124094/pubmed\" id=\"22124094\" target=\"_blank\">",
"        22124094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weber JS, K&auml;hler KC, and Hauschild A, &ldquo;Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(21):2691-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/52/19270/abstract-text/22614989/pubmed\" id=\"22614989\" target=\"_blank\">",
"        22614989",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wolchok JD, Neyns B, Linette G, et al, &ldquo;Ipilimumab Monotherapy in Patients With Pretreated Advanced Melanoma: A Randomised, Double-Blind, Multicentre, Phase 2, Dose-Ranging Study,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(2):155-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/52/19270/abstract-text/20004617/pubmed\" id=\"20004617\" target=\"_blank\">",
"        20004617",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wolchok JD, Weber JS, Hamid O, et al, \"Ipilimumab Efficacy and Safety in Patients With Advanced Melanoma: A Retrospective Analysis of HLA Subtype From Four Trials,\"",
"      <i>",
"       Cancer Immun",
"      </i>",
"      , 2010, 10:9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/52/19270/abstract-text/20957980/pubmed\" id=\"20957980\" target=\"_blank\">",
"        20957980",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16084 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-89ED0DCEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_52_19270=[""].join("\n");
var outline_f18_52_19270=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12706580\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12743392\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14225438\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10940809\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10940812\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15670372\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15670373\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12706630\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12706635\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12706584\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12707872\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10940813\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12706609\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12706585\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10940805\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12706601\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12706590\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12706591\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299539\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12757387\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12706586\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12706587\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12706588\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12706589\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322871\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12706632\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276709\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12706610\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12706620\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16084\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16084|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/33/40468?source=related_link\">",
"      Ipilimumab: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_52_19271="Aspirin and extended-release dipyridamole: Drug information";
var content_f18_52_19271=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aspirin and extended-release dipyridamole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/57/2965?source=see_link\">",
"    see \"Aspirin and extended-release dipyridamole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F161522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aggrenox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F161523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aggrenox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F161543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiplatelet Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F161526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Stroke prevention:",
"     </b>",
"     Oral: One capsule (dipyridamole 200 mg, aspirin 25 mg) twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Alternative regimen for patients with intolerable headache:",
"     </b>",
"     Oral: One capsule at bedtime and low-dose aspirin in the morning. Return to usual dose (1 capsule twice daily) as soon as tolerance to headache develops (usually within a week).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Carotid artery stenosis, symptomatic (including recent carotid endarterectomy) (unlabeled use):",
"     </b>",
"     Oral: One capsule (dipyridamole 200 mg, aspirin 25 mg) twice daily (Guyatt, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hemodialysis graft patency (unlabeled use):",
"     </b>",
"     Oral: One capsule (dipyridamole 200 mg, aspirin 25 mg) twice daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F161527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F161528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use in patients with severe renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F161529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid use in patients with severe hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F161506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, variable release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aggrenox&reg;: Aspirin 25 mg [immediate release] and dipyridamole 200 mg [extended release] [contains lactose, sucrose]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F161491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F161508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Capsule should be swallowed whole; do not crush or chew. May be administered with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F161507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduction in the risk of stroke in patients who have had transient ischemia of the brain or ischemic stroke due to thrombosis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8096765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemodialysis graft patency; symptomatic carotid artery stenosis (including recent carotid endarterectomy)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F161551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Aggrenox&reg; may be confused with Aggrastat&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F161541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (39%; tolerance usually develops)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (18%), dyspepsia (18%), nausea (16%), diarrhea (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Cardiac failure (2%), syncope (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (6%), pain (6%), amnesia (2%), malaise (2%), seizure (2%), confusion (1%), somnolence (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Purpura (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (8%), GI bleeding (4%), melena (2%), rectal bleeding (2%), hemorrhoids (1%), GI hemorrhage (1%), anorexia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemorrhage (3%), anemia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (6%), back pain (5%), weakness (2%), arthritis (2%), arthrosis (1%), myalgia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (2%), epistaxis (2%), upper respiratory tract infection (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agitation, allergic reaction, allergic vasculitis, alopecia, anaphylaxis, anemia (aplastic), angina pectoris, angioedema, antepartum and postpartum bleeding, arrhythmia, asthma, bronchospasm, bruising, cerebral edema, cerebral hemorrhage, chest pain, cholelithiasis, coagulopathy, coma, deafness, dehydration, disseminated intravascular coagulation (DIC), dizziness, dyspnea, ecchymosis, fever, flushing, gastritis, gastrointestinal perforation, gastrointestinal ulceration, gingival bleeding, hearing impairment, hematemesis, hematoma, hematuria, hemoptysis, hepatic function abnormality, hepatic failure, hepatitis, hyper-/hypoglycemia, hyper-/hypokalemia, hyperpnea, hypotension, hypothermia, interstitial nephritis, intracranial hemorrhage, jaundice, laryngeal edema, metabolic acidosis, migraine, palpitation, pancreatitis, pancytopenia, papillary necrosis, paresthesia, PT time prolonged, proteinuria, pruritus, pulmonary edema, rash, renal failure, renal insufficiency, respiratory alkalosis, Reye's syndrome, rhabdomyolysis, Stevens-Johnson syndrome, subarachnoid hemorrhage, supraventricular tachycardia, tachycardia, tachypnea, taste loss, thirst, thrombocytopenia, thrombocytosis, tinnitus, urticaria, uterine hemorrhage",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F161511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dipyridamole, aspirin, or any component of the formulation; allergy to NSAIDs; patients with the syndrome of asthma, rhinitis, and nasal polyps; children &lt;16 years of age with viral infections; pregnancy (third trimester; aspirin)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Patients with hereditary fructose and/or galactose intolerance",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F161495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Salicylate sensitivity: Patients with sensitivity to tartrazine dyes, nasal polyps, and asthma may have an increased risk of salicylate sensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tinnitus: Discontinue use if tinnitus or impaired hearing occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with hypotension, unstable angina, and/or recent MI; discontinue use 24 hours prior to pharmacologic (I.V. dipyridamole) stress testing;",
"     <b>",
"      Note:",
"     </b>",
"     Amount of aspirin provided may not be adequate for cardiac indications (eg, MI prophylaxis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with acquired or inherited platelet and bleeding disorders; monitor for signs and symptoms of GI ulcers and bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with erosive gastritis or peptic ulcer disease. Avoid use with history of active peptic ulcer disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Heavy ethanol use (&gt;3 drinks/day) may increase bleeding risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; avoid use in severe hepatic failure. Elevated transaminases and hepatic failure have been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; avoid use in severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly who are at high risk for adverse events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Avoid use in children due to risk of Reye&rsquo;s syndrome in certain viral illness associated with aspirin component.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: ASA should be avoided (if possible) in surgical patients for 1-2 weeks prior to surgery, to reduce the risk of excessive bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactose/sucrose: Formulation contains lactose and/or sucrose; use in patients with fructose and/or galactose intolerance is contraindicated in the Canadian labeling.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F161537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F161500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Salicylates may diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: Dipyridamole may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: Dipyridamole may enhance the therapeutic effect of Adenosine. Dose reduction of adenosine may be needed.  Management: Reduction of the initial dose of adenosine may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alendronate: Aspirin may enhance the adverse/toxic effect of Alendronate. Specifically gastrointestinal adverse events.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Salicylates may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Dipyridamole may enhance the bradycardic effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the anticoagulant effect of Salicylates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Salicylates may increase the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Salicylates may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Weigh potential benefits of drotrecogin against increased bleeding risk in patients who have received  platelet inhibitors including aspirin (over 650 mg daily within 1 week). Monitor for bleeding and stop infusion if clinically important bleeding occurs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Floctafenine may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ginkgo Biloba: May enhance the anticoagulant effect of Salicylates. Management: Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin: Aspirin may enhance the anticoagulant effect of Heparin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Salicylates may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Salicylates may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Influenza Virus Vaccine (Live/Attenuated): May enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Nasal) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Aspirin. An increased risk of bleeding may be associated with use of this combination. Ketorolac (Systemic) may diminish the cardioprotective effect of Aspirin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Salicylates may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Aspirin. Aspirin may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, aspirin may decrease absorption of ascorbic acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Aspirin may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).  Management: Concurrent use of aspirin at doses beyond cardioprotective levels is not recommended.  While concurrent use of low-dose aspirin with a COX-2 inhibitor is permissable, patients should be monitored closely for signs/symptoms of GI ulceration/bleeding.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): May enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Aspirin may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of aspirin with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Acid Phosphate: May increase the serum concentration of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Salicylates may increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: Salicylates may diminish the therapeutic effect of Probenecid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regadenoson: Dipyridamole may enhance the therapeutic effect of Regadenoson.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of other Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: Aspirin may enhance the antiplatelet effect of Ticagrelor. Aspirin may diminish the therapeutic effect of Ticagrelor. More specifically, the benefits of ticagrelor relative to clopidogrel may be diminished in patients receiving daily aspirin doses greater than 100-150 mg daily.  Management: Avoid daily aspirin doses greater than 100 mg in patients receiving ticagrelor.  Canadian recommendations are to avoid daily aspirin doses greater than 150 mg.  Daily low-dose aspirin (U.S.: 75-100 mg; Canada: 75-150 mg) is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiludronate: Aspirin may decrease the serum concentration of Tiludronate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: BCRP/ABCG2 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Salicylates may increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Varicella Virus-Containing Vaccines: Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F161519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (due to GI irritation).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F161502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F161513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have shown an increase in aspirin-related fetal toxicity with this combination. Refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F161533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F161514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Both aspirin and dipyridamole are excreted in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F161515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F161512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 12-hour",
"     </b>",
"     (Aggrenox Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25-200 mg (60): $317.64",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F161504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemoglobin, hematocrit, signs or symptoms of bleeding, signs or symptoms of stroke or transient ischemic attack",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F161516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aggrenox (BE, CO, CZ, DE, GR, HK, ID, IL, IT, PH, PT, RU, TH, TW);",
"     </li>",
"     <li>",
"      Asasantin (HN, NL);",
"     </li>",
"     <li>",
"      Asasantin Retard (CH, DK, FI, GB, IE, NO, NZ, SE);",
"     </li>",
"     <li>",
"      Asasantin SR (AU);",
"     </li>",
"     <li>",
"      Asasantine LP (FR);",
"     </li>",
"     <li>",
"      De Li Shu (CL);",
"     </li>",
"     <li>",
"      Heng Yi (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F161494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The antithrombotic action results from additive antiplatelet effects. Dipyridamole inhibits the uptake of adenosine into platelets, endothelial cells, and erythrocytes. Aspirin inhibits platelet aggregation by irreversible inhibition of platelet cyclooxygenase and thus inhibits the generation of thromboxane A",
"     <sub>",
"      2",
"     </sub>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F161510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/52/19271/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al,  &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1295-1301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/52/19271/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/52/19271/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cryer B, Verlin RG, Cooper SA, et al, &ldquo;Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Ibuprofen Effects on Thromboxane B2 Concentrations in Aspirin-Treated Healthy Adult Volunteers,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2005, 27(2):185-191.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/52/19271/abstract-text/15811481/pubmed\" id=\"15811481\" target=\"_blank\">",
"        15811481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dixon BS, Beck GJ, Vazquez MA, et al, &ldquo;Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(21):2191-201.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/52/19271/abstract-text/19458364/pubmed\" id=\"19458364\" target=\"_blank\">",
"        19458364",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2012, 141(2 Suppl):7-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/52/19271/abstract-text/22315257/pubmed\" id=\"22315257\" target=\"_blank\">",
"        22315257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/52/19271/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8664 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-C3C4DA4C00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_52_19271=[""].join("\n");
var outline_f18_52_19271=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161522\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161523\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161543\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161526\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161527\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161528\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161529\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161506\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161491\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161508\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161507\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8096765\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161551\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161541\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161511\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161495\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161537\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161500\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161519\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161502\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161513\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161533\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161514\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161515\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161512\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161504\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161516\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161494\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161510\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8664\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8664|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/57/2965?source=related_link\">",
"      Aspirin and extended-release dipyridamole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_52_19272="Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis";
var content_f18_52_19272=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/52/19272/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/52/19272/contributors\">",
"     John P Atkinson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/52/19272/contributors\">",
"     Marco Cicardi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/52/19272/contributors\">",
"     Bruce Zuraw, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/52/19272/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/52/19272/contributors\">",
"     Sarbjit Saini, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/52/19272/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/52/19272/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/52/19272/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary angioedema (HAE) is a disease characterized by recurrent episodes of angioedema,",
"    <strong>",
"     without",
"    </strong>",
"    urticaria or pruritus, which most often affect the skin or mucosal tissues of the upper respiratory and gastrointestinal tracts. Although the swelling is self-limited, laryngeal involvement may cause fatal asphyxiation. Prior to the availability of effective therapy, this disorder was associated with a mortality rate of approximately 30 percent due to asphyxiation from laryngeal swelling.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, triggering and exacerbating factors, and prognosis of hereditary angioedema are discussed in this topic review. The evaluation, diagnosis, and acute and prophylactic therapies of this disorder are discussed separately:",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=see_link\">",
"     \"Hereditary angioedema: Pathogenesis and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=see_link\">",
"     \"Hereditary angioedema: Treatment of acute attacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29658?source=see_link\">",
"     \"Hereditary angioedema: Prevention of attacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hereditary angioedema types I and II are the focus of this topic review. These disorders are caused by deficiency or dysfunction of the C1 inhibitor protein. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=see_link&amp;anchor=H20554842#H20554842\">",
"     \"Hereditary angioedema: Pathogenesis and diagnosis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hereditary angioedema with normal C1 inhibitor (type III hereditary angioedema) is a clinically similar disorder, seen mostly in women, in which C1 inhibitor is normal. Some patients have factor XII defects. Type III HAE is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5080?source=see_link\">",
"     \"Type III hereditary angioedema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of hereditary angioedema is estimated at 1 individual per 50,000, with reported ranges from 1:10,000 to 1:150,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Males and females are affected equally, and there are no known differences in prevalence among ethnic groups [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Age of onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age at which attacks begin is variable, with rare reports of initial episodes of angioedema in the perinatal period [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/5\">",
"     5",
"    </a>",
"    ]. Approximately 40 percent of patients experience their first attack before age five, and 75 percent, by age 15, although repeated attacks in preadolescent children are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Thus, for the majority of patients, the disease first presents in childhood or adolescence. Attack frequency usually increases after puberty. In most cases, the diagnosis is eventually made in the second or third decade of life and can be further delayed if there is no family history.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HAE demonstrate characteristic abnormalities in the complement system, upon which the diagnosis is based. These are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=see_link\">",
"     \"Hereditary angioedema: Pathogenesis and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other than abnormal complement studies, patients with HAE are usually healthy and most commonly have normal routine laboratory values, although hypergammaglobulinemia has been noted in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Characteristic features of angioedema attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attacks most often affect three anatomical locations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The skin (cutaneous attacks)",
"     </li>",
"     <li>",
"      The gastrointestinal tract (gastrointestinal attacks)",
"     </li>",
"     <li>",
"      The upper airway",
"      <span class=\"nowrap\">",
"       (laryngeal/pharyngeal",
"      </span>",
"      attacks)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many attacks involve only one site at a time, although combination attacks, such as cutaneous attacks that spread to involve the larynx, are not uncommon. Attacks are always self-limited, lasting two to four days, and range in severity from inconvenient cutaneous swelling to life-threatening laryngeal edema [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Approximately 50 percent of patients experience all three manifestations during the course of their lives [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/6\">",
"     6",
"    </a>",
"    ]. Other general observations about HAE include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attack frequency varies from weekly to one or two episodes per year [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/12\">",
"       12",
"      </a>",
"      ]. Untreated, patients with frequent attacks may miss up to 100 to 150 work days per year [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/6\">",
"       6",
"      </a>",
"      ]. A few subjects remain asymptomatic and are identified as having hereditary C1-INH deficiency only as a result of family screening [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/1,5\">",
"       1,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Disease severity differs markedly among affected members within families, despite the presence of the same mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/5\">",
"       5",
"      </a>",
"      ]. Disease severity may also vary significantly in the same patient over time. The factors determining disease severity are unknown. A study found that severity correlated with the presence of elevated levels of IgM autoantibodies to the C1 inhibitor protein [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/10\">",
"       10",
"      </a>",
"      ]. This was noted in patients who had never received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/57/23444?source=see_link\">",
"       C1 inhibitor concentrate",
"      </a>",
"      for treatment, as well as in patients who had, so that it did not appear to be related to exposure to this agent. Nor was it proposed to have a direct role in determining disease severity. Rather, it was hypothesized that antibody formation may be a secondary phenomenon resulting from frequent activation of inflammatory pathways during attacks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=see_link&amp;anchor=H20554842#H20554842\">",
"       \"Hereditary angioedema: Pathogenesis and diagnosis\", section on 'Pathogenesis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2208859\">",
"    <span class=\"h3\">",
"     Prodromal symptoms and skin changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prodromal symptoms include fatigue, nausea, and flu-like symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/13\">",
"     13",
"    </a>",
"    ]. Some patients develop skin changes that are usually described as a serpentine, mottled,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    &ldquo;chicken-wire&rdquo; pattern of erythematous discoloration (",
"    <a class=\"graphic graphic_picture graphicRef79093 \" href=\"UTD.htm?26/15/26879\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. These findings can be mistaken for urticaria but more closely resemble erythema marginatum. Skin changes were noted consistently in 26 percent of patients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/18\">",
"     18",
"    </a>",
"    ]. Some patients experience episodes of prodromal symptoms that are not always followed by angioedema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cutaneous attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous attacks are common and temporarily disfiguring, although not generally dangerous. Skin swelling was present in 97 percent of 131,110 edema episodes in a retrospective series of 221 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/5\">",
"     5",
"    </a>",
"    ]. The extremities, face, and genitals are most commonly affected, although any site can be involved (",
"    <a class=\"graphic graphic_picture graphicRef71169 \" href=\"UTD.htm?28/59/29617\">",
"     picture 2",
"    </a>",
"    ). Swelling occurs in nondependent areas and is nonpitting. Cutaneous attacks are often associated with pain and dysfunction in addition to swelling [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/19\">",
"     19",
"    </a>",
"    ]. An episode typically begins in the skin with a peculiar tingling or sensation of fullness and irritation, followed by swelling and a sense of tightness in the next two to three hours. The angioedema builds over the first 24 hours, then gradually subsides over 48 to 72 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/20\">",
"     20",
"    </a>",
"    ]. Swelling may last up to five days in some patients. Attacks can also last longer if the swelling spreads from one site to another.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Laryngeal attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngeal swelling can occur in isolation, or in association with swelling of the lips, tongue, uvula, and soft palate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/5\">",
"     5",
"    </a>",
"    ]. Laryngeal edema occurs in approximately one-half of all patients over their lifetimes; however, only a few percent experience recurrent episodes, and in the large retrospective series mentioned above, laryngeal attacks accounted for less than 1 percent of all angioedema episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/5\">",
"     5",
"    </a>",
"    ]. Laryngeal attacks are less common in patients over the age of 45 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/20\">",
"     20",
"    </a>",
"    ]. Tooth extraction and oral surgery are common triggers. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Triggers and exacerbating factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Laryngeal swelling usually develops over hours, with a reported mean of seven hours [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/21\">",
"     21",
"    </a>",
"    ]. However, there are disturbing reports of fulminant laryngeal attacks, including a nine-year-old boy with a family history of HAE, but no previous attacks who died of asphyxiation 20 minutes after the apparent onset of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Although each laryngeal attack has the potential to become life-threatening, the majority resolves before complete airway obstruction, and one large series documented only two intubations and four cricothyrotomies among 342 laryngeal attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 70 fatal laryngeal attacks, researchers proposed that three phases of an attack can be distinguished [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The predyspnea phase, which starts with the first noticeable symptom and ends when dyspnea develops (average length, 3.7 hours, range 0 to 11 hours): During this phase, patients typically reported the sensation of a lump or feeling of tightness in the throat or swallowing difficulties, but not frank dyspnea. Six patients did not appear to have a predyspnea phase at all, as their initial symptom was dyspnea.",
"     </li>",
"     <li>",
"      The dyspnea phase, from onset of dyspnea to loss of consciousness (average length 41 minutes, range 2 minutes to 4 hours).",
"     </li>",
"     <li>",
"      The loss of consciousness phase, which starts with loss of consciousness and ends with death (average length 9 minutes, range 2 to 20 minutes).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, there is a window of opportunity in the predyspnea phase in which patients can seek and receive help, followed by a much shorter period in the dyspnea phase. In this study, 63 patients had not been diagnosed with HAE at the time of death, and seven had. Possible triggers were apparent in a minority of patients (eight had preceding upper respiratory tract infections and six had tooth extractions). The mean age of death by asphyxiation in undiagnosed patients was 40.6 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Gastrointestinal attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal attacks present as varying degrees of gastrointestinal colic, nausea, vomiting,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/24\">",
"     24",
"    </a>",
"    ]. These symptoms result from bowel wall edema. Gastrointestinal attacks are experienced by a majority of patients with HAE, and can be the principal presentation in one-quarter of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/5,12\">",
"     5,12",
"    </a>",
"    ]. A few families have been reported in which bowel attacks were the only manifestation.",
"   </p>",
"   <p>",
"    In a large, mostly retrospective, observational study of over 33,000 gastrointestinal attacks in 153 patients with HAE, symptoms and patterns of symptom development were analyzed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/25\">",
"     25",
"    </a>",
"    ]. The patients included in this series had received treatment with analgesics or spasmolytics only. All attacks were painful, with a mean pain score of 8.4 on a subjective scale of 1 (minimal) to 10 (maximal). Three quarters included nausea, vomiting, and abdominal distension, and 41 percent involved diarrhea. Four percent of patients experienced circulatory collapse. At least one prodromal symptom occurred at the onset of 70 percent of the attacks, and symptoms included fatigue, irritability, sensitivity to noise, hunger, and erythema marginatum. Attacks lasted four days on average, from the onset of prodromal symptoms to complete resolution, and peaked on the second day.",
"   </p>",
"   <p>",
"    Gastrointestinal attacks can be challenging to diagnose and the clinician must determine if the abdominal symptoms are due to angioedema or to an unrelated process. Patients who have had previous gastrointestinal attacks should be questioned carefully to ascertain if their current symptoms are similar to past episodes. Because of the clinical similarities between bowel attacks of angioedema and true surgical emergencies, as many as one-third of patients with undiagnosed HAE may undergo unwarranted abdominal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/6,26\">",
"     6,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H521587\">",
"    <span class=\"h4\">",
"     Objective findings",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most abdominal attacks are NOT associated with fever, peritoneal signs, or an elevated white blood cell count. However, these signs and symptoms can occur in severe attacks, as can hypovolemia from fluid losses, or hemoconcentration from plasma extravasation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vasodilation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CT scan of the abdomen and pelvis and ultrasonography are the most useful modalities in the evaluation of gastrointestinal attacks of HAE. The most common early finding is bowel wall edema, although this may resolve rapidly [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. Ascites may be the only finding during later stages of the attack.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2209216\">",
"    <span class=\"h3\">",
"     Unusual manifestations of HAE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unusual forms of attacks include episodic swelling of the bladder and urethra, circumscribed induration of muscles, chest tightness or pain, renal colic, joint swelling, and pleural or pericardial fluid accumulations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/5,31\">",
"     5,31",
"    </a>",
"    ]. There is sometimes accompanying or preceding cutaneous swelling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with HAE are otherwise healthy. However, there may be an association with autoimmune diseases and enhanced autoantibody production. Autoimmune conditions were reported in 19 of 157 patients (12 percent) in one series of patients with HAE [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/9\">",
"     9",
"    </a>",
"    ]. Associated disorders include thyroiditis, systemic lupus erythematosus (SLE), Sj&ouml;gren's syndrome, inflammatory bowel disease, glomerulonephritis, and a nonrheumatoid erosive arthritis of the wrists and hips [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. It has been proposed that the depressed levels of C4 seen in patients with HAE may contribute to the development of autoimmune disease, since C4 is important in the solubilization and clearance of immune complexes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Chronic overactivation of B cells (as determined by heightened expression of Toll-like receptor 9), has also been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/37\">",
"     37",
"    </a>",
"    ]. High rates of positivity for antinuclear antibodies were found in two series (16 and 28 percent, compared with 5 percent in the general population) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pancreatitis has been reported in patients with HAE, although it is not clear if the two disorders are pathologically related [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/9,39-43\">",
"     9,39-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TRIGGERS AND EXACERBATING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients report a variety of triggers for episodes of angioedema. Stress and dental procedures are the most common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20556359\">",
"    <span class=\"h2\">",
"     Physical triggers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild trauma, including dental work, is a common trigger and will precipitate episodes of angioedema in many patients. Intubation is another important trigger. Prophylaxis for prevention of attacks associated with dental work or surgery is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29658?source=see_link\">",
"     \"Hereditary angioedema: Prevention of attacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tongue-piercing, and snoring-induced local trauma of the soft palate have been implicated in isolated case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Genital swelling in women can be precipitated by sexual intercourse, as well as bicycle or horse riding [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/46\">",
"     46",
"    </a>",
"    ]. The reason one type of insult precipitates attacks, while another does not, is poorly understood.",
"   </p>",
"   <p>",
"    Other triggers that have been reported (although not all necessarily validated) include stress, excitement, cold exposure, prolonged sitting or standing, and ingestion of certain foods [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/35,47\">",
"     35,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Helicobacter pylori infections can trigger gastrointestinal attacks, and eradication of this infection can lead to significant reduction in the frequency of gastrointestinal attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following medications can exacerbate the frequency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity of HAE attacks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Estrogen-containing medications, such as hormone replacement therapy and contraceptives [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/50\">",
"       50",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Hormonal changes in women'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      , a selective estrogen receptor modulator (SERM) that has mixed",
"      <span class=\"nowrap\">",
"       agonist/antagonist",
"      </span>",
"      actions on the estrogen receptor. In one reported case, a patient with HAE who developed increased episodes on tamoxifen was successfully treated with the aromatase inhibitor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"       letrozole",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Angiotensin-converting enzyme (ACE) inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/47\">",
"       47",
"      </a>",
"      ]. In contrast, the experience of one author (MC) is that angiotensin II receptor blockers (ARBs) are well-tolerated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Hormonal changes in women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of hormonal fluctuations, including pregnancy, on women with HAE is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/18,52-55\">",
"     18,52-55",
"    </a>",
"    ]. The largest study was a retrospective questionnaire-based survey of 150 postpubertal women with HAE (both on and off therapy) from eight European countries, which reported the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/53\">",
"     53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disease worsened with puberty in 62 percent and did not change for the others.",
"     </li>",
"     <li>",
"      Attacks were associated with the perimenstrual or menstrual period in 35 percent.",
"     </li>",
"     <li>",
"      Use of oral contraceptives containing both estrogen and progesterone worsened disease severity in 80 percent of respondents. In contrast, progesterone-only contraceptives improved disease in 64 percent. Intrauterine devices were well-tolerated by 83 percent.",
"     </li>",
"     <li>",
"      Pregnancy was associated with more attacks in 38 percent, fewer in 30 percent, and no change in 32 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/53\">",
"       53",
"      </a>",
"      ]. Most women reported that the effects during an initial pregnancy were similar in subsequent pregnancies. Women who had attacks in association with menses were more likely to have worsening of disease during pregnancy, indicating that a subset of women is particularly sensitive to hormonal triggers.",
"     </li>",
"     <li>",
"      Delivery did not precipitate attacks in most women, as noted in other studies [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/18,54\">",
"       18,54",
"      </a>",
"      ]. The majority (89 percent) were not given prophylactic treatment in preparation for delivery, and yet attacks during or within two days of delivery occurred in only 6 percent.",
"     </li>",
"     <li>",
"      Of the 29 percent of participants who had experienced menopause, 55 percent noticed no change in disease activity. A worsening of attacks was reported by 32 percent.",
"     </li>",
"     <li>",
"      There were no detectable differences in the rates of gynecologic disease, infertility, or spontaneous abortion in women with HAE compared to those in the general population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another study followed 22 women with HAE through 35 pregnancies and found an increase in attack rates during pregnancy or in the post-partum period in 83 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/55\">",
"     55",
"    </a>",
"    ]. All women received replacement C1 inhibitor therapy during pregnancy and just prior to delivery, and none experienced attacks during labor or delivery. These patients were followed at a referral center, and so the severity of their disease may have been greater than that of patients with HAE treated elsewhere.",
"   </p>",
"   <p>",
"    Recommendations for the gynecologic and obstetric care of women with HAE are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29658?source=see_link&amp;anchor=H17326295#H17326295\">",
"     \"Hereditary angioedema: Prevention of attacks\", section on 'Gynecologic and obstetric care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for patients with hereditary angioedema is variable. Once attacks have begun, they generally continue throughout the patient's life, although the frequency of attacks can be dramatically reduced by therapy.",
"   </p>",
"   <p>",
"    Prior to the introduction of effective therapies for HAE, up to one-third of patients died of asphyxiation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/18\">",
"     18",
"    </a>",
"    ]. However, despite effective therapies, deaths secondary to laryngeal attacks still occur with some regularity, although data are limited. A series of Austrian, Swiss, and German patients published in 2004 cited a mortality rate as high as 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19272/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary angioedema (HAE) is a rare disorder caused by deficiency or dysfunction of the C1 inhibitor. HAE is characterized clinically by recurrent episodes of angioedema, without accompanying hives or pruritus, which most commonly affect the skin, bowel, or upper airway. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HAE affects men and women equally. There are no known racial predilections. Although symptoms often begin in childhood, the disease is usually diagnosed during puberty or early adulthood, when attacks become more frequent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An attack of HAE usually involves one site at a time (skin, viscera, or larynx). A prodrome of fatigue or erythematous rash is noticed by some patients. Attacks build in severity for 24 hours and then subside over the next 24 to 72 hours. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most life-threatening type of attack involves the upper airway, and any swelling in this area should be regarded as an emergency. Laryngeal attacks usually develop over hours, but there are reports of precipitous airway closure. Laryngeal edema occurs in approximately one-half of all patients over their lifetimes, although only a few percent experience recurrent episodes. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Laryngeal attacks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastrointestinal attacks are experienced by a majority of patients with HAE and present as varying degrees of gastrointestinal colic, nausea, vomiting",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diarrhea, which result from bowel wall edema. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Gastrointestinal attacks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cutaneous attacks are common and temporarily disfiguring, although not generally dangerous. The extremities, face, and genitals are most commonly affected, although any site can be involved (",
"      <a class=\"graphic graphic_picture graphicRef71169 \" href=\"UTD.htm?28/59/29617\">",
"       picture 2",
"      </a>",
"      ). Swelling occurs in nondependent areas and is nonpitting. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Cutaneous attacks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mild trauma, including dental work, is the most common trigger for cutaneous and laryngeal attacks. Other triggers that have been reported include estrogens, ACE inhibitors, stress, H. pylori infection, and menstruation. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Triggers and exacerbating factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once attacks have begun, they generally continue throughout the patient's life, although the frequency of attacks can be dramatically reduced by therapy. The mortality rate for patients with hereditary angioedema, despite effective therapies, has been estimated to be as high as 13 percent. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105904555\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors of this topic and the editorial staff at UpToDate, Inc. would like to acknowledge Dr. Albert L Sheffer, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/1\">",
"      Roche O, Blanch A, Caballero T, et al. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol 2005; 94:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/2\">",
"      Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010; 6:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/3\">",
"      Huang YT, Lin YZ, Wu HL, et al. Hereditary angioedema: a family study. Asian Pac J Allergy Immunol 2005; 23:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/4\">",
"      Moran E, Isaacs GS, Naidoo B, Pudifin DJ. Hereditary C1 esterase deficiency in a Zulu kindred. S Afr Med J 2009; 99:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/5\">",
"      Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006; 119:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/6\">",
"      Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/7\">",
"      Donaldson VH, Rosen FS. Hereditary angioneurotic edema: a clinical survey. Pediatrics 1966; 37:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/8\">",
"      Cicardi M, Bergamaschini L, Marasini B, et al. Hereditary angioedema: an appraisal of 104 cases. Am J Med Sci 1982; 284:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/9\">",
"      Brickman CM, Tsokos GC, Balow JE, et al. Immunoregulatory disorders associated with hereditary angioedema. I. Clinical manifestations of autoimmune disease. J Allergy Clin Immunol 1986; 77:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/10\">",
"      Varga L, Sz&eacute;plaki G, Visy B, et al. C1-inhibitor (C1-INH) autoantibodies in hereditary angioedema. Strong correlation with the severity of disease in C1-INH concentrate na&iuml;ve patients. Mol Immunol 2007; 44:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/11\">",
"      Cicardi M, Agostoni A. Hereditary angioedema. N Engl J Med 1996; 334:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/12\">",
"      Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol 2005; 139:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/13\">",
"      Prematta MJ, Bewtra AK, Levy RJ, et al. Per-attack reporting of prodromal symptoms concurrent with C1-inhibitor treatment of hereditary angioedema attacks. Adv Ther 2012; 29:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/14\">",
"      Farkas H, Harmat G, F&aacute;y A, et al. Erythema marginatum preceding an acute oedematous attack of hereditary angioneurotic oedema. Acta Derm Venereol 2001; 81:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/15\">",
"      Starr JC, Brasher GW. Erythema marginatum preceding hereditary angioedema. J Allergy Clin Immunol 1974; 53:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/16\">",
"      Williamson DM. Reticulate erythema--a prodrome in hereditary angio-oedema. Br J Dermatol 1979; 101:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/17\">",
"      Yucelten D, Kus S. Chicken-wire erythema, but not urticaria, as the presenting sign of hereditary angioedema. Eur J Dermatol 2006; 16:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/18\">",
"      Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 1976; 84:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/19\">",
"      Kusuma A, Relan A, Knulst AC, et al. Clinical impact of peripheral attacks in hereditary angioedema patients. Am J Med 2012; 125:937.e17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/20\">",
"      Bork K, Hardt J, Schicketanz KH, Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med 2003; 163:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/21\">",
"      Bork K, Siedlecki K, Bosch S, et al. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 2000; 75:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/22\">",
"      Jensen NF, Weiler JM. C1 esterase inhibitor deficiency, airway compromise, and anesthesia. Anesth Analg 1998; 87:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/23\">",
"      Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012; 130:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/24\">",
"      Nzeako UC, Longhurst HJ. Many faces of angioedema: focus on the diagnosis and management of abdominal manifestations of hereditary angioedema. Eur J Gastroenterol Hepatol 2012; 24:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/25\">",
"      Bork K, Staubach P, Eckardt AJ, Hardt J. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol 2006; 101:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/26\">",
"      Sheffer AL, Craig JM, Willms-Kretschmer K, et al. Histopathological and ultrastructural observations on tissues from patients with hereditary angioneurotic edema. J Allergy 1971; 47:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/27\">",
"      Prada AE, Zahedi K, Davis AE 3rd. Regulation of C1 inhibitor synthesis. Immunobiology 1998; 199:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/28\">",
"      Cohen N, Sharon A, Golik A, et al. Hereditary angioneurotic edema with severe hypovolemic shock. J Clin Gastroenterol 1993; 16:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/29\">",
"      Dinkel HP, Maroske J, Schrod L. Sonographic appearances of the abdominal manifestations of hereditary angioedema. Pediatr Radiol 2001; 31:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/30\">",
"      Farkas H, Harmat G, Kaposi PN, et al. Ultrasonography in the diagnosis and monitoring of ascites in acute abdominal attacks of hereditary angioneurotic oedema. Eur J Gastroenterol Hepatol 2001; 13:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/31\">",
"      Bonnaud I, Rouaud V, Guyot M, et al. Exceptional stroke-like episodes in a patient with type I autosomal angioedema. Neurology 2012; 78:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/32\">",
"      Koide M, Shirahama S, Tokura Y, et al. Lupus erythematosus associated with C1 inhibitor deficiency. J Dermatol 2002; 29:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/33\">",
"      Palazzi C, D'Amico E, Cacciatore P, et al. Non-rheumatoid erosive arthritis associated with type I hereditary angioedema. Clin Rheumatol 2005; 24:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/34\">",
"      Khan S, Tarzi MD, Dor&eacute; PC, et al. Secondary systemic lupus erythematosus: an analysis of 4 cases of uncontrolled hereditary angioedema. Clin Immunol 2007; 123:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/35\">",
"      Agostoni A, Ayg&ouml;ren-P&uuml;rs&uuml;n E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004; 114:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/36\">",
"      Alper CA. Inherited deficiencies of complement components in man. Immunol Lett 1987; 14:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/37\">",
"      Kessel A, Peri R, Perricone R, et al. The autoreactivity of B cells in hereditary angioedema due to C1 inhibitor deficiency. Clin Exp Immunol 2012; 167:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/38\">",
"      Farkas H, Csuka D, G&aacute;cs J, et al. Lack of increased prevalence of immunoregulatory disorders in hereditary angioedema due to C1-inhibitor deficiency. Clin Immunol 2011; 141:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/39\">",
"      Cutler AF, Yousif EA, Blumenkehl ML. Hereditary angioedema associated with pancreatitis. South Med J 1992; 85:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/40\">",
"      Ben Maamer A, Zaafouri H, Haoues N, Cherif A. Acute pancreatitis due to hereditary angioedema. Tunis Med 2011; 89:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/41\">",
"      Matesic D, Fern&aacute;ndez P&eacute;rez ER, Vlahakis NE, Hagan JB. Acute pancreatitis due to hereditary angioedema. Ann Allergy Asthma Immunol 2006; 97:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/42\">",
"      Czaller I, Moln&aacute;r K, Csuka D, et al. Successful outcome using C1-inhibitor concentrate in acute pancreatitis caused by hereditary angioedema. Gastroenterol Nurs 2011; 34:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/43\">",
"      Cancian M, Vettore G, Realdi G. An uncommon cause of acute pancreatitis. Hereditary angioedema-induced acute pancreatitis. Gastroenterology 2011; 140:33, 370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/44\">",
"      Trachsel D, Hammer J. A vote for inhaled adrenaline in the treatment of severe upper airway obstruction caused by piercing of the tongue in hereditary angioedema. Intensive Care Med 1999; 25:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/45\">",
"      Bork K, Koch P. Episodes of severe dyspnea caused by snoring-induced recurrent edema of the soft palate in hereditary angioedema. J Am Acad Dermatol 2001; 45:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/46\">",
"      Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012; 129:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/47\">",
"      Ricketti AJ, Cleri DJ, Ramos-Bonner LS, Vernaleo JR. Hereditary angioedema presenting in late middle age after angiotensin-converting enzyme inhibitor treatment. Ann Allergy Asthma Immunol 2007; 98:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/48\">",
"      Farkas H, F&uuml;st G, Fekete B, et al. Eradication of Helicobacter pylori and improvement of hereditary angioneurotic oedema. Lancet 2001; 358:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/49\">",
"      Visy B, F&uuml;st G, Bygum A, et al. Helicobacter pylori infection as a triggering factor of attacks in patients with hereditary angioedema. Helicobacter 2007; 12:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/50\">",
"      Bork K, Fischer B, Dewald G. Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy. Am J Med 2003; 114:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/51\">",
"      Rousset-Jablonski C, Thalabard JC, Gompel A. Tamoxifen contraindicated in women with hereditary angioedema? Ann Oncol 2009; 20:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/52\">",
"      Bork K, Wulff K, Hardt J, et al. Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol 2009; 124:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/53\">",
"      Bouillet L, Longhurst H, Boccon-Gibod I, et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol 2008; 199:484.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/54\">",
"      Chinniah N, Katelaris CH. Hereditary angioedema and pregnancy. Aust N Z J Obstet Gynaecol 2009; 49:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19272/abstract/55\">",
"      Martinez-Saguer I, Rusicke E, Ayg&ouml;ren-P&uuml;rs&uuml;n E, et al. Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate. Am J Obstet Gynecol 2010; 203:131.e1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8103 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-0C50FA751B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_52_19272=[""].join("\n");
var outline_f18_52_19272=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Age of onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Characteristic features of angioedema attacks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2208859\">",
"      - Prodromal symptoms and skin changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cutaneous attacks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Laryngeal attacks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Gastrointestinal attacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H521587\">",
"      Objective findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2209216\">",
"      - Unusual manifestations of HAE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Associated conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TRIGGERS AND EXACERBATING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20556359\">",
"      Physical triggers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Hormonal changes in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H105904555\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/8103\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/8103|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/15/26879\" title=\"picture 1\">",
"      HAE prodromal rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/59/29617\" title=\"picture 2\">",
"      Hereditary angioedema",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/4/33864?source=related_link\">",
"      Hereditary angioedema: Pathogenesis and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29658?source=related_link\">",
"      Hereditary angioedema: Prevention of attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33657?source=related_link\">",
"      Hereditary angioedema: Treatment of acute attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/61/5080?source=related_link\">",
"      Type III hereditary angioedema",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_52_19273="Cardiac tamponade";
var content_f18_52_19273=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiac tamponade",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/52/19273/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/52/19273/contributors\">",
"     Brian D Hoit, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/52/19273/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/52/19273/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/52/19273/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/52/19273/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/52/19273/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/52/19273/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal pericardium is a fibroelastic sac containing a thin layer of fluid that surrounds the heart. When larger amounts of fluid accumulate (pericardial effusion) or when the pericardium becomes scarred and inelastic, one of three pericardial compressive syndromes may occur:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac tamponade &ndash; Cardiac tamponade, which may be acute or subacute, is characterized by the accumulation of pericardial fluid under pressure. Variants include low pressure (occult) and regional cardiac tamponade.",
"     </li>",
"     <li>",
"      Constrictive pericarditis &ndash; Constrictive pericarditis is the result of scarring and consequent loss of elasticity of the pericardial sac. Pericardial constriction is typically chronic, but variants include subacute, transient, and occult constriction.",
"     </li>",
"     <li>",
"      Effusive-constrictive pericarditis &ndash; Effusive-constrictive pericarditis is characterized by underlying constrictive physiology with a coexisting pericardial effusion, usually with cardiac tamponade. Such patients may be mistakenly thought to have only cardiac tamponade; however, elevation of the right atrial and pulmonary wedge pressures after drainage of the pericardial fluid points to the underlying constrictive process.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In both cardiac tamponade and constrictive pericarditis, cardiac filling is impeded by an external force. The normal pericardium can stretch to accommodate physiologic changes in cardiac volume. However, after its reserve volume is exceeded the pericardium markedly stiffens. An important pathophysiologic feature of both cardiac tamponade and constrictive pericarditis is greatly enhanced ventricular interaction or interdependence, in which the hemodynamics of the left and right heart chambers are directly influenced by each other to a much greater degree than normal.",
"   </p>",
"   <p>",
"    The physiology, clinical presentation, diagnosis, and treatment of cardiac tamponade will be reviewed here. Issues related to constrictive pericarditis and the evaluation and management of pericardial diseases that do not compromise hemodynamics are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link\">",
"     \"Diagnosis and treatment of pericardial effusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cardiac tamponade, the primary abnormality is compression of all cardiac chambers due to increased pericardial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The pericardium has some degree of elasticity; but once the elastic limit is reached, the heart must compete with the intrapericardial fluid for the fixed intrapericardial volume. As cardiac tamponade progresses, the cardiac chambers become smaller and chamber diastolic compliance is reduced. The following consequences result from this constrained cardiac filling:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progressive changes in systemic venous return &ndash; Venous return is normally bimodal with peaks during ventricular systole and early diastole. The effusion produces compression throughout the cardiac cycle, with cardiac volume becoming minimal during ejection. Thus, as cardiac tamponade becomes more severe, venous return is progressively shifted to systole as the peak associated with early diastolic filling diminishes. When cardiac tamponade is very severe, total venous return falls, the cardiac chambers shrink, and cardiac output and blood pressure fall.",
"     </li>",
"     <li>",
"      Respiratory variation in venous return &ndash; Inspiratory decline in thoracic pressure is transmitted through the pericardium to the right side of the heart. As a result, systemic venous return increases with inspiration. In cardiac tamponade, the rigid pericardium prevents the free wall from expanding. The ensuing distension of the right ventricle is limited to the interventricular septum, causing it to bulge to the left, reducing left ventricular compliance and contributing to decreased filling of the left ventricle during inspiration. This concept is referred to as ventricular interaction or ventricular interdependence.",
"      <br/>",
"      <br/>",
"      These changes will occur once pericardial pressure becomes substantially higher than ventricular diastolic pressures. However, in less severe disease, the degree to which they occur is related in part to the rate of pericardial fluid accumulation and to pericardial compliance, both of which are related to the underlying cause [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/1,3\">",
"       1,3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acute bleeding (eg, due to trauma) into a relatively stiff pericardium can rapidly lead to cardiac tamponade. As intrapericardial volume increases, there is an initial small increase in intrapericardial pressure followed by an almost vertical ascent (",
"      <a class=\"graphic graphic_figure graphicRef75068 \" href=\"UTD.htm?3/55/3966\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In comparison, chronic accumulation of a pericardial effusion (eg, due to renal failure or malignancy) allows the pericardial compliance to increase gradually. As a result, intrapericardial pressure increases more slowly until a critical point is reached when an almost vertical ascent is again seen (",
"      <a class=\"graphic graphic_figure graphicRef75068 \" href=\"UTD.htm?3/55/3966\">",
"       figure 1",
"      </a>",
"      ). In this setting, cardiac tamponade may not occur until two liters or more have accumulated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Very little fluid needs to accumulate to produce cardiac tamponade once the pericardium can no longer stretch [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/1\">",
"     1",
"    </a>",
"    ]. At this point, the initial removal of fluid during pericardiocentesis produces the largest reduction in intrapericardial pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of cardiac tamponade include all of the causes of pericardial effusion or hemorrhage into the pericardium (",
"    <a class=\"graphic graphic_table graphicRef67851 \" href=\"UTD.htm?7/0/7181\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef78847 \" href=\"UTD.htm?33/52/34636\">",
"     table 2",
"    </a>",
"    ). In one series, cardiac tamponade occurred in 14 percent of patients with idiopathic pericarditis and 61 percent of those with neoplastic, tuberculous, or purulent pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=see_link\">",
"     \"Etiology of pericardial disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1050?source=see_link\">",
"     \"Pericardial disease associated with malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2633?source=see_link\">",
"     \"Tuberculous pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac tamponade has been described in less than one percent of patients with an acute myocardial infarction treated with fibrinolytic therapy; the risk may be lower in patients treated with percutaneous coronary intervention. The two major mechanisms are left ventricular free wall rupture and hemorrhagic pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/5\">",
"     5",
"    </a>",
"    ]. Cardiac tamponade is a frequently complication of type A aortic dissection, occurring in 19 percent of patients in an international registry [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24055?source=see_link&amp;anchor=H9#H9\">",
"     \"Pericardial complications of myocardial infarction\", section on 'Risk of tamponade'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of patients with cardiac tamponade largely depends upon the length of time over which pericardial fluid accumulates and the clinical situation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute cardiac tamponade occurs within minutes, due to trauma, rupture of the heart or aorta, or as a complication of an invasive diagnostic or therapeutic procedure. This generally results in a picture resembling cardiogenic shock that requires urgent reduction in pericardial pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=see_link&amp;anchor=H6092649#H6092649\">",
"       \"Initial evaluation and management of penetrating thoracic trauma in adults\", section on 'Pericardial tamponade'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Subacute cardiac tamponade occurs over days to weeks and can be associated with neoplastic, uremic, or idiopathic pericarditis. Symptoms include dyspnea, chest discomfort or fullness, peripheral edema, and fatigability.",
"     </li>",
"     <li>",
"      Low pressure (occult) cardiac tamponade, a subset of subacute cardiac tamponade, occurs in patients who are severely hypovolemic.",
"     </li>",
"     <li>",
"      Regional cardiac tamponade occurs when a loculated, eccentric effusion or localized hematoma produces regional cardiac tamponade in which only selected chambers are compressed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acute cardiac tamponade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute cardiac tamponade is sudden in onset, may be associated with chest pain, tachypnea, and dyspnea, and is life-threatening if not promptly treated. The jugular venous pressure is markedly elevated, and may be associated with venous distension in the forehead and scalp. The heart sounds are often muted. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Physical findings'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H26\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hypotension is common due to the decline in cardiac output. Patients in cardiogenic shock typically have cool extremities, peripheral cyanosis, and decreased urine output. As noted above, the pericardial effusion in such patients is usually small because the pericardium is stiff (",
"    <a class=\"graphic graphic_figure graphicRef75068 \" href=\"UTD.htm?3/55/3966\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Subacute cardiac tamponade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subacute cardiac tamponade is usually a less dramatic process than acute cardiac tamponade. Patients may be asymptomatic early in the course, but, once intrapericardial pressure reaches a critical value, they complain of dyspnea, chest discomfort or fullness, peripheral edema, fatigability, or other symptoms referable to increased filling pressures and limited cardiac output.",
"   </p>",
"   <p>",
"    The physical examination in subacute severe cardiac tamponade may reveal hypotension with a narrow pulse pressure, reflecting the limited stroke volume. However, patients with preexisting hypertension may remain hypertensive due to increased sympathetic activity in the setting of cardiac tamponade.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Low pressure cardiac tamponade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are severely hypovolemic because of traumatic hemorrhage, hemodialysis or ultrafiltration, or overdiuresis at presentation may have low pressure cardiac tamponade in which the intracardiac and pericardial diastolic pressures are only 6 to 12 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/1\">",
"     1",
"    </a>",
"    ]. The hemodynamic significance of these effusions can be demonstrated on echocardiography by right heart chamber collapse and respiratory variations in transvalvular flows. A fluid challenge with a rapid infusion of one liter of isotonic saline in the catheterization laboratory will usually elicit typical cardiac tamponade hemodynamics.",
"   </p>",
"   <p>",
"    The clinical characteristics of low pressure cardiac tamponade were illustrated in a series of 279 patients from a single institution who underwent combined pericardiocentesis and cardiac catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients were considered to have cardiac tamponade if intrapericardial pressures were equal to right atrial pressure prior to pericardiocentesis. Among 143 patients with cardiac tamponade, low pressure cardiac tamponade was diagnosed in 29 patients who had an initial intrapericardial pressure &lt;7 mmHg and a right atrial pressure after pericardiocentesis &lt;4 mmHg.",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Echocardiographic abnormalities (eg, size of the pericardial effusion, right sided chamber collapse, and exaggerated respiratory changes in mitral and tricuspid valve flow) were similar in frequency and magnitude to patients with classic cardiac tamponade. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Echocardiography'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The spectrum of etiologies was similar to patients with classic cardiac tamponade. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical findings commonly associated with cardiac tamponade (eg, elevated heart rate, jugular venous distention, and pulsus paradoxus) were significantly less common in low pressure cardiac tamponade than in classic cardiac tamponade. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Physical findings'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Regional cardiac tamponade",
"    </span>",
"    &nbsp;&mdash;&nbsp;A loculated, eccentric effusion or localized hematoma can produce regional cardiac tamponade in which only selected chambers are compressed. As a result, the typical physical, hemodynamic, and echocardiographic signs of cardiac tamponade are often absent, including pulsus paradoxus, diastolic pressure equalization and chamber compression in standard apical and parasternal views.",
"   </p>",
"   <p>",
"    Regional cardiac tamponade is most often seen after pericardiotomy or myocardial infarction. Clinical suspicion should be heightened in these settings. Establishing the diagnosis is challenging and may require additional echocardiographic views (eg, subcostal or transesophageal) and other advanced imaging techniques (eg, computed tomography).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PHYSICAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of findings may be present on physical examination, depending upon the type and severity of cardiac tamponade [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/9\">",
"     9",
"    </a>",
"    ]. Physical findings such as sinus tachycardia, even in the absence of frank hypotension, may indicate significant hemodynamic compromise from cardiac tamponade and serve as an indication for immediate pericardiocentesis. In contrast, Kussmaul's sign (the absence of an inspiratory decline in jugular venous pressure) is not usually seen in cardiac tamponade. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=see_link&amp;anchor=H20#H20\">",
"     \"Examination of the jugular venous pulse\", section on 'Kussmaul's sign'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Sinus tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus tachycardia is seen in almost all patients, allowing for at least partial maintenance of cardiac output. One exception is when the underlying disease is associated with bradycardia, as with a pericardial effusion and subacute cardiac tamponade associated with hypothyroidism. Tachycardia also may not be seen in patients with early cardiac tamponade even though they have signs of a hemodynamically significant effusion, such as an elevated jugular venous pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Elevated jugular venous pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The jugular venous pressure is almost always elevated in cardiac tamponade and may be associated with venous distension in the forehead and scalp. The x descent is preserved while the y descent is attenuated or absent because of the limited or absent late diastolic filling of the ventricle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=see_link\">",
"     \"Examination of the jugular venous pulse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pulsus paradoxus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulsus paradoxus, defined as an abnormally large decrease in systolic blood pressure (&gt;10 mmHg) on inspiration, is a common finding in moderate to severe cardiac tamponade and is the direct consequence of ventricular interdependence. The limitation on outward expansion of the right ventricle as blood flows in during inspiration results in bulging of the interventricular septum into the left ventricle, leading to a large reduction in left ventricular filling that contributes to a large decrease in stroke volume (",
"    <a class=\"graphic graphic_waveform graphicRef55709 \" href=\"UTD.htm?7/35/7734\">",
"     waveform 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef63439 \" href=\"UTD.htm?6/0/6154\">",
"     waveform 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef70731 \" href=\"UTD.htm?31/27/32180\">",
"     waveform 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. However, not all patients with cardiac tamponade have pulsus paradoxus (eg, those with chronic hypertension leading to elevated ventricular diastolic pressures or those with a co-existent atrial septal defect). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11158?source=see_link\">",
"     \"Pulsus paradoxus in pericardial disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Pericardial rub",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pericardial rub may be heard in patients with cardiac tamponade due to inflammatory pericarditis (",
"    <a class=\"graphic graphic_movie graphicRef56608 \" href=\"UTD.htm?0/18/291\">",
"     movie 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242973981\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients suspected of having cardiac tamponade should be evaluated with an electrocardiogram, chest radiograph, and echocardiography. Other imaging techniques, such as computed tomography (CT) and cardiovascular magnetic resonance (CMR), are not usually necessary for the diagnosis of a pericardial effusion if echocardiography is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Electrocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram (ECG) in cardiac tamponade typically shows sinus tachycardia and may also show low voltage. If pericarditis is present, the ECG findings typical of that disorder are also seen (",
"    <a class=\"graphic graphic_waveform graphicRef77572 \" href=\"UTD.htm?42/53/43866\">",
"     waveform 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23669?source=see_link\">",
"     \"Electrocardiogram in pericarditis and pericardial effusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electrical alternans is characterized by beat-to-beat alterations in the QRS complex and, in some cases, other electrocardiographic waves that reflect the swinging of the heart in the pericardial fluid (",
"    <a class=\"graphic graphic_waveform graphicRef72525 \" href=\"UTD.htm?42/27/43450\">",
"     waveform 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef66715 \" href=\"UTD.htm?31/42/32420\">",
"     movie 2",
"    </a>",
"    ). Electrical alternans is relatively specific but not very sensitive for cardiac tamponade; rarely, this phenomenon is seen with very large pericardial effusions alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/1,12\">",
"     1,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35558?source=see_link&amp;anchor=H3#H3\">",
"     \"ECG tutorial: Miscellaneous diagnoses\", section on 'Electrical alternans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested that low QRS voltage in patients with a pericardial effusion is actually a specific manifestation of cardiac tamponade, not of the effusion. This possibility was illustrated in a study of 43 patients with a pericardial effusion; cardiac tamponade was present in 23 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/13\">",
"     13",
"    </a>",
"    ]. Low QRS voltage (defined as maximum QRS amplitude &lt;0.5 mV in the limb leads) was found in 14 of the 23 patients with cardiac tamponade (61 percent), but in none with effusion without cardiac tamponade. The low voltage resolved within one week after treatment of cardiac tamponade by either pericardiocentesis or antiinflammatory medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Chest x-ray",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chest x-ray showing an enlarged cardiac silhouette with clear lung fields may be seen in slowly developing cardiac tamponade (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57640 \" href=\"UTD.htm?10/56/11136\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/9\">",
"     9",
"    </a>",
"    ]. Cardiomegaly is not usually seen in acute cardiac tamponade since at least 200 mL of pericardial fluid must accumulate before the cardiac silhouette enlarges [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cardiac tamponade is a clinical diagnosis, two dimensional and Doppler echocardiography play major roles in the identification of pericardial effusion and in assessing its hemodynamic significance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. The use of echocardiography for the evaluation of all patients with suspected pericardial disease was highly recommended by a 2003 task force of the American College of Cardiology (ACC), the American Heart Association (AHA), and the American Society of Echocardiography (ASE) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/14\">",
"     14",
"    </a>",
"    ]. In patients who do not have cardiac tamponade on initial assessment, but in whom the suspicion is high, repeat echocardiography during clinical follow-up may be appropriate to detect early signs of developing cardiac tamponade in the presence of large or rapidly accumulating effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most cases of cardiac tamponade, a moderate to large effusion is present and swinging of the heart within the effusion may be seen (",
"    <a class=\"graphic graphic_movie graphicRef66715 \" href=\"UTD.htm?31/42/32420\">",
"     movie 2",
"    </a>",
"    ). Echocardiographic findings suggesting hemodynamic compromise are the result of transiently reversed right atrial and right ventricular diastolic transmural pressures. Cardiac chamber collapse typically occurs before clinical hemodynamic failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27077?source=see_link\">",
"     \"Echocardiographic evaluation of the pericardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following are the major echocardiographic signs of cardiac tamponade, which may not be seen in all patients due to other underlying conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chamber collapse &ndash; Collapse of any cardiac chamber, but usually the right sided chambers, occurs when intrapericardial pressure exceeds intracardiac pressure within a particular chamber [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/9,16\">",
"       9,16",
"      </a>",
"      ]. Both the right atrium and right ventricle are compliant structures. As a result, increased intrapericardial pressure leads to their collapse when intracavitary pressures are only slightly exceeded by those in the pericardium [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Diastolic collapse of the right atrium (RA) &ndash; At end-diastole (during atrial relaxation), the RA volume is minimal, but pericardial pressure is maximal, causing the RA to buckle (",
"      <a class=\"graphic graphic_movie graphicRef74765 \" href=\"UTD.htm?37/37/38483\">",
"       movie 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/18\">",
"       18",
"      </a>",
"      ]. RA collapse, especially when it persists for more than one-third of the cardiac cycle, is highly sensitive and specific for cardiac tamponade. In contrast, brief RA collapse can occur in the absence of cardiac tamponade [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Diastolic collapse of the right ventricle (RV) &ndash; RV diastolic collapse occurs in early diastole when the RV volume is still low (",
"      <a class=\"graphic graphic_movie graphicRef57972 \" href=\"UTD.htm?15/3/15408\">",
"       movie 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef64027 \" href=\"UTD.htm?29/24/30094\">",
"       movie 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef59345 \" href=\"UTD.htm?29/35/30270\">",
"       movie 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/16\">",
"       16",
"      </a>",
"      ]. RV diastolic collapse is less sensitive for the presence of cardiac tamponade than RA diastolic collapse, but is very specific for cardiac tamponade [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/19\">",
"       19",
"      </a>",
"      ]. RV collapse may not occur when the RV is hypertrophied or its diastolic pressure is greatly elevated [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Left sided chamber collapse &ndash; Left atrial collapse is seen in about 25 percent of patients with hemodynamic compromise and is very specific for cardiac tamponade [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/1,9,16,20,21\">",
"       1,9,16,20,21",
"      </a>",
"      ]. Left ventricular collapse is less common, since the wall of the left ventricle is more muscular, but can be seen in cases of regional cardiac tamponade [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/9,16,21\">",
"       9,16,21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory variation in volumes and flows &ndash; Reciprocal changes in left and right ventricular volumes occur with respiration and, during inspiration, the ventricular and atrial septa move leftward, a process reversed with expiration (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51257 \" href=\"UTD.htm?20/13/20692\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef80346 \" href=\"UTD.htm?34/13/35033\">",
"       waveform 6",
"      </a>",
"      ). As noted above, these changes play a central role in the pathogenesis of pulsus paradoxus. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Pulsus paradoxus'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The respiratory variation of mitral and tricuspid flow velocities is greatly increased and out of phase, reflecting the increased ventricular interdependence in which the hemodynamics of the left and right heart chambers are directly influenced by each other to a much greater degree than normal. Normally there is no more than 20 to 25 percent variation in the amplitude of inflow and outflow signals across the valves during respiration. However, in cardiac tamponade, mitral flow variation exceeds 35 percent, and tricuspid valve flow exceeds 80 to 100 percent. This pattern is seen at all sampling sites and is best appreciated at slow sweep speeds (",
"      <a class=\"graphic graphic_waveform graphicRef63439 \" href=\"UTD.htm?6/0/6154\">",
"       waveform 2",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Increased respiratory variation of carotid arterial and aortic blood flow may also be seen [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IVC plethora &ndash; Dilatation and less than a 50 percent reduction in the diameter of the dilated inferior vena cava (IVC) during inspiration, reflecting a marked elevation in central venous pressure, is frequently seen in patients with cardiac tamponade (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58804 \" href=\"UTD.htm?24/55/25457\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79134 \" href=\"UTD.htm?40/27/41392\">",
"       image 4",
"      </a>",
"      ). In one report, IVC plethora was associated with pulsus paradoxus and was present in 92 percent of those with pericardial effusion who required pericardial drainage [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/23\">",
"       23",
"      </a>",
"      ]. It is highly sensitive but not at all specific for cardiac tamponade.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The correlation between clinical and echocardiographic findings was evaluated in a prospective study of 110 patients with a moderate to large pericardial effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/24\">",
"     24",
"    </a>",
"    ]. The reference standard was clinical cardiac tamponade (venous hypertension, pulsus paradoxus, or otherwise unexplained arterial hypotension, and resolution of the syndrome after removal of the pericardial effusion), which was present in 38 patients. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Any chamber collapse had a sensitivity and specificity of 90 and 65 percent, respectively.",
"     </li>",
"     <li>",
"      The sensitivity was lower and specificity higher (75 and 91 percent) for abnormal right-sided venous flows (systolic predominance and expiratory diastolic reversal), but the latter could not be evaluated in more than one-third of patients.",
"     </li>",
"     <li>",
"      The specificity was highest (98 percent) for the combination of right atrial and right ventricular collapse plus abnormal venous flow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     CT and CMR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other imaging techniques, such as computed tomography (CT) and cardiovascular magnetic resonance (CMR), are not usually necessary for the evaluation of a pericardial effusion if echocardiography is available. However, pericardial effusion may be first detected by CT.",
"   </p>",
"   <p>",
"    CT or CMR findings associated with cardiac tamponade include pericardial effusion, distention of the venae cavae and hepatic veins, deformity and compression of the cardiac chambers, bowing of the interventricular septum, and reflux of contrast into the azygos vein and inferior vena cava [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/25\">",
"     25",
"    </a>",
"    ]. One report suggested that coronary sinus compression on CT is an early specific indicator of cardiac tamponade [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/26\">",
"     26",
"    </a>",
"    ]. In another study, hemodynamically-significant pericardial effusion on echocardiography was correlated with CT findings of right ventricular wall flattening and pericardial thickening with a positive predictive value of 79 and 67 percent, respectively; accuracy increased when the effusions were large [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not typically performed as the initial diagnostic test, cardiac catheterization can reveal two major findings in patients with cardiac tamponade: equilibration of average intracardiac diastolic pressures (usually between 10 and 30 mmHg) and the inspiratory increase in right-sided pressures and reduction in left-sided pressures that are responsible for pulsus paradoxus (",
"    <a class=\"graphic graphic_waveform graphicRef63439 \" href=\"UTD.htm?6/0/6154\">",
"     waveform 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef70731 \" href=\"UTD.htm?31/27/32180\">",
"     waveform 3",
"    </a>",
"    ). Patients who are hypovolemic at presentation may have low pressure cardiac tamponade with intracardiac diastolic pressures of 6 to 12 mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Low pressure cardiac tamponade'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H242973994\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac tamponade is associated with a variety of abnormalities that lead to changes on the electrocardiogram, chest x-ray, and echocardiogram. The clinical diagnosis is usually suspected based on the history and physical examination findings, which may include (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Clinical presentation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13\">",
"     'Physical findings'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chest pain",
"     </li>",
"     <li>",
"      Syncope or presyncope",
"     </li>",
"     <li>",
"      Dyspnea and tachypnea",
"     </li>",
"     <li>",
"      Hypotension",
"     </li>",
"     <li>",
"      Tachycardia",
"     </li>",
"     <li>",
"      Peripheral edema",
"     </li>",
"     <li>",
"      Elevated jugular venous pressure",
"     </li>",
"     <li>",
"      Pulsus paradoxus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of a pericardial effusion on echocardiography with evidence of cardiac chamber collapse, flow variation, or dilation of the inferior vena cava is consistent with, and highly suggestive of, cardiac tamponade. However, the diagnosis of cardiac tamponade can only be confirmed by the hemodynamic and clinical response to pericardial fluid drainage. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Treatment'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link&amp;anchor=H19#H19\">",
"     \"Diagnosis and treatment of pericardial effusion\", section on 'Pericardial fluid drainage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7723963\">",
"    <span class=\"h2\">",
"     Approach to the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When evaluating a patient with dyspnea, chest pain, fatigue, elevated jugular venous pressure (JVP), and edema (or some combination of these symptoms), a diagnosis of cardiac tamponade should be considered. However, the differential diagnosis will vary according to the chronicity of the patient&rsquo;s symptoms.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute cardiac tamponade, in which patients typically present with elevated JVP and hypotension, must be distinguished from an acute myocardial infarction (especially with right ventricular involvement), large pulmonary embolus, and an aortic dissection. The former is associated with characteristic electrocardiographic changes of infarction and the latter, in the absence of cardiac tamponade, should not cause an increase in JVP. Furthermore, neither of these disorders is associated with pulsus paradoxus.",
"     </li>",
"     <li>",
"      Subacute cardiac tamponade, in which patients typically present with dyspnea, fatigue, elevated JVP, and edema, must also be distinguished from constrictive pericarditis, congestive heart failure, and advanced liver disease with cirrhosis. Echocardiography is critically important in making this distinction, as it may identify other cardiac pathology consistent with congestive heart failure or constrictive pericarditis. In addition, patients with cirrhosis typically have jaundice and abnormalities of hepatic synthetic function (eg, elevated prothrombin time). A large pleural effusion can also produce signs of cardiac tamponade that resolve after thoracentesis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2546629\">",
"    <span class=\"h2\">",
"     Comparison with constrictive pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac tamponade and constrictive pericarditis, while having several features in common, differ in how they alter diastolic filling of the ventricles, leading to different clinical manifestations and findings on physical examination, echocardiography, and hemodynamic assessment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Features that are common to cardiac tamponade and constrictive pericarditis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diastolic dysfunction &ndash; Constrictive pericarditis is an important cause of diastolic dysfunction or diastolic heart failure.",
"     </li>",
"     <li>",
"      Heightened ventricular interdependence. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Respiratory variation in ventricular inflow velocities &ndash; Both constrictive pericarditis and cardiac tamponade may present with increased respiratory variation of ventricular inflow. While pulsus paradoxus (the physical examination finding that correlates with increased variation of ventricular inflow velocities) is often present in constrictive pericarditis, in our experience it is more commonly seen in cardiac tamponade. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link&amp;anchor=H10#H10\">",
"       \"Constrictive pericarditis\", section on 'Physical examination'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11158?source=see_link\">",
"       \"Pulsus paradoxus in pericardial disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Elevated central venous, pulmonary venous, and ventricular diastolic pressures.",
"     </li>",
"     <li>",
"      Pulmonary hypertension with pulmonary artery systolic pressure between 35 and 50 mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Features that are distinct between cardiac tamponade and constrictive pericarditis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In cardiac tamponade, the pericardial space is open and transmits respiratory variation in thoracic pressure to the heart. In contrast, patients with constrictive pericarditis have a thickened, rigid pericardium which prevents the normal inspiratory decrease in intrathoracic pressure from being transmitted to the heart. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link&amp;anchor=H15194964#H15194964\">",
"       \"Constrictive pericarditis\", section on 'Doppler'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=see_link&amp;anchor=H20#H20\">",
"       \"Examination of the jugular venous pulse\", section on 'Kussmaul's sign'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In cardiac tamponade, systemic venous return increases with inspiration, enlarging the right heart and encroaching on the left, while in constrictive pericarditis systemic venous return does not increase with inspiration under resting conditions. However, in one study of six patients with chronic constrictive pericarditis, right atrial pressure increased following deep inspiration or manual abdominal compression [",
"      <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In cardiac tamponade, there is equalization of the right atrial pressure, right and left ventricular diastolic pressures, and pulmonary arterial diastolic pressures. This is different from constrictive pericarditis, where the right atrial pressure is constant during inspiration, while the pulmonary arterial diastolic pressure decreases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive treatment of cardiac tamponade is achieved by removal of the pericardial fluid, thereby relieving the elevated intrapericardial pressure and improving hemodynamic status. While an occasional patient with few or no clinical signs of hemodynamic compromise may be observed with serial physical examinations and echocardiograms, most patients with tamponade will require early drainage of the pericardial effusion. Supportive care with fluid resuscitation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inotropic support may prove temporarily beneficial but should not be considered a substitute for drainage of the effusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Removal of pericardial fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to drain a pericardial effusion in someone with suspected cardiac tamponade must take into account the clinical assessment, echocardiographic findings, and the risk of the procedure. Cardiac tamponade with overt hemodynamic compromise requires urgent removal of pericardial fluid, which produces a rapid and dramatic improvement in cardiac and systemic hemodynamics [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pericardial fluid removal can be accomplished by catheter pericardiocentesis, open surgical drainage with or without pericardiectomy (pericardial &ldquo;window&rdquo;), or video-assisted thoracoscopic pericardiectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Catheter pericardiocentesis, with echocardiographic guidance, permits the operator to select the best location and angle for puncture, permits precise measurement of hemodynamics, is less expensive than surgery, and facilitates the diagnosis of effusive constrictive pericarditis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25159?source=see_link\">",
"       \"Technique of pericardiocentesis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link&amp;anchor=H23#H23\">",
"       \"Constrictive pericarditis\", section on 'Effusive constrictive pericarditis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical drainage has the advantages of permitting diagnostic pericardial biopsies to be taken and pericardiectomy to be performed, if needed. Direct surgical visualization may also be preferable if fluid has reaccumulated after catheter drainage, the effusion is loculated, there is a special need for biopsy material, or the patient has a coagulopathy. However, surgical drainage requires general anesthesia, which may worsen hemodynamic compromise if needle drainage is not performed first to reduce the severity of the cardiac tamponade.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Catheter pericardiocentesis is our treatment of choice in most patients, which is in agreement with the 2004 European Society of Cardiology guidelines on pericardial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/9\">",
"     9",
"    </a>",
"    ]. Subsequent monitoring with two-dimensional and Doppler echocardiography prior to discharge from the hospital is warranted to confirm adequate fluid removal and to detect possible recurrent fluid accumulation. The 2003",
"    <span class=\"nowrap\">",
"     ACC/AHA/ASE",
"    </span>",
"    task force on echocardiography highly recommended follow-up echocardiography to evaluate for recurrence of effusion or to diagnose early constriction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fluid obtained at pericardial drainage should be examined for Gram stain, bacterial cultures, acid-fast bacilli stain and culture, polymerase chain reaction, cytology, and carcinoembryonic antigen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link\">",
"     \"Diagnosis and treatment of pericardial effusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pericardiocentesis is technically more challenging, with more associated risk, if there is less than 1 cm of effusion, loculation, or evidence of fibrin and adhesions. However, when acute trauma leads to the rapid development of a small effusion and cardiac tamponade, such as when a vessel is punctured during an interventional procedure, emergent pericardiocentesis can be a life-saving procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=see_link\">",
"     \"Emergency pericardiocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with hemorrhagic cardiac tamponade due to cardiac rupture, immediate surgery is indicated. Medical therapy aimed at hemodynamic stabilization should also be instituted. This includes fluids, vasopressors, pericardiocentesis, and intraaortic-balloon pump counterpulsation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=see_link&amp;anchor=H2#H2\">",
"     \"Mechanical complications of acute myocardial infarction\", section on 'Rupture of the left ventricular free wall'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H344531768\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early cardiac tamponade with minimal or no evidence of hemodynamic compromise may be treated conservatively, with careful monitoring, serial echocardiographic studies, avoidance of volume depletion, and therapy aimed at the underlying cause of the pericardial effusion.",
"   </p>",
"   <p>",
"    Volume expansion with agents such as blood, plasma,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    , or saline may be used, but only as a temporizing measure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/19\">",
"     19",
"    </a>",
"    ]. The efficacy of volume expansion was evaluated in a study of 49 patients with large pericardial effusion and hemodynamic criteria for cardiac tamponade who were treated with intravenous administration of 500 ml of normal saline over ten minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/31\">",
"     31",
"    </a>",
"    ]. Cardiac index increased by &gt;10 percent in 47 percent of patients, remained unchanged in 22 percent, and decreased in 31 percent. Volume expansion significantly increased intrapericardial pressure, right atrial pressure, and left ventricular end-diastolic pressure. Systolic blood pressure &lt;100 mmHg was predictive of favorable response to volume expansion.",
"   </p>",
"   <p>",
"    The value of inotropic support, with or without vasodilators, is uncertain. In theory,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    might be the preferred agent to reverse the hypotension, but endogenous inotropic stimulation is often maximal in patients with cardiac tamponade [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Positive pressure mechanical ventilation should be avoided, if possible, in patients with acute cardiac tamponade because it further reduces cardiac filling [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/32\">",
"     32",
"    </a>",
"    ]. Among patients with cardiac arrest and pericardial effusion, the benefit of external cardiac compression is markedly reduced since additional cardiac filling is difficult to achieve [",
"    <a class=\"abstract\" href=\"UTD.htm?18/52/19273/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/49/34577?source=see_link\">",
"       \"Patient information: Cardiac tamponade (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27549078\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac tamponade results from an accumulation of pericardial fluid under pressure, leading to impaired cardiac filling and hemodynamic compromise. Types of cardiac tamponade include acute, subacute, low pressure (occult), and regional. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Physiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A key feature of cardiac tamponade is greatly enhanced ventricular interaction or interdependence, in which the hemodynamics of the left and right heart chambers are directly influenced by each other to a much greater degree than normal. Heightened ventricular interdependence coupled with progressive systolic predominance of and inspiratory increase in systemic venous return are largely responsible for the diagnostic physical and imaging signs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Physiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presenting symptoms of cardiac tamponade vary according to the acuteness of the presentation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with acute cardiac tamponade typically have chest pain, dyspnea,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tachypnea associated with trauma or a cardiac procedure. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Acute cardiac tamponade'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with subacute, low pressure, or regional cardiac tamponade most commonly present with one or more of the following: fatigue, dyspnea, chest pain, and edema. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Subacute cardiac tamponade'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Low pressure cardiac tamponade'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Regional cardiac tamponade'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A number of findings may be present on physical examination, depending upon the type and severity of cardiac tamponade. These may include sinus tachycardia, elevated jugular venous pressure, hypotension, and an exaggerated inspiratory decrease in systolic blood pressure (pulsus paradoxus). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Physical findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients suspected of having cardiac tamponade should be evaluated with an electrocardiogram, chest radiograph, and echocardiography. (See",
"      <a class=\"local\" href=\"#H242973981\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac tamponade can be suspected based on the history and physical examination, electrocardiogram (tachycardia, low voltage, electrical alternans), chest x-ray (enlarged cardiac silhouette with clear lung fields), and echocardiogram (chamber collapses, abnormal venous flows, exaggerated respiratory variation of cardiac and venous flows). However, the diagnosis of cardiac tamponade can best be confirmed by the hemodynamic and clinical response to pericardial fluid drainage. (See",
"      <a class=\"local\" href=\"#H242973994\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Definitive treatment of cardiac tamponade is achieved by removal of the pericardial fluid. While an occasional patient with few or no clinical signs of hemodynamic compromise may be observed with serial physical examinations and echocardiograms, most patients with cardiac tamponade will require early drainage of the pericardial effusion. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients with a documented pericardial effusion and clinical evidence of hemodynamic compromise (ie, tachycardia and hypotension producing a picture of cardiogenic shock) consistent with cardiac tamponade, urgent drainage of the pericardial effusion should be performed. Drainage of the effusion can be performed percutaneously using catheter drainage or surgically. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Removal of pericardial fluid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with a documented large pericardial effusion who are hemodynamically stable without evidence of cardiac tamponade, and in whom sampling the fluid is not needed for diagnostic purposes, we suggest initial observation with serial physical examinations and echocardiograms rather than urgent drainage of the pericardial effusion (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supportive care with fluid resuscitation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inotropic support may prove temporarily beneficial but should not be considered a substitute for drainage of a hemodynamically significant pericardial effusion. (See",
"      <a class=\"local\" href=\"#H344531768\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/1\">",
"      Spodick DH. Acute cardiac tamponade. N Engl J Med 2003; 349:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/2\">",
"      Troughton RW, Asher CR, Klein AL. Pericarditis. Lancet 2004; 363:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/3\">",
"      Reddy PS, Curtiss EI, O'Toole JD, Shaver JA. Cardiac tamponade: hemodynamic observations in man. Circulation 1978; 58:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/4\">",
"      Permanyer-Miralda G. Acute pericardial disease: approach to the aetiologic diagnosis. Heart 2004; 90:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/5\">",
"      Figueras J, Barrab&eacute;s JA, Serra V, et al. Hospital outcome of moderate to severe pericardial effusion complicating ST-elevation acute myocardial infarction. Circulation 2010; 122:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/6\">",
"      Gilon D, Mehta RH, Oh JK, et al. Characteristics and in-hospital outcomes of patients with cardiac tamponade complicating type A acute aortic dissection. Am J Cardiol 2009; 103:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/7\">",
"      Reddy PS, Curtiss EI, Uretsky BF. Spectrum of hemodynamic changes in cardiac tamponade. Am J Cardiol 1990; 66:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/8\">",
"      Sagrist&agrave;-Sauleda J, Angel J, Sambola A, et al. Low-pressure cardiac tamponade: clinical and hemodynamic profile. Circulation 2006; 114:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/9\">",
"      Maisch B, Seferovi�� PM, Risti�� AD, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 2004; 25:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/10\">",
"      Shabetai R, Fowler NO, Fenton JC, Masangkay M. Pulsus paradoxus. J Clin Invest 1965; 44:1882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/11\">",
"      Fitchett DH, Sniderman AD. Inspiratory reduction in left heart filling as a mechanism of pulsus paradoxus in cardiac tamponade. Can J Cardiol 1990; 6:348.",
"     </a>",
"    </li>",
"    <li>",
"     Chou TC. Electrocardiography in Clinical Practice: Adults and Pediatrics, 4th ed, WB Saunders, Philadelphia 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/13\">",
"      Bruch C, Schmermund A, Dagres N, et al. Changes in QRS voltage in cardiac tamponade and pericardial effusion: reversibility after pericardiocentesis and after anti-inflammatory drug treatment. J Am Coll Cardiol 2001; 38:219.",
"     </a>",
"    </li>",
"    <li>",
"     Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline for the clinical application of echocardiography www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/15\">",
"      Plotnick GD, Rubin DC, Feliciano Z, Ziskind AA. Pulmonary hypertension decreases the predictive accuracy of echocardiographic clues for cardiac tamponade. Chest 1995; 107:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/16\">",
"      Reydel B, Spodick DH. Frequency and significance of chamber collapses during cardiac tamponade. Am Heart J 1990; 119:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/17\">",
"      Leimgruber PP, Klopfenstein HS, Wann LS, Brooks HL. The hemodynamic derangement associated with right ventricular diastolic collapse in cardiac tamponade: an experimental echocardiographic study. Circulation 1983; 68:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/18\">",
"      Gillam LD, Guyer DE, Gibson TC, et al. Hydrodynamic compression of the right atrium: a new echocardiographic sign of cardiac tamponade. Circulation 1983; 68:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/19\">",
"      Kerber RE, Gascho JA, Litchfield R, et al. Hemodynamic effects of volume expansion and nitroprusside compared with pericardiocentesis in patients with acute cardiac tamponade. N Engl J Med 1982; 307:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/20\">",
"      Torelli J, Marwick TH, Salcedo EE. Left atrial tamponade: diagnosis by transesophageal echocardiography. J Am Soc Echocardiogr 1991; 4:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/21\">",
"      Fusman B, Schwinger ME, Charney R, et al. Isolated collapse of left-sided heart chambers in cardiac tamponade: demonstration by two-dimensional echocardiography. Am Heart J 1991; 121:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/22\">",
"      Bhagwat AR, Hoit BD. Respiratory variation of carotid artery flow in cardiac tamponade. Am Heart J 1996; 132:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/23\">",
"      Himelman RB, Kircher B, Rockey DC, Schiller NB. Inferior vena cava plethora with blunted respiratory response: a sensitive echocardiographic sign of cardiac tamponade. J Am Coll Cardiol 1988; 12:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/24\">",
"      Merc&eacute; J, Sagrist&agrave;-Sauleda J, Permanyer-Miralda G, et al. Correlation between clinical and Doppler echocardiographic findings in patients with moderate and large pericardial effusion: implications for the diagnosis of cardiac tamponade. Am Heart J 1999; 138:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/25\">",
"      Restrepo CS, Lemos DF, Lemos JA, et al. Imaging findings in cardiac tamponade with emphasis on CT. Radiographics 2007; 27:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/26\">",
"      Gold MM, Spindola-Franco H, Jain VR, et al. Coronary sinus compression: an early computed tomographic sign of cardiac tamponade. J Comput Assist Tomogr 2008; 32:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/27\">",
"      Kolski BC, Kakimoto W, Levin DL, Blanchard DG. Echocardiographic assessment of the accuracy of computed tomography in the diagnosis of hemodynamically significant pericardial effusions. J Am Soc Echocardiogr 2008; 21:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/28\">",
"      Traylor JJ, Chan K, Wong I, et al. Large pleural effusions producing signs of cardiac tamponade resolved by thoracentesis. Am J Cardiol 2002; 89:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/29\">",
"      Meyer TE, Sareli P, Marcus RH, et al. Mechanism underlying Kussmaul's sign in chronic constrictive pericarditis. Am J Cardiol 1989; 64:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/30\">",
"      Uramoto H, Hanagiri T. Video-assisted thoracoscopic pericardiectomy for malignant pericardial effusion. Anticancer Res 2010; 30:4691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/31\">",
"      Sagrist&agrave;-Sauleda J, Angel J, Sambola A, Permanyer-Miralda G. Hemodynamic effects of volume expansion in patients with cardiac tamponade. Circulation 2008; 117:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/52/19273/abstract/32\">",
"      Little WC, Freeman GL. Pericardial disease. Circulation 2006; 113:1622.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4921 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-77.94.48.4-442DE206A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_52_19273=[""].join("\n");
var outline_f18_52_19273=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27549078\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acute cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Subacute cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Low pressure cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Regional cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PHYSICAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Sinus tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Elevated jugular venous pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pulsus paradoxus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Pericardial rub",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H242973981\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Electrocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      CT and CMR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H242973994\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7723963\">",
"      Approach to the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2546629\">",
"      Comparison with constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Removal of pericardial fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H344531768\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27549078\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4921\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4921|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/56/11136\" title=\"diagnostic image 1\">",
"      Chest x-ray of a pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/13/20692\" title=\"diagnostic image 2\">",
"      Doppler echo cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?24/55/25457\" title=\"diagnostic image 3\">",
"      2D TTE Subcostal view normal IVC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/27/41392\" title=\"diagnostic image 4\">",
"      Subcostal view IVC during cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4921|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/55/3966\" title=\"figure 1\">",
"      Chronic versus acute tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4921|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?0/18/291\" title=\"movie 1\">",
"      Pericardial friction rub",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?31/42/32420\" title=\"movie 2\">",
"      Pericardial effusion four chamber echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?37/37/38483\" title=\"movie 3\">",
"      Pericardial effusion with tamponade subcostal echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?15/3/15408\" title=\"movie 4\">",
"      Pericardial effusion with tamponade 4 chamber view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?29/24/30094\" title=\"movie 5\">",
"      Pericardial effusion with tamponade subcostal view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?29/35/30270\" title=\"movie 6\">",
"      Pericardial effusion with tamponade short axis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4921|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/0/7181\" title=\"table 1\">",
"      Causes of pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/52/34636\" title=\"table 2\">",
"      Causes of pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4921|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?7/35/7734\" title=\"waveform 1\">",
"      Hemodynamic tracing acute cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?6/0/6154\" title=\"waveform 2\">",
"      Pulsus paradoxus mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?31/27/32180\" title=\"waveform 3\">",
"      Pulsus alternans and pulsus paradoxus arterial waveforms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/53/43866\" title=\"waveform 4\">",
"      ECG in pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/27/43450\" title=\"waveform 5\">",
"      ECG in electrical alternans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?34/13/35033\" title=\"waveform 6\">",
"      M-mode echocardiography in cardiac tamponade",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=related_link\">",
"      Clinical presentation and diagnostic evaluation of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=related_link\">",
"      Diagnosis and treatment of pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/46/35558?source=related_link\">",
"      ECG tutorial: Miscellaneous diagnoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27077?source=related_link\">",
"      Echocardiographic evaluation of the pericardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23669?source=related_link\">",
"      Electrocardiogram in pericarditis and pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=related_link\">",
"      Emergency pericardiocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=related_link\">",
"      Etiology of pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=related_link\">",
"      Examination of the jugular venous pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/21/23898?source=related_link\">",
"      Initial evaluation and management of penetrating thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/19/39225?source=related_link\">",
"      Mechanical complications of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/49/34577?source=related_link\">",
"      Patient information: Cardiac tamponade (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24055?source=related_link\">",
"      Pericardial complications of myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1050?source=related_link\">",
"      Pericardial disease associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11158?source=related_link\">",
"      Pulsus paradoxus in pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25159?source=related_link\">",
"      Technique of pericardiocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2633?source=related_link\">",
"      Tuberculous pericarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_52_19274="Hyperacute rejection Light";
var content_f18_52_19274=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78954%7ENEPH%2F79378%7ENEPH%2F59928%7ENEPH%2F66537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78954%7ENEPH%2F79378%7ENEPH%2F59928%7ENEPH%2F66537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Renal allograft biopsy showing hyperacute rejection by light microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of a glomerulus in hyperacute rejection. There is a thrombus in the afferent arteriole (arrow) and there is extensive necrosis of the glomerular tuft (which has few cells) and the surrounding parenchyma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Renal allograft biopsy showing hyperacute rejection with marked vascular injury by light microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph in hyperacute rejection showing marked vascular injury with visible fibrin strands on the intimal surface (arrow). The vascular wall is largely replaced by fibrinoid necrosis; there is only minimal neutrophil infiltration despite the extensive vascular damage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Renal allograft biopsy showing hyperacute rejection with fibrin by immunofluorescence microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence microscopy in hyperacute rejection showing extensive fibrin deposition in a glomerulus (right) and in the vascular wall and lumen of an artery (left). The arterial lumen is markedly narrowed due to intraluminal fibrin deposition.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Renal allograft biopsy showing hyperacute rejection with IgM by immunofluorescence microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immunofluorescence microscopy in hyperacute rejection showing the almost pathognomonic deposition of IgM around the wall of a small artery. The lumen (L) is markedly narrowed by intraluminal fibrin deposition (arrow) which comprises most of the space between the remaining lumen and the immunoglobulin positive vascular wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_52_19274=[""].join("\n");
var outline_f18_52_19274=null;
var title_f18_52_19275="Home recording in OSA";
var content_f18_52_19275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Advantages and disadvantages of portable monitoring for obstructive sleep apnea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Advantages",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Increased accessibility",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Patient acceptance",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       May be done in the home",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Convenience",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Decreased labor costs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Can easily be done for more than one night",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Disadvantages",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Absence of a trained technologist to correct and clarify artifacts and make ongoing equipment adjustment",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inability to intervene in medically unstable patients",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Potential data loss or distortion",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Potential for misinterpretation of the results due to limited data",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inability to perform subsequent multiple sleep latency testing according to standard protocol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Varied sensor technology",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No measurement of sleep",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No published standards for scoring or interpretation",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_52_19275=[""].join("\n");
var outline_f18_52_19275=null;
var title_f18_52_19276="Prev venous cath infection";
var content_f18_52_19276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevention of infection with peripheral venous catheters",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Replacement and relocation of catheter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In adults, unless clinically indicated, replace catheter at four days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In adults, replace heparin locks every 96 hours.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In pediatric patients, leave peripheral venous catheters in place until intravenous therapy is completed, unless a complication occurs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For catheters inserted under emergency conditions, insert a new catheter at a different site within 24 hours.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Replacement of catheter-site dressing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Replace dressing when the catheter is removed or replaced, or when the dressing becomes damp, loosened, or soiled. Replace dressings more frequently in diaphoretic patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        There is no need to remove a gauze or opaque dressing if the patient has no clinical signs of infection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Replacement of administration sets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Replace administration sets, including secondary sets and add-on devices, no more frequently than at 72-hour intervals, unless clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Replace tubing used to administer blood, blood products, or lipid emulsions within 24 hours of initiating the infusion.",
"        <strong>",
"         No recommendation*",
"        </strong>",
"        for replacement of tubing used for intermittent infusions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Replace tubing used to administer propofol infusions every 6 or 12 hours, depending on its use.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hang time for parenteral fluids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complete infusion of lipids or lipid-containing parenteral nutrition fluids (eg, 3-in-1 solutions) within 24 hours of hanging the fluid. When lipid emulsions are given alone, complete the infusion within 12 hours of hanging the emulsion.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Complete infusion of blood or blood products within four hours of hanging the blood.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         No recommendation*",
"        </strong>",
"        for the hang time of intravenous fluids, including nonlipid-containing parenteral nutrition fluids.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *&nbsp;No recommendation is made when there is insufficient data in the literature.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_52_19276=[""].join("\n");
var outline_f18_52_19276=null;
var title_f18_52_19277="PCN all st given ceph";
var content_f18_52_19277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F57958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F57958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Use of cephalosporins in patients with positive skin tests to penicillin",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Reference",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of reactions",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cephalosporin skin testing",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Girard JP (1968)",
"       </td>",
"       <td class=\"centered\">",
"        23",
"       </td>",
"       <td class=\"centered\">",
"        2 (8.7)",
"       </td>",
"       <td class=\"centered\">",
"        No",
"       </td>",
"       <td>",
"        Both reactions to cephaloridine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Assem ESK (1974)",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        3 (100)",
"       </td>",
"       <td class=\"centered\">",
"        No",
"       </td>",
"       <td>",
"        All reactions to cephaloridine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Warrington RJ (1978)",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Solley GO (1982)",
"       </td>",
"       <td class=\"centered\">",
"        27",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        No",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Saxon A (1987)",
"       </td>",
"       <td class=\"centered\">",
"        62",
"       </td>",
"       <td class=\"centered\">",
"        1 (1.6)",
"       </td>",
"       <td class=\"centered\">",
"        No",
"       </td>",
"       <td>",
"        Cephalosporin not noted",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blanca M (1989)",
"       </td>",
"       <td class=\"centered\">",
"        16",
"       </td>",
"       <td class=\"centered\">",
"        2 (12.5)",
"       </td>",
"       <td class=\"centered\">",
"        No",
"       </td>",
"       <td>",
"        Both reactions to cefamandole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shepherd GM (1993)",
"       </td>",
"       <td class=\"centered\">",
"        9",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        No",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Audicana M (1994)",
"       </td>",
"       <td class=\"centered\">",
"        12",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pichichero ME (1998)",
"       </td>",
"       <td class=\"centered\">",
"        39",
"       </td>",
"       <td class=\"centered\">",
"        2 (5.1)",
"       </td>",
"       <td class=\"centered\">",
"        No",
"       </td>",
"       <td>",
"        Reaction to cefaclor and ?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Novalbos A (2001)",
"       </td>",
"       <td class=\"centered\">",
"        23",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Macy E (2002)",
"       </td>",
"       <td class=\"centered\">",
"        42",
"       </td>",
"       <td class=\"centered\">",
"        1 (2.4)",
"       </td>",
"       <td class=\"centered\">",
"        No",
"       </td>",
"       <td>",
"        Reaction to cefixime",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Romano A (2004)",
"       </td>",
"       <td class=\"centered\">",
"        75",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        Yes",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Greenberger PA (2005)",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        No",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Park MA (2010)",
"       </td>",
"       <td class=\"centered\">",
"        87",
"       </td>",
"       <td class=\"centered\">",
"        2 (2.4)",
"       </td>",
"       <td class=\"centered\">",
"        No",
"       </td>",
"       <td>",
"        Reactions to cefazolin, cephalexin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         377",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         13 (3.4)",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         &nbsp;",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         &nbsp;",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Summary of penicillin skin test-positive patients challenged with cephalosporins, excluding patients selectively allergic to amoxicillin or ampicillin (skin test positive to an aminopenicillin but negative to penicillin G-derived major and minor determinants).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_52_19277=[""].join("\n");
var outline_f18_52_19277=null;
var title_f18_52_19278="Time to recovery in patients with unipolar major depression";
var content_f18_52_19278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F53095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F53095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Time to recovery in patients with unipolar major depression",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 314px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Time to recovery from the first (squares, N = 314) and second (triangles, N = 181) prospectively observed episodes of major depression in patients with major depressive disorder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Coryell W, HS Akiskal, AC Leon, et al. The time course of nonchronic major depressive disorder. Uniformity across episodes and samples. National Institute of Mental Health Collaborative Program on the Psychobiology of Depression--Clinical Studies. Arch Gen Psychiatry 1994; 51:405. Copyright &copy; 1994 American Medical Association. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_52_19278=[""].join("\n");
var outline_f18_52_19278=null;
var title_f18_52_19279="RLL atelectasis CT";
var content_f18_52_19279=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60573&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan of right lower lobe atelectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan of right lower lobe atelectasis showing a nearly triangular opacity in the right paraspinal region (arrow). In this patient with bronchogenic carcinoma, a mucoid bronchogram in the atelectatic lobe is evidence of the bronchial obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_52_19279=[""].join("\n");
var outline_f18_52_19279=null;
